Alexandria Medical Evidence Library
Library/Cancer/Breast Cancer

Cancer evidence library

Breast Cancer

A living PubMed evidence library for breast cancer research, treatment, outcomes, risks, and emerging therapies.

PubMed only Research ranked Conflicts shown Data downloadable

Living evidence synopsis

What the current PubMed collection shows.

Alexandria currently organizes 1,577 non-retracted PubMed-indexed records for Breast Cancer. The structured collection includes 14 guideline or consensus records, 216 evidence syntheses/systematic reviews/meta-analyses, and 151 randomized or phase III studies. 305 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 803 of 1,577 included records.

Engine 0.3.2 Snapshot v13 Updated 2026-11-02 Download source data · CSV
PubMed records1,577Non-retracted records included
Last 24 months305Records found by the recent-research search
High-priority evidence367Syntheses, reviews, randomized and phase III studies
Effect estimates488Machine-readable values extracted from abstracts
COI statements50.9%Coverage within PubMed records
Funding records457PMIDs with grant/funding metadata
Evidence data

Research landscape

Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.

Publication activity

Records by publication year

Latest 12 represented years
2
2017
1
2019
4
2020
7
2021
59
2022
275
2023
365
2024
75
2025
722
2026
67
2027
Evidence composition

Study designs

Other or unclassified701
Preclinical/laboratory366
Randomized trials141
Meta-analyses135
Systematic reviews81
Cohort studies35
Prospective cohorts33
Observational studies19
Case reports18
Phase II trials17
Transparency

Conflict-of-interest reporting

Not reported in PubMed record774
Reported no conflicts376
COI statement present345
Declared financial/industry relationship82

Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.

Abstract result signals

Extracted result direction

Not extractable from abstract1446
Harm signal43
Neutral/null signal43
Supportive signal36
Mixed signal9
Reported outcomes

Numerical results extracted from PubMed abstracts

Each value remains attached to its original PMID. Alexandria does not pool these results or imply that unlike populations and endpoints are directly comparable.

Non-pooled ratio measures

Hazard, risk, and odds ratios reported in abstracts

Reference = 1.0
0.250.51.02.04.0
not_reported Odds Ratio · PMID 42248318 · 2027
0.58 95% CI 0.52–0.65
not_reported Hazard Ratio · PMID 42248318 · 2027
0.75 95% CI 0.69–0.83
not_reported Hazard Ratio · PMID 42248318 · 2027
0.80 95% CI 0.72–0.89
not_reported Hazard Ratio · PMID 42927325 · 2027
0.56 95% CI 0.34–0.94
not_reported Hazard Ratio · PMID 42927325 · 2027
0.31 95% CI 0.11–0.91
not_reported Odds Ratio · PMID 41658476 · 2026
3.91 95% CI 1.44–10.62
not_reported Odds Ratio · PMID 41658476 · 2026
11.35 95% CI 3.45–37.34
not_reported Odds Ratio · PMID 41658476 · 2026
0.21 95% CI 0.04–0.97
not_reported Odds Ratio · PMID 41658476 · 2026
0.68 95% CI 0.51–0.90
not_reported Odds Ratio · PMID 41658476 · 2026
0.92 95% CI 0.85–0.99
not_reported Odds Ratio · PMID 42456331 · 2026
2.70 95% CI 1.40–5.10
not_reported Odds Ratio · PMID 42456331 · 2026
9.30 95% CI 3.30–26.00
not_reported Odds Ratio · PMID 42456331 · 2026
4.10 95% CI 1.60–10.90
recurrence Hazard Ratio · PMID 42229584 · 2026
0.82
View extracted numerical results 60
PublicationOutcomeMeasureReported valueSource
Clinicopathological response and survival outcomes of HER2-low versus HER2-zero early breast Cancer: A systematic review and Meta-analysis.Clinica chimica acta; international journal of clinical chemistry · 2027 not_reported Odds Ratio 0.58 95% CI 0.52–0.65 PMID 42248318
Clinicopathological response and survival outcomes of HER2-low versus HER2-zero early breast Cancer: A systematic review and Meta-analysis.Clinica chimica acta; international journal of clinical chemistry · 2027 not_reported Hazard Ratio 0.75 95% CI 0.69–0.83 PMID 42248318
Clinicopathological response and survival outcomes of HER2-low versus HER2-zero early breast Cancer: A systematic review and Meta-analysis.Clinica chimica acta; international journal of clinical chemistry · 2027 not_reported Hazard Ratio 0.8 95% CI 0.72–0.89 PMID 42248318
Timing of cranial radiotherapy in HER2-positive breast Cancer brain metastases treated with Pyrotinib: a multicentre real-world cohort study.Clinical and translational radiation oncology · 2027 not_reported Hazard Ratio 0.56 95% CI 0.34–0.94 P = 0.028 PMID 42927325
Timing of cranial radiotherapy in HER2-positive breast Cancer brain metastases treated with Pyrotinib: a multicentre real-world cohort study.Clinical and translational radiation oncology · 2027 not_reported Hazard Ratio 0.31 95% CI 0.11–0.91 P = 0.025 PMID 42927325
Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort.Clinical and translational radiation oncology · 2027 not_reported Percentage Comparison 11.0percent vs 4.3percent PMID 42935767
Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort.Clinical and translational radiation oncology · 2027 not_reported Percentage Comparison 4.8percent vs 0.8percent PMID 42935767
Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 not_reported Odds Ratio 3.91 95% CI 1.439–10.624 PMID 41658476
Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 not_reported Odds Ratio 11.35 95% CI 3.45–37.345 PMID 41658476
Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 not_reported Odds Ratio 0.208 95% CI 0.045–0.967 PMID 41658476
Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 not_reported Odds Ratio 0.676 95% CI 0.506–0.904 PMID 41658476
Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 not_reported Odds Ratio 0.921 95% CI 0.855–0.993 PMID 41658476
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 progression-free survival Percentage Comparison 23.7percent vs 5.3percent p = 0.01 PMID 42337391
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 progression-free survival Percentage Comparison 88.1percent vs 57.9percent p = 0.01 PMID 42337391
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 not_reported Percentage Comparison 87.5percent vs 48.0percent PMID 42337391
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 not_reported Percentage Comparison 20.8percent vs 4.0percent p = 0.08 PMID 42337391
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 not_reported Percentage Comparison 16.5percent vs 21.1percent p = 0.45 PMID 42337391
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 not_reported Percentage Comparison 47.1percent vs 47.4percent p = 0.45 PMID 42337391
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 not_reported Percentage Comparison 43.9percent vs 28.3percent p = 0.01 PMID 42337391
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 not_reported Percentage Comparison 9.8percent vs 1.9percent p = 0.01 PMID 42337391
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 not_reported Percentage Comparison 6.1percent vs 0.4percent p = 0.01 PMID 42337391
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 not_reported Percentage Comparison 7.3percent vs 1.9percent p = 0.01 PMID 42337391
The hidden costs of choice: Increased postoperative risks in patient-preference mastectomy for breast cancer.American journal of surgery · 2026 not_reported Odds Ratio 2.7 95% CI 1.4–5.1 PMID 42456331
The hidden costs of choice: Increased postoperative risks in patient-preference mastectomy for breast cancer.American journal of surgery · 2026 not_reported Odds Ratio 9.3 95% CI 3.3–26.0 PMID 42456331
The hidden costs of choice: Increased postoperative risks in patient-preference mastectomy for breast cancer.American journal of surgery · 2026 not_reported Odds Ratio 4.1 95% CI 1.6–10.9 PMID 42456331
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 recurrence Hazard Ratio 0.82 P = 0.03 PMID 42229584
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 recurrence Hazard Ratio 0.75 95% CI 0.63–0.9 PMID 42229584
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 recurrence Hazard Ratio 0.89 95% CI 0.74–1.06 PMID 42229584
SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 not_reported Percentage Comparison 28.8percent vs 19.2percent P = 0.18 PMID 42323161
Multicenter randomized effectiveness/implementation trial of a digital self-management support tool to improve the quality of life during adjuvant hormonal therapy for patients with early breast cancer: The HOPE trial.Contemporary clinical trials · 2026 not_reported Odds Ratio 12.0 PMID 42501860
Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial.European journal of cancer (Oxford, England : 1990) · 2026 not_reported Odds Ratio 1.03 95% CI 0.96–1.11 p = 0.007 PMID 42308863
Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial.Breast (Edinburgh, Scotland) · 2026 not_reported Odds Ratio 5.0 PMID 42632205
Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial.Breast (Edinburgh, Scotland) · 2026 recurrence Odds Ratio 9.1 PMID 42632205
Association Between Decision Regret and Psychosocial Outcomes Following Surgery Among Women with Unilateral Nonhereditary Breast Cancer.Annals of surgical oncology · 2026 not_reported Odds Ratio 18.0 PMID 42467156
Carborane-modified paclitaxel analogues: Position-dependent modulation of mitotic catastrophe and lysosomal function.European journal of medicinal chemistry · 2026 not_reported Odds Ratio 2.0 PMID 42623741
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.JAMA oncology · 2026 not_reported Odds Ratio 4.0 PMID 42530945
Magnetic Resonance Elastography in Breast Cancer: A Prospective Study on Optimal Imaging Frequency Selection and Differentiation of Molecular Subtypes.Journal of magnetic resonance imaging : JMRI · 2026 not_reported Odds Ratio 5.37 PMID 42525485
Magnetic Resonance Elastography in Breast Cancer: A Prospective Study on Optimal Imaging Frequency Selection and Differentiation of Molecular Subtypes.Journal of magnetic resonance imaging : JMRI · 2026 not_reported Odds Ratio 0.27 PMID 42525485
Association between sentinel lymph node number and prognosis in cT1-2N0M0 early breast cancer patients with negative sentinel lymph nodes: a single‑center retrospective cohort study.Annals of medicine · 2026 not_reported Hazard Ratio 1.02 p = 0.95 PMID 42608978
Association between sentinel lymph node number and prognosis in cT1-2N0M0 early breast cancer patients with negative sentinel lymph nodes: a single‑center retrospective cohort study.Annals of medicine · 2026 not_reported Hazard Ratio 0.91 p = 0.95 PMID 42608978
Research transparency

Funding and conflicts of interest

Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.

COI statement coverage50.9%774 records have no COI statement exposed in PubMed.
Funding metadata coverage29.0%Coverage indicates whether grant/funding metadata was present, not independence or study quality.
Most frequently reported funding agencies
NCI NIH HHS211
National Natural Science Foundation of China62
NIH HHS30
Cancer Research UK28
NHLBI NIH HHS27
National Natural Science Foundation of China (National Science Foundation of China)27
Wellcome Trust25
Medical Research Council24
View records with declared financial or industry relationships 12

Prospective Clinical Trial on Expanding the Eligibility Criteria for Targeted Axillary Dissection after Neoadjuvant Systemic Therapy in Breast Cancers with Advanced Nodal Disease.

Disclosure: Ava Kwong reports institutional clinical trial research funding for breast cancer from Roche Hong Kong Limited, Merck Sharp & Dohme (Asia) Limited, Gilead Sciences Inc. and Olema Pharmaceuticals Inc; institutional research funding for genetic testing from AstraZeneca; and donation of Probes and IceCure Machine to The University of Hong Kong (HKU) from IceCure Medical Ltd for a cryosurgery study.

PMID 42663773 · 2026

Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial.

Declaration of competing interests The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Manjiri M Bakre reports a relationship with OncoStem Diagnostics Pvt Ltd that includes: board membership, employment, and equity or stocks.TDD, SG, BAS, PS, DKS, NK, and MS are employees of OncoStem Diagnostics Pvt Ltd. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

PMID 42632205 · 2026

Multicenter randomized effectiveness/implementation trial of a digital self-management support tool to improve the quality of life during adjuvant hormonal therapy for patients with early breast cancer: The HOPE trial.

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ines Vaz-Luis reports financial support was provided by French National Cancer Institute. Maria Alice Franzoi reports financial support was provided by Breast Cancer Research Foundation. Maria Alice Franzoi reports a relationship with Resilience Care that includes: funding grants. Maria Alice Franzoi reports a relationship with Gilead Sciences Inc. that includes: funding grants. Maria Alice Franzoi reports a relationship with Novartis that includes: speaking and lecture fees. Ines Vaz-Luis reports a relationship with Amgen Inc. that includes: speaking and lecture fees. Ines Vaz-Luis reports a relationship with AstraZeneca Pharmaceuticals LP that includes: speaking and lecture fees. Ines Vaz-Luis reports a relationship with Pfizer that includes: consulting or advisory and speaking and lecture fees. Ines Vaz Luis reports a relationship with Novartis that includes: speaking and lecture fees and travel reimbursement. Ines Vaz-Luis reports a relationship with Resilience Care that includes: funding grants. Arlindo Ferreira reports a relationship with Resilience Care that includes: employment. Stefan Michels reports a relationship with Roche that includes: consulting or advisory. Stefan Michels reports a relationship with IQVIA that includes: consulting or advisory. Stefan Michels reports a relationship with Kedrion that includes: consulting or advisory. Stefan Michels reports a relationship with Servier that includes: consulting or advisory. Stefan Michels reports a relationship with Yuhan that includes: consulting or advisory. Adeline Morel reports a relationship with Novartis that includes: consulting or advisory and travel reimbursement. Adeline Morel reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory and travel reimbursement. Adeline Morel reports a relationship with Daiichi Sankyo Inc. that includes: consulting or advisory and travel reimbursement. Adeline Morel reports a relationship with Gilead Sciences Inc. that includes: consulting or advisory and travel reimbursement. Adeline Morel reports a relationship with Lilly that includes: travel reimbursement. Adeline Morel reports a relationship with Pfizer that includes: travel reimbursement. Adeline Morel reports a relationship with Sandoz Inc. that includes: travel reimbursement. Adeline Morel reports a relationship with Roche that includes: travel reimbursement. Adeline Morel reports a relationship with MSD Merck Sharp & Dohme AG that includes: travel reimbursement. Adeline Morel reports a relationship with Bristol-Myers Squibb Company that includes: consulting or advisory. Fanny Le Du reports a relationship with AstraZeneca Pharmaceuticals LP that includes: speaking and lecture fees and travel reimbursement. Fanny Le Du reports a relationship with Pfizer that includes: speaking and lecture fees and travel reimbursement. Fanny Le Du reports a relationship with Novartis that includes: speaking and lecture fees and travel reimbursement. Fanny Le Du reports a relationship with Lilly that includes: speaking and lecture fees and travel reimbursement. Fanny Le Du reports a relationship with MSD Merck Sharp & Dohme AG that includes: speaking and lecture fees. Fanny Le Du reports a relationship with Roche that includes: speaking and lecture fees and travel reimbursement. Fanny Le Du reports a relationship with Daiichi Sankyo Inc. that includes: funding grants. Fanny Le Du reports a relationship with Gilead Sciences Inc. that includes: travel reimbursement. Has patent pending to. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

PMID 42501860 · 2026

Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects.

A.J. Webb reports grants from the European Union Seventh Framework Programme during the conduct of the study, as well as grants from Horizon Europe - PRE-ACT Project outside the submitted work. T. Rattay reports grants from the National Institute of Health and Care Research outside the submitted work. D.K. De Ruysscher reports grants from AstraZeneca and Bristol Myers Squibb, other support from Pfizer, and nonfinancial support from Olink outside the submitted work. L. Veldeman reports grants from the European Commission Seventh Framework during the conduct of the study. C.J. Talbot reports grants from Horizon Europe during the conduct of the study. No disclosures were reported by the other authors.

PMID 42440347 · 2026

Cascade-responsive biomimetic nanoparticles remodel tumor metabolism and potentiate ferroptosis for synergistic therapy of aggressive breast cancer.

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Yaqin Tang has patent pending to Chongqing University of Technology. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

PMID 42574922 · 2027

Adaptation of a breast reconstruction decision aid for Spanish-speaking, Latina survivors using rapid qualitative analysis and a multilingual community engagement model.

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Conflict of Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: MCP was a consultant for UCB Biopharma and Epi Q Inc in 2024 on topics unrelated to this manuscript. No other authors have competing interests to disclose.

PMID 42641227 · 2026

Italian guidelines for age range and test interval in breast cancer screening programmes: GRADE-ADOLOPMENT of the European guidelines.

Declarations. Conflict of interest: Silvia Deandrea is the President of the Italian Mammography Screening Group; Marco Rosselli Del Turco was a medical consultant for senology at FORA s.p.a. Paolo Giorgi Rossi is a member of the panel that developed the European guidelines on breast cancer screening and diagnosis, referred document for the ADOLOPMENT process; Livia Giordano is a member of the panel that developed the European guidelines on breast cancer screening and diagnosis, referred document for the ADOLOPMENT process; Elena Parmelli was a contract staff member at the Joint Research Centre (JRC) of the European Commission, Ispra, VA (Italy); Cannatà Vittorio has been Vice-President of the Italian Association of Medical Physics (AIFM); Isabella Castellano has been professional consultant for symposium “Choosing the best therapy in ER + /HER2- breast cancer” (Token of attendance at the National Congress of Anatomic Pathology, October 2019), Myriad Genetics, s.r.l.; Stefano Pacifici is the President of the Italian Association of Senology Radiographers (AITeRS); Trianni Annalisa is a member of the Italian Association of Medical Physics (AIFM); Paola Golinelli was reimbursed for participation in the European Federation of Organization for Medical Physics (EFOMP) Working Group on mammographic tomosynthesis equipment. Pierpaolo Pattacini received a software by I-CAD. The other authors have no relevant financial or non-financial interest to disclose. Competing interests: All panellists were required to disclose all financial, non-financial, personal, and institutional interests relevant to the scope of the guidelines by completing a standardized form, following SNLG guidance. The Scientific Committee (SC) assessed each individual interest, and ultimately, no panellist was excluded from the voting procedures. This policy was upheld throughout the entire process, including the selection of panel members, the generation and prioritization of research questions, and participation in the formulation of recommendations. The SC consistently monitored the declaration of conflicts of interest (COI). Ethical approval: Ethical approval was not necessary for this kind of scientific work. Informed consent: Not applicable.

PMID 39460891 · 2024

Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer.

M.V. Dieci reports personal fees from Eli Lilly and Company, Novartis, Pfizer, Roche, Gilead Sciences, Daiichi Sankyo, MSD, AstraZeneca, Exact Sciences, and Menarini Stemline, grants from Roche and AstraZeneca, and nonfinancial support from Eli Lilly and Company, Roche, AstraZeneca, and Daiichi Sankyo outside the submitted work, as well as being a co-inventor of a patent for WO2022023235 related to In Vitro Method for the Prognosis of Patients Suffering from HER2-positive Breast Cancer and a patent for WO2023117807 related to Development and Validation of an In Vitro Method for the Prognosis of Patients Suffering from HER2-positive Breast Cancer licensed to Università di Padova. E. Gasparini reports personal fees from Eli Lilly and Company, Novartis, Daiichi Sankyo, Pfizer, and Gilead Sciences outside the submitted work. P. Schmid reports grants and personal fees from AstraZeneca, Merck, Novartis, Pfizer, and Roche, personal fees from Bayer, Boehringer Ingelheim, Puma Biotechnology, Eisai, and Celgene, and grants from Astellas Pharma, Genentech, OncoGenex, and Medivation Bio outside the submitted work. A. Zambelli reports personal fees from Merck, Novartis, Eli Lilly and Company, Gilead Sciences, Bristol Myers Squibb, and Exact Sciences, grants and personal fees from Pfizer, and personal fees and nonfinancial support from Roche, AstraZeneca, Daiichi Sankyo, and BeOne outside the submitted work. A. Favaretto reports personal fees from Bristol Myers Squibb, GSK, and Novartis and nonfinancial support from Amgen outside the submitted work. G.V. Bianchi reports personal fees from Eli Lilly and Company, Menarini Stemline, Daiichi Sankyo, and Novartis outside the submitted work. G. Arpino reports grants, personal fees, and nonfinancial support from Roche, Novartis, Eli Lilly and Company, Pfizer, Helsinn, and Gilead Sciences outside the submitted work. S. Cinieri reports personal fees from Lilly Oncology, Bayer, Novartis, Roche, Pfizer, and Menarini Stemline outside the submitted work, as well as being a president of AIOM (Italian Association of Medical Oncology) Foundation (current 2-year term). C. Zamagni reports grants, personal fees, and nonfinancial support from Daiichi Sankyo, AstraZeneca, Roche, Novartis, Pfizer, MSD, Eisai, GSK, Menarini Stemline, and Gilead Sciences and grants and personal fees from Eli Lilly and Company and Exact Sciences outside the submitted work. S. Spazzapan reports personal fees from Novartis Italy, Pfizer Italy, AstraZeneca, Daiichi Sankyo, and Gentili Pharma and other support from Roche Italia, Novartis Italy, Daiichi Sankyo, and Pfizer Italy outside the submitted work. L. Del Mastro reports personal fees from Eli Lilly and Company, Novartis, MSD, Exact Sciences, Olema, Signatur Biosciences, and Agendia, personal fees and nonfinancial support from Roche, Menarini Stemline, AstraZeneca, and Daiichi Sankyo, grants, personal fees, and nonfinancial support from Gilead Sciences, and grants and personal fees from Pfizer outside the submitted work. M. de Laurentiis reports personal fees from AstraZeneca, Novartis, Eli Lilly and Company, Pfizer, Gilead Sciences, MSD, Exact Sciences, Daiichi Sankyo, and Menarini Stemline, grants and personal fees from Roche, and other support from Arvinas outside the submitted work. A. Musolino reports grants and personal fees from Eli Lilly and Company, Roche, Pfizer, Gilead Sciences, MSD, AstraZeneca, Novartis, and Daiichi Sankyo outside the submitted work. P. Conte reports grants and nonfinancial support from Merck during the conduct of the study. V. Guarneri reports grants from Merck during the conduct of the study, as well as grants and personal fees from Eli Lilly and Company, AstraZeneca, Roche, Novartis, Pfizer, MSD, Gilead Sciences, Menarini Stemline, Daiichi Sankyo, and Bristol Myers Squibb and personal fees from AbbVie outside the submitted work. No disclosures were reported by the other authors.

PMID 42467210 · 2026
01

Current Standard-of-Care Sources

Alexandria uses this label only for PubMed-indexed guidelines or consensus documents. These are source publications, not individualized recommendations.

02

Highest-Priority Research

systematic reviewn=907567

Beyond predictive performance: A systematic review and critical methodological appraisal of AI/ML and conventional modelling strategies in breast, colorectal, and pancreatic Cancer.

Artificial intelligence in medicine · 2026

BACKGROUND: Predictive modelling for cancer risk, treatment-related complications, and survival is central to precision oncology. Conventional logistic regression (LR) and Cox proportional hazards (CoxPH) regression remain widely used but are limited when modelling nonlinear interactions, high-dimensional imaging features, and multimodal clinical-metabolic predictors. Artificial intelligence (AI) and machine learning (ML) methods offer expanded capability through automated feature extraction, ensemble learning, and flexible survival modelling, but the evidence on when AI/ML adds value over conventional models across cancer sites and predictive tasks remains fragmented. OBJECTIVE: To systemat…

PMID 42641254
systematic reviewn=80033

Artificial Intelligence in Breast Cancer Diagnosis, Treatment, and Perioperative Management: A Systematic Review of Current Applications and Future Perspectives.

La Clinica terapeutica · 2026

BACKGROUND: Breast cancer is the most frequently diagnosed malignancy in women globally, accounting for approximately 2.30 million new cases and 666,103 deaths in 2022. Artificial intelligence technologies including machine learning, deep learning, radiomics, and natural language processing have been widely applied across the breast cancer care continuum. However, no systematic review restricted to primary studies with patient-level or image-level data has synthesized evidence spanning all clinical domains simultaneously. OBJECTIVES: To evaluate the performance, methodological quality, and clinical relevance of artificial intelligence primary studies across screening and diagnostic imaging, …

PMID 42922241
clinical guideline

CAR Practice Guidelines on Breast Imaging and Interventions: Contrast-Enhanced Mammography.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026

This guideline presents Part II of the Canadian Association of Radiologists (CAR) Practice Guidelines on Breast Imaging and Intervention and addresses the clinical application of contrast-enhanced mammography (CEM). Reflecting the expanding evidence base and increasing clinical adoption of CEM since 2016, this guideline provides updated recommendations on indications, examination technique, contrast administration, image interpretation, reporting standards, quality control, and patient safety. Particular emphasis is placed on the role of CEM in diagnostic problem-solving, preoperative staging, and selected screening scenarios when breast MRI is unavailable or contraindicated. This guideline …

PMID 42198829
systematic reviewn=16504

Prevalence of anxiety and depression in breast cancer patients: a meta-analysis.

Frontiers in psychology · 2026

INTRODUCTION: Depression and anxiety are frequently reported among women with breast cancer, but prevalence estimates vary substantially across settings and assessment instruments. This meta-analysis synthesized recent international evidence and examined overall, severity-stratified, and instrument-specific prevalence estimates. METHODS: We searched PubMed, Web of Science, Embase, the Cochrane Library, APA PsycINFO, and Scopus for observational studies published from January 2015 through September 10, 2026. Proportions were pooled with a random-effects model after Freeman-Tukey double-arcsine transformation. Prespecified subgroup analyses examined region, assessment instrument, and study des…

PMID 42952549
meta analysisn=115182

Clinicopathological response and survival outcomes of HER2-low versus HER2-zero early breast Cancer: A systematic review and Meta-analysis.

Clinica chimica acta; international journal of clinical chemistry · 2027

BACKGROUND: Breast cancer is the most common malignant tumor in women. Human epidermal growth factor receptor 2 (HER2) is a key biomarker for classification and treatment. A subgroup with HER2-low expression has been identified, but existing evidence is heterogeneous. This systematic review and meta-analysis compared pathological response and survival outcomes between HER2-low and HER2-zero early-stage breast cancer to clarify prognostic features. METHODS: This study followed PRISMA guidelines and was registered in PROSPERO (CRD420251120506). PubMed, Embase, Web of Science, ClinicalTrials.gov, and major oncology conferences were searched through September 2025. Cohort studies of early-stage …

PMID 42248318
clinical guideline

Pharmacotherapy for older adults with cancer: a digest of the Japanese clinical practice guidelines (second edition)-breast cancer.

International journal of clinical oncology · 2026

BACKGROUND: The number of older adults with early breast cancer is rising in aging societies. Optimal perioperative systemic therapy for this population remains challenging, owing to heterogeneity in functional status, comorbidities, and the limited representation of older patients in clinical trials. METHODS: This article presents an English digest of the Japanese Clinical Practice Guidelines for Pharmacotherapy in Older Adults with Cancer (Second Edition), focusing on perioperative systematic therapy for early breast cancer. The guidelines were developed in accordance with the Minds 2020 methodology, incorporating systematic reviews, the Evidence-to-Decision framework, and multidisciplinar…

PMID 42629540
meta analysisn=720210

Sensitive Period Analysis of Adulthood BMI and Cancer Risk: An Individual Participant Data Meta-Analysis of Over 720,000 Participants in the ABACus 2 Consortium.

International journal of cancer · 2026

At least 13 cancers are linked to obesity. We analyse time-to-event data using Sensitive Period Analysis to explore whether associations between body mass index (BMI) and cancer incidence vary throughout adulthood to inform cancer prevention strategies, policy and weight management trials of optimal intervention ages. Using the European Prospective Investigation into Cancer and Nutrition cohort, Atherosclerosis Risk in Communities study, Women's Health Initiative, Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial, NIH-AARP Diet and Health, we predicted BMI throughout adulthood. We landmarked to predefined ages of interest (AOI), ages 30 to 65 (5-yearly). Super-landmarking and a two-…

PMID 41952250
clinical guideline

Preventing common shape deformities and complications in therapeutic mammoplasty: A practical guide.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026

Therapeutic mammoplasty (TM) combines wide local excision with immediate volume displacement, enabling oncologically safe breast conservation while maintaining breast shape. Despite its benefits, postoperative complications and aesthetic deformities remain clinically relevant and may adversely affect patient satisfaction. Common sequelae include nipple-areola complex (NAC) malposition or necrosis, fat necrosis, bottoming-out, boxy breast contours, wound breakdown, and radiotherapy-associated fibrosis. This expert-opinion technical note draws on contemporary literature and operative experience from high-volume oncoplastic units to present practical strategies for preventing common deformities…

PMID 42413454
clinical guideline

S1 guideline sweat gland carcinoma.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026

The current classification of sweat gland carcinomas is based on histomorphological characteristics and distinguishes between more than 20 entities. Most patients are older, but some subtypes also affect middle-aged and younger patients. The majority of tumors arise de novo. Sweat gland carcinomas have nonspecific clinical features. The tumors are usually located in the head and neck area and on extremities, with the exception of extramammary Paget's carcinoma, which has an anogenital predilection. Sweat gland carcinomas occurring in the armpit may pose a histomorphological challenge in distinguishing them from metastatic or primary breast cancer. The diagnosis is made histopathologically vi…

PMID 42412045
clinical guideline

American Society of Breast Surgeons, Society of Breast Imaging, and College of American Pathology 2026 Guidelines for the Management of Proliferative Lesions With Atypia and Lobular Carcinoma In Situ.

JAMA surgery · 2026

IMPORTANCE: Many patients are diagnosed with atypical lesions or lobular carcinoma in situ (LCIS); however, evidence- and consensus-based guidelines for the management of many of these lesions are limited. OBSERVATIONS: The American Society of Breast Surgeons, in collaboration with the Society of Breast Imaging and College of American Pathology, assembled a steering group to create guidelines for the management of atypical lesions and LCIS, inclusive of flat epithelial atypia (FEA), atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), classic LCIS (C-LCIS), and the variant LCIS forms pleomorphic LCIS (P-LCIS) and florid LCIS (F-LCIS). The natural history of ADH, ALH, and C-…

PMID 42616513
meta analysisn=1135888

The associations between household food insecurity and cancer: A comprehensive systematic review and meta-analysis of observational studies among adults.

Social science & medicine (1982) · 2026

BACKGROUND: Household food insecurity (HFI) is a critical social determinant of health that can adversely influence cancer prevention, treatment, and survivorship, while a cancer diagnosis with its financial and functional consequences may also increase the risk of HFI. This study aimed to examine the associations between HFI and cancer-related outcomes. METHODS: A systematic search was done in PubMed, Embase, Scopus, Web of Science, and Cochrane Library until July 29, 2025. Eligible studies were observational in adults (≥18 years) evaluating the associations between HFI and cancer outcomes, with effects operating in both directions. The quality assessment was done using the Newcastle-Ottawa…

PMID 42685390
clinical guideline

CAR Practice Guidelines on Breast Imaging and Interventions: Breast Intervention and Biopsy Procedures.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026

This guideline presents Part V of the Canadian Association of Radiologists (CAR) Practice Guidelines on Breast Imaging and Intervention and addresses image-guided breast intervention and biopsy procedures. This guideline provides comprehensive recommendations for stereotactic-, tomosynthesis-, ultrasound-, and MRI-guided biopsy, as well as preoperative localization and post-procedural management. Key areas include indications and contraindications, biopsy device and needle selection, tissue marker placement, documentation, radiologic-pathologic correlation, quality assurance, and personnel qualifications. Emphasis is placed on minimally invasive, image-guided procedures as the standard of ca…

PMID 42198851
03

Latest Research — Last 24 Months

04

Treatment Options Studied in the PubMed Collection

These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.

higher-confidence evidence

Antineoplastic Agents

105 linked PMIDs5380 reported cumulative sample signal
Research status
mostly neutral
Outcomes represented
reported clinical outcomes, quality of life, mortality, recurrence, adverse events
Populations represented
general population; triple-negative breast cancer; HER2-positive breast cancer; HER2; triple-negative breast cancer; PD-L1; triple-negative breast cancer; ER; triple-negative breast cancer; HER2
Mechanism
Current clinical interventions for solid tumors are confronted with multiple prominent challenges, including intratumoral hypoxia, constitutively activated endogenous antioxidant defense systems, and inefficient tumor targeting In this study, a multifunctional nanoliposome carrier is developed by co-encapsulation of hemoglobin (Hb), ferric citrate (FC), and chlorin e6 (Ce6), and surface-modified with the iRGD (CRGDKGPDC) peptide to facilitate active tumor targeting and enhance subsequent intratumoral penetration
PMID 39392491PMID 39611862PMID 42888908PMID 38963577PMID 39162830PMID 38761270PMID 39169605PMID 42531966
moderate-confidence evidence

radiotherapy

54 linked PMIDs18240 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, quality of life, mortality, overall survival, adverse events, recurrence, disease-free survival
Populations represented
general population; advanced; early-stage breast cancer; early-stage; HER2
Mechanism
The controlled release of 1-MT inhibits IDO1 activity and reduces L-tryptophan levels, suppressing regulatory T-cell function and mitigating the immunosuppressive tumor microenvironment In breast cancer mouse models, MnO2-R848@CM exhibited highly effective homotargeting properties, rapidly accumulating and persisting at tumor sites
PMID 42413454PMID 37556002PMID 42731947PMID 42765659PMID 39903309PMID 36867303PMID 38012460PMID 42894912
limited evidence

Biomarkers, Tumor

43 linked PMIDs185551 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, recurrence, overall survival, disease-free survival, recurrence-free survival, mortality
Populations represented
general population; HER2; triple-negative breast cancer; metastatic; metastatic breast cancer; metastatic; HER2; early-stage
Mechanism
Consequently, this study is designed to elucidate cellular heterogeneity within the tumor microenvironment (TME) and to identify prospective therapeutic targets, thus enabling individualized treatment approaches for individuals with BRCA, which remains crucial There is a need for novel targets to improve the prognosis of patients with breast cancer
PMID 39708255PMID 42628452PMID 42594438PMID 42772092PMID 42702176PMID 42400645PMID 42284987PMID 39808355
preliminary evidence

Erb-b2 Receptor Tyrosine Kinases

27 linked PMIDs255852 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival, progression-free survival, response rate, adverse events, recurrence, quality of life, objective response rate
Populations represented
HER2-positive breast cancer; HER2; HER2; metastatic; previously treated; HER2; ER; PR; HER2; metastatic breast cancer; metastatic; previously treated; HER2; HER2; older adults
Mechanism
Collectively, these findings identify myricetin as a promising mitochondrial-targeting compound capable of overcoming trastuzumab resistance in HER2+ breast cancer and support its further development as a therapeutic candidate Circ-PPID directly binds to N-acetyltransferase 10 (NAT10) in the nucleus and blocks the interaction between NAT10 and HER2 mRNA, reducing N4-acetylcytidine (ac4C) modification on HER2 exon 25, leading to HER2 mRNA decay
PMID 39342336PMID 42586176PMID 38340287PMID 37103612PMID 36988874PMID 36807216PMID 42700699PMID 38276982
limited evidence

MicroRNAs

24 linked PMIDs— reported cumulative sample signal
Research status
mostly supportive
Outcomes represented
reported clinical outcomes, recurrence, overall survival
Populations represented
general population; triple-negative breast cancer; triple-negative breast cancer; advanced; metastatic
Mechanism
Using miR-155 and miR-10b as model targets, the influence of spacer split position on assay performance was systematically evaluated and further interpreted through structural prediction analysis Through bioinformatics analysis, DSCR9, microRNA-504-5p (miR-504-5p), and G protein-coupled receptor 65 (GPR65) were identified as targets implicated in breast cancer development
PMID 42858625PMID 42659818PMID 42594438PMID 42721511PMID 42702176PMID 38030946PMID 39287790PMID 37248366
limited evidence

Reactive Oxygen Species

23 linked PMIDs6 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, mortality
Populations represented
general population; triple-negative breast cancer; triple-negative breast cancer; metastatic; advanced
Mechanism
Current clinical interventions for solid tumors are confronted with multiple prominent challenges, including intratumoral hypoxia, constitutively activated endogenous antioxidant defense systems, and inefficient tumor targeting In this study, a multifunctional nanoliposome carrier is developed by co-encapsulation of hemoglobin (Hb), ferric citrate (FC), and chlorin e6 (Ce6), and surface-modified with the iRGD (CRGDKGPDC) peptide to facilitate active tumor targeting and enhance subsequent intratumoral penetration
PMID 42710097PMID 42594439PMID 42580200PMID 42941828PMID 38824214PMID 37097396PMID 37848569PMID 42612499
preliminary evidence

ERBB2 protein, human

20 linked PMIDs246312 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival, progression-free survival, recurrence, quality of life, adverse events
Populations represented
HER2; HER2-positive breast cancer; HER2; metastatic; previously treated; HER2; ER; PR; HER2; HER2; older adults; early-stage breast cancer; early-stage; HER2
Mechanism
To address these mechanisms, future therapeutic optimization should move beyond single‑agent selection and toward mechanism‑guided combination therapy, rational sequencing of ADCs with different targets or payloads and the design of next‑generation ADCs Collectively, these findings identify myricetin as a promising mitochondrial-targeting compound capable of overcoming trastuzumab resistance in HER2+ breast cancer and support its further development as a therapeutic candidate
PMID 42700699PMID 38276982PMID 42854434PMID 42934137PMID 42924615PMID 39271787PMID 39342336PMID 42586176
preliminary evidence

Trastuzumab

17 linked PMIDs1075 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival, mortality, recurrence
Populations represented
HER2-positive breast cancer; HER2; HER2; metastatic breast cancer; metastatic; HER2; general population; HER2; older adults; HER2-positive breast cancer; metastatic; HER2
Mechanism
Collectively, these findings identify myricetin as a promising mitochondrial-targeting compound capable of overcoming trastuzumab resistance in HER2+ breast cancer and support its further development as a therapeutic candidate Circ-PPID directly binds to N-acetyltransferase 10 (NAT10) in the nucleus and blocks the interaction between NAT10 and HER2 mRNA, reducing N4-acetylcytidine (ac4C) modification on HER2 exon 25, leading to HER2 mRNA decay
PMID 39342336PMID 42962156PMID 42586176PMID 38340287PMID 37103612PMID 37120775PMID 42509656PMID 38480976
preliminary evidence

Protein Kinase Inhibitors

16 linked PMIDs79035 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, mortality, adverse events, overall survival, progression-free survival, serious adverse events, objective response rate, response rate
Populations represented
triple-negative breast cancer; general population; HER2; metastatic; HER2; triple-negative breast cancer; ER; PR; HER2; advanced
Mechanism
Triple-negative breast cancer (TNBC) remains a highly aggressive malignancy with limited therapeutic targets and frequent treatment resistance In this study, a new series of hydrazide-hydrazone/thiourea derivatives (MIH-31-46) was rationally designed, synthesized, and evaluated as potential anticancer agents targeting vascular endothelial growth factor receptor-2 (VEGFR-2)
PMID 42753957PMID 42636671PMID 42759396PMID 37162644PMID 42731184PMID 42800115PMID 38598164PMID 42784856
limited evidence

Doxorubicin

15 linked PMIDs11 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival
Populations represented
general population; triple-negative breast cancer; localized
Mechanism
The mCLPS1/anti-mPEG BsAb significantly enhanced the therapeutic efficacy of mPEGylated liposomal doxorubicin (LD) in targeting α9-nAChR-positive breast cancer Mechanistically, COL5A1 interacted with TGM2, inhibiting its K48-linked ubiquitination-mediated degradation, thereby enhancing chemoresistance and increasing IL-6 secretion
PMID 38884850PMID 38198045PMID 37133768PMID 37921980PMID 41964565PMID 38161196PMID 37231169PMID 37594703
limited evidence

Antineoplastic Agents, Phytogenic

13 linked PMIDs— reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, mortality
Populations represented
general population; triple-negative breast cancer
Mechanism
Mechanistically, scandine N4-oxide inhibited the secretion of chemokines by regulating JAK2/STAT3 signaling pathway of M2 type microglial cells, thereby suppressing the recruitment of MDSCs CONCLUSION: XXP exhibits pharmacological activity that inhibits 4T1 breast cancer cell proliferation and promotes apoptosis in vitro and in vivo
PMID 42716268PMID 42710725PMID 38568289PMID 37955690PMID 42648410PMID 42632405PMID 42967601PMID 38145425
preliminary evidence

Receptors, Estrogen

11 linked PMIDs139703 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, recurrence, progression-free survival, quality of life, adverse events, overall survival, objective response rate, response rate
Populations represented
ER; ER; PR; HER2; early-stage; stage I; HER2; HER2; metastatic breast cancer; locally advanced; advanced; metastatic; first-line; HER2; triple-negative breast cancer; ER; PR; HER2
Mechanism
Various concentrations of α1- and α2- AR-specific agonists and antagonists were incubated in vitro with estrogen receptor-positive (ER +) MCF-7, and ER (-) MDA MB-231 cells to examine the secretions of VEGF-A, VEGF-C, and nitric oxide (NO), and expression of signaling molecules- p-ERK, p-CREB, and p-Akt on the proliferation of breast cancer cell lines Cellular proliferation, VEGF-A and NO secretion, expression of p-ERK, p-CREB, and p-Akt were enhanced in MCF-7 cells treated with α1-AR agonist while VEGF-C secretion alone was enhanced in MDA MB-231 cells
PMID 37634223PMID 42839117PMID 38526769PMID 42319457PMID 41528428PMID 42762561PMID 42632205PMID 42579983
preliminary evidence

endocrine therapy

11 linked PMIDs2261 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, quality of life
Populations represented
general population; advanced; ER; HER2; HER2
Mechanism
Mechanistically, the inclusion of ALDOA exon 7.2 enhances the translation efficiency of the transcript, resulting in increased ALDOA protein expression, mTOR pathway activity, and the promotion of TAM resistance in breast cancer cells Therefore, this study provides a promising therapeutic avenue targeting ALDOA to combat TAM resistance
PMID 38332357PMID 39191498PMID 38100011PMID 39164523PMID 42964294PMID 42501860PMID 36350381PMID 42964697
limited evidence

Paclitaxel

11 linked PMIDs280 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes
Populations represented
general population; triple-negative breast cancer
Mechanism
Here, a computational framework has been developed which can be used to identify key genes that can be linked with clinical drug response and progression of cancer, offering an immense opportunity to predict potential prognostic biomarkers and therapeutic targets For mitochondria targeting, triphenylphosphonium (TPP) with a delocalized charge and hydrophobic nature was utilized as a moiety to facilitate penetration through a phospholipid membrane of mitochondria
PMID 42623741PMID 38153604PMID 41964565PMID 39443414PMID 38446390PMID 37148401PMID 42162664PMID 42601012
preliminary evidence

Proto-Oncogene Proteins c-akt

10 linked PMIDs9500 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival, progression-free survival, objective response rate, response rate, adverse events, quality of life
Populations represented
general population; triple-negative breast cancer; metastatic breast cancer; metastatic; first-line; ER; HER2; metastatic breast cancer; early-stage; advanced; metastatic
Mechanism
CONCLUSION: XXP exhibits pharmacological activity that inhibits 4T1 breast cancer cell proliferation and promotes apoptosis in vitro and in vivo Tumor cell lines (MCF-7 and MDA-MB-231) and the non-tumor mammary epithelial cell line MCF-10A were treated with T4 alone or in combination with the thyroid hormone receptor antagonist 1-850
PMID 42648410PMID 42705592PMID 42941986PMID 38869753PMID 38767753PMID 36754932PMID 42668127PMID 42727187
limited evidence

tamoxifen

10 linked PMIDs1780 reported cumulative sample signal
Research status
conflicting evidence
Outcomes represented
reported clinical outcomes
Populations represented
general population
Mechanism
These findings highlight the intricate relationship between TAM, gut microbiota, and BA metabolism, suggesting that targeting the gut-liver FXR axis with HDCA may serve as a promising therapeutic strategy for alleviating TAM-associated liver injury TAM-induced eryptosis is characterized by breakdown of membrane asymmetry, inhibition of AChE activity, Ca2+ accumulation, cell shrinkage, and oxidative stress
PMID 38332357PMID 39191498PMID 39349870PMID 42953174PMID 41482667PMID 37848569PMID 39164523PMID 38393520
05

Conflicting Research

higher-confidence evidence

Antineoplastic Agents · multiple reported outcomes

84 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 80harm: 1null: 2benefit: 1
PMID 39392491PMID 42825487PMID 38700795PMID 39012405PMID 42878787PMID 39738632PMID 39611862PMID 42888908PMID 40445852PMID 39001910
higher-confidence evidence

radiotherapy · multiple reported outcomes

63 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 57null: 5harm: 1
PMID 42413454PMID 42958221PMID 37755486PMID 42830996PMID 36928164PMID 37556002PMID 42731947PMID 42765659PMID 39903309PMID 42479004
higher-confidence evidence

tamoxifen · multiple reported outcomes

18 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
benefit: 1null: 1unknown: 16
PMID 38332357PMID 39191498PMID 42384406PMID 42892237PMID 39349870PMID 42963866PMID 42955022PMID 42953174PMID 41482667PMID 42967149
higher-confidence evidence

Contrast Media · multiple reported outcomes

17 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 14harm: 2benefit: 1
PMID 42198829PMID 42198826PMID 42537885PMID 42867374PMID 42791173PMID 39060886PMID 42166016PMID 42947077PMID 39496884PMID 42141291
higher-confidence evidence

Erb-b2 Receptor Tyrosine Kinases · multiple reported outcomes

17 studies

Status: apparently conflicting; different clinical questions. Population: HER2. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 14harm: 1benefit: 1null: 1
PMID 41345476PMID 42825938PMID 37120775PMID 42229584PMID 42632205PMID 42308863PMID 42930185PMID 42613139PMID 42700699PMID 38276982
higher-confidence evidence

ERBB2 protein, human · multiple reported outcomes

14 studies

Status: apparently conflicting; different clinical questions. Population: HER2. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 12benefit: 1null: 1
PMID 41345476PMID 42825938PMID 42308863PMID 42930185PMID 42613139PMID 42700699PMID 38276982PMID 38363315PMID 38758231PMID 42854434
higher-confidence evidence

Aromatase Inhibitors · multiple reported outcomes

6 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
benefit: 1null: 1unknown: 3mixed: 1
PMID 38332357PMID 39191498PMID 31839281PMID 37592052PMID 42735742PMID 39136781
moderate-confidence evidence

Erb-b2 Receptor Tyrosine Kinases · multiple reported outcomes

5 studies

Status: apparently conflicting; different clinical questions. Population: metastatic breast cancer; metastatic; first-line; HER2. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
benefit: 1null: 1unknown: 3
PMID 42836919PMID 42898011PMID 42854349PMID 38310597PMID 36920662
moderate-confidence evidence

radiotherapy · multiple reported outcomes

5 studies

Status: apparently conflicting; different clinical questions. Population: HER2. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 4mixed: 1
PMID 34380636PMID 42904112PMID 42964571PMID 42509656PMID 36897549
higher-confidence evidence

Analgesics, Opioid · reported clinical outcomes

4 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 2harm: 1null: 1
PMID 42864611PMID 42686359PMID 38777932PMID 36753003
moderate-confidence evidence

Tryptophan · reported clinical outcomes

4 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
harm: 1unknown: 2null: 1
PMID 42033145PMID 39708255PMID 37097396PMID 37014514
moderate-confidence evidence

radiotherapy · multiple reported outcomes

4 studies

Status: apparently conflicting; different clinical questions. Population: early-stage breast cancer; early-stage. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 2harm: 1benefit: 1
PMID 33368762PMID 42531378PMID 42753688PMID 38506978
06

Failed or Negative Trials

07

Emerging and Experimental Research

08

Evidence Gaps

Detailed risk-of-bias assessment remains limited

PubMed abstracts often do not include enough methodological detail for a complete study-level risk-of-bias assessment.

R

Complete Ranked PubMed Index

The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.

Current Standard Of Care80 records
Rank112.0
Clinical guideline or consensus statement

CAR Practice Guidelines on Breast Imaging and Interventions: Contrast-Enhanced Mammography.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42198829

This guideline presents Part II of the Canadian Association of Radiologists (CAR) Practice Guidelines on Breast Imaging and Intervention and addresses the clinical application of contrast-enhanced mammography (CEM). Reflecting the expanding evidence base and increasing clinical adoption of CEM since 2016, this guideline provides updated recommendations on indications, examination technique, contrast administration, image interpretation, reporting standards, quality control, and patient safety. Particular emphasis i…

Rank110.0
Clinical guideline or consensus statement

CAR Practice Guidelines on Breast Imaging and Interventions: Breast Magnetic Resonance Imaging.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42198826

This guideline presents Part IV of the Canadian Association of Radiologists (CAR) Practice Guidelines on Breast Imaging and Intervention and addresses breast magnetic resonance imaging (MRI). As the most sensitive imaging modality for breast cancer detection, MRI plays an established and expanding role in screening, staging, problem-solving, and treatment monitoring. This guideline provides updated recommendations on indications, technical requirements, contrast administration, reporting standards, quality assuranc…

Rank110.0
Clinical guideline or consensus statement

CAR Practice Guidelines on Breast Imaging and Interventions: Mammography and Digital Breast Tomosynthesis.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42198822

This guideline presents Part I of the Canadian Association of Radiologists (CAR) Practice Guidelines on Breast Imaging and Intervention and focuses on mammography and digital breast tomosynthesis (DBT). Developed by the CAR Breast Imaging Working Group, this guideline provides updated, evidence-based recommendations for screening and diagnostic mammography, reflecting advances in digital imaging, tomosynthesis, artificial intelligence, and quality assurance since the previous consolidated guidelines published in 20…

Rank110.0
Clinical guideline or consensus statement

Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42462191

UNLABELLED: ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the https://www.asco.org/practice-patients/guidelines/guideline-methodology. ASCO Guidelines follow the https://www.asco.org/about-asco/legal/conflict-interest-coi.Clinical Practice Guidelines and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options. It is inten…

Rank110.0
Clinical guideline or consensus statement

CAR Practice Guidelines on Breast Imaging and Interventions: Breast Ultrasound.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42198835

This guideline presents Part III of the Canadian Association of Radiologists (CAR) Practice Guidelines on Breast Imaging and Intervention and focuses on breast ultrasound. Recommendations address the diagnostic, supplemental screening, and interventional roles of ultrasound in contemporary breast imaging practice. Topics include clinical indications, equipment and technical performance, axillary assessment, documentation, structured reporting using BI-RADS®, quality assurance, and personnel qualifications, with att…

Rank110.0
Clinical guideline or consensus statement

CAR Practice Guidelines on Breast Imaging and Interventions: Breast Intervention and Biopsy Procedures.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42198851

This guideline presents Part V of the Canadian Association of Radiologists (CAR) Practice Guidelines on Breast Imaging and Intervention and addresses image-guided breast intervention and biopsy procedures. This guideline provides comprehensive recommendations for stereotactic-, tomosynthesis-, ultrasound-, and MRI-guided biopsy, as well as preoperative localization and post-procedural management. Key areas include indications and contraindications, biopsy device and needle selection, tissue marker placement, docume…

Rank110.0
Clinical guideline or consensus statement

CAR/BRC Recommendations for Management of Axillary Lymphadenopathy Following COVID-19 Vaccination.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42175918

Axillary lymphadenopathy following vaccination has long been recognized as a benign, self-limited immune response, but its increased frequency during the COVID 19 vaccination campaign created diagnostic uncertainty and contributed to delays in breast imaging and unnecessary follow-up. Early conservative guidance, issued in the context of limited evidence, led to postponed screening examinations and increased patient anxiety. Since then, robust prospective and longitudinal data have demonstrated an extremely low, ne…

Rank110.0
Clinical guideline or consensus statement

Italian guidelines for age range and test interval in breast cancer screening programmes: GRADE-ADOLOPMENT of the European guidelines.

La Radiologia medica · 2024 · PMID 39460891

A guideline panel formulated a set of recommendations for breast cancer screening and diagnosis to implement clinical activities in Italy in alignment with the European Breast Cancer Guidelines on Screening and Diagnosis (European Commission Initiative on Breast Cancer-ECIBC). The panel issued national recommendations through adopting, adapting, and/or developing recommendations from the European guidelines (ADOLOPMENT approach). This process utilizes the Grading of Recommendations Assessment, Development, and Eval…

Rank110.0
Clinical guideline or consensus statement

S1 guideline sweat gland carcinoma.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026 · PMID 42412045

The current classification of sweat gland carcinomas is based on histomorphological characteristics and distinguishes between more than 20 entities. Most patients are older, but some subtypes also affect middle-aged and younger patients. The majority of tumors arise de novo. Sweat gland carcinomas have nonspecific clinical features. The tumors are usually located in the head and neck area and on extremities, with the exception of extramammary Paget's carcinoma, which has an anogenital predilection. Sweat gland carc…

Rank110.0
Clinical guideline or consensus statement

Preventing common shape deformities and complications in therapeutic mammoplasty: A practical guide.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42413454

Therapeutic mammoplasty (TM) combines wide local excision with immediate volume displacement, enabling oncologically safe breast conservation while maintaining breast shape. Despite its benefits, postoperative complications and aesthetic deformities remain clinically relevant and may adversely affect patient satisfaction. Common sequelae include nipple-areola complex (NAC) malposition or necrosis, fat necrosis, bottoming-out, boxy breast contours, wound breakdown, and radiotherapy-associated fibrosis. This expert-o…

Rank110.0
Clinical guideline or consensus statement

American Society of Breast Surgeons, Society of Breast Imaging, and College of American Pathology 2026 Guidelines for the Management of Proliferative Lesions With Atypia and Lobular Carcinoma In Situ.

JAMA surgery · 2026 · PMID 42616513

IMPORTANCE: Many patients are diagnosed with atypical lesions or lobular carcinoma in situ (LCIS); however, evidence- and consensus-based guidelines for the management of many of these lesions are limited. OBSERVATIONS: The American Society of Breast Surgeons, in collaboration with the Society of Breast Imaging and College of American Pathology, assembled a steering group to create guidelines for the management of atypical lesions and LCIS, inclusive of flat epithelial atypia (FEA), atypical ductal hyperplasia (ADH…

Rank110.0
Clinical guideline or consensus statement

Pharmacotherapy for older adults with cancer: a digest of the Japanese clinical practice guidelines (second edition)-breast cancer.

International journal of clinical oncology · 2026 · PMID 42629540

BACKGROUND: The number of older adults with early breast cancer is rising in aging societies. Optimal perioperative systemic therapy for this population remains challenging, owing to heterogeneity in functional status, comorbidities, and the limited representation of older patients in clinical trials. METHODS: This article presents an English digest of the Japanese Clinical Practice Guidelines for Pharmacotherapy in Older Adults with Cancer (Second Edition), focusing on perioperative systematic therapy for early br…

Rank110.0
Clinical guideline or consensus statement

ESR Essentials: diagnostic work-up in patients with symptomatic breast disease-practice recommendations by the European Society of Breast Imaging.

European radiology · 2025 · PMID 39085641

Breast complaints are frequent reasons for consultations in primary care or breast clinics. Breast pain, breast lumps, and nipple discharge are the most common complaints. Less common symptoms such as skin changes and axillary abnormalities also require specific diagnostic approaches. Imaging the symptomatic breast should be performed by appropriately trained breast radiologists following the best practice guidelines and quality standards. Full-field digital mammography (FFDM), digital breast tomosynthesis (DBT), a…

Rank109.7
Systematic review or meta-analysis

Brain metastases in triple-negative breast cancer: a systematic review of current trends, treatment strategies, and outcomes.

Journal of neuro-oncology · 2026 · PMID 42550373

PURPOSE: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a high risk of early central nervous system dissemination and poor outcomes after brain metastasis (BM). This systematic review summarizes current evidence on incidence, treatment strategies, outcomes, guidelines, and ongoing trials in TNBC-associated BM. METHODS: The review followed PRISMA guidance and was registered in the Open Science Framework (OSF.IO/6TDRF). MEDLINE, Scopus, Web of Science, DOAJ, and ClinicalTrials.gov we…

Rank107.7
Systematic review or meta-analysis

Risk of locoregional recurrence after breast cancer surgery by molecular subtype-a systematic review and network meta-analysis.

Irish journal of medical science · 2024 · PMID 39331262

BACKGROUND: The prevention of locoregional recurrence (LRR) is crucial in breast cancer, as it translates directly into reduced breast cancer-related death. Breast cancer is subclassified into distinct intrinsic biological subtypes with varying clinical outcomes. AIMS: To perform a systematic review and network meta-analysis (NMA) to determine the rate of LRR by breast cancer molecular subtype. METHODS: A NMA was performed as per PRISMA-NMA guidelines. Molecular subtypes were classified by St Gallen expert consensu…

Rank107.0
Clinical guideline or consensus statementResult signal: harm

Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.

BJOG : an international journal of obstetrics and gynaecology · 2022 · PMID 34672090

This paper deals with the use of hormone replacement therapy (HRT) after the removal of fallopian tubes and ovaries to prevent ovarian cancer in premenopausal high risk women. Some women have an alteration in their genetic code, which makes them more likely to develop ovarian cancer. Two well-known genes which can carry an alteration are the BRCA1 and BRCA2 genes. Examples of other genes associated with an increased risk of ovarian cancer include RAD51C, RAD51D, BRIP1, PALB2 and Lynch syndrome genes. Women with a s…

Rank102.6
Systematic review or meta-analysis

Topical non-steroidal agents for the prevention of radiation dermatitis: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023 · PMID 36928164

PURPOSE: Radiation dermatitis (RD) is a common side effect of radiation therapy, affecting a majority of breast and head and neck cancer patients with a negative impact on quality of life. Currently, no consensus exists regarding the prevention of RD. METHODS: PubMed, Embase and Cochrane databases (1946 to December 2022) were searched using PRISMA guidelines to identify randomized controlled trials (RCTs) that investigated the use of topical non-steroidal agents in the prevention of RD in patients undergoing radiot…

Rank100.0
Systematic review or meta-analysis

Measures of Thriving in Breast Cancer: A COSMIN Systematic Review of Psychometric Properties.

Oncology nursing forum · 2026 · PMID 42690383

PROBLEM IDENTIFICATION: Thriving, a construct reflecting personal growth, resilience, and emotional vitality after adversity, is gaining attention in oncology and health-related quality-of-life research. However, consensus is lacking on which patient-reported outcome measures (PROMs) best assess thriving in individuals with breast cancer. LITERATURE SEARCH: A systematic search across nine databases identified studies reporting the development or psychometric evaluation of PROMs for thriving in adults. DATA EVALUATI…

Rank98.0
Systematic review or meta-analysis

Assessment methods of pathological complete response in neoadjuvant head and neck cancer clinical trials: a scoping review.

The journal of pathology. Clinical research · 2026 · PMID 42811432

Head and neck cancer (HNC) trials have demonstrated pathological complete response (pCR) in patients receiving neoadjuvant treatment prior to surgery; however, systematic reviews have reported marked variation in pCR rates. This scoping review was designed to determine the definition, criteria, and assessment methodologies for pCR in interventional neoadjuvant HNC clinical trials. The review was conducted in accordance with the JBI Manual for Evidence Synthesis and the protocol prospectively registered. Medical dat…

Rank97.0
Systematic review or meta-analysis

Assessment tools for stigma in breast cancer patients based on COSMIN guidelines: a systematic review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023 · PMID 38150049

OBJECTIVE: The objective of this study was to conduct a systematic review of the measurement properties and methodological quality of stigma assessment tools designed for breast cancer patients. The aim was to provide clinical medical staff with a foundation for selecting high-quality assessment tools. METHODS: A comprehensive computer search was carried out across various databases, including SinoMed, China National Knowledge Infrastructure (CNKI), Wanfang Database, China Science and Technology Journal Database(VI…

Rank93.0
Systematic review or meta-analysis

Local treatment in oligometastasis from breast cancer: an overview.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023 · PMID 37106239

Oligometastasic breast cancer (OMBC) consists of breast cancer patient with a limited number of systemic metastases (≤ 5), all of them candidates for local ablative treatment with the intention of achieving long-term control of the metastasis and, eventually, an increase in survival The first consensus for the management of patients with oligometastatic breast cancer (OMBC) was published in 2007, establishing that a more aggressive multidisciplinary strategy is recommended in order to increase the survival while ma…

Rank85.0
Randomized clinical study

A Hidden Hurdle: The Plastic Surgery Bottleneck in Breast Cancer Care.

The American surgeon · 2026 · PMID 42089447

Timely surgical intervention is critical in breast cancer, with consensus supporting surgery within eight weeks of diagnosis to optimize survival. Immediate breast reconstruction (IBR) has been associated with delays related to insurance status, socioeconomic factors, race, and reconstructive intent. While barriers to accessing IBR have been studied, few investigations have quantified their impact on surgical timing and outcomes. A literature review was conducted using PubMed to identify studies published between 2…

Rank85.0
Randomized clinical study

Abundance is not survival: Intratumoural immune-cell fate as a missing endpoint in antibody-drug conjugate and checkpoint blockade combinations for triple-negative breast cancer.

Critical reviews in oncology/hematology · 2026 · PMID 42810559

Antibody-drug conjugates (ADCs) have reshaped metastatic triple-negative breast cancer, and combining them with checkpoint inhibitors is close to consensus: cytotoxic payloads kill tumour cells in ways that release antigen and expose damage-associated signals. We argue that a specific endpoint is missing from both sides of the question. Preclinical ADC studies report the abundance and activation phenotype of intratumoural immune populations, not their survival, and that reflects endpoint convention, not technical l…

Rank77.4
Multicenter clinical study

Ultrasound-based deep learning in the establishment of a breast lesion risk stratification system: a multicenter study.

European radiology · 2023 · PMID 36418619

OBJECTIVES: To establish a breast lesion risk stratification system using ultrasound images to predict breast malignancy and assess Breast Imaging Reporting and Data System (BI-RADS) categories simultaneously. METHODS: This multicenter study prospectively collected a dataset of ultrasound images for 5012 patients at thirty-two hospitals from December 2018 to December 2020. A deep learning (DL) model was developed to conduct binary categorization (benign and malignant) and BI-RADS categories (2, 3, 4a, 4b, 4c, and 5…

Rank70.0
Multicenter clinical study

Multiparametric MRI for non-mass enhancement breast lesions: a prospective diagnostic accuracy study.

European radiology · 2026 · PMID 42166016

OBJECTIVES: To evaluate the diagnostic accuracy of multiparametric breast MRI combining dynamic contrast-enhanced imaging with diffusion-weighted imaging (DWI) for differentiating benign from malignant non-mass enhancement (NME) breast lesions. MATERIALS AND METHODS: This prospective diagnostic accuracy study recruited patients from seven tertiary centers with centralized imaging over a 20-month period. The index test was multiparametric MRI, including morphological assessment, kinetic curve analysis, and DWI with …

Diagnosis And Screening307 records
Rank110.4
Systematic review or meta-analysis

Prevalence of anxiety and depression in breast cancer patients: a meta-analysis.

Frontiers in psychology · 2026 · PMID 42952549

INTRODUCTION: Depression and anxiety are frequently reported among women with breast cancer, but prevalence estimates vary substantially across settings and assessment instruments. This meta-analysis synthesized recent international evidence and examined overall, severity-stratified, and instrument-specific prevalence estimates. METHODS: We searched PubMed, Web of Science, Embase, the Cochrane Library, APA PsycINFO, and Scopus for observational studies published from January 2015 through September 10, 2026. Proport…

Rank110.0
Systematic review or meta-analysis

Clinicopathological response and survival outcomes of HER2-low versus HER2-zero early breast Cancer: A systematic review and Meta-analysis.

Clinica chimica acta; international journal of clinical chemistry · 2027 · PMID 42248318

BACKGROUND: Breast cancer is the most common malignant tumor in women. Human epidermal growth factor receptor 2 (HER2) is a key biomarker for classification and treatment. A subgroup with HER2-low expression has been identified, but existing evidence is heterogeneous. This systematic review and meta-analysis compared pathological response and survival outcomes between HER2-low and HER2-zero early-stage breast cancer to clarify prognostic features. METHODS: This study followed PRISMA guidelines and was registered in…

Rank110.0
Clinical guideline or consensus statement

ESR Essentials: diagnostic work-up in patients with symptomatic breast disease-practice recommendations by the European Society of Breast Imaging.

European radiology · 2025 · PMID 39085641

Breast complaints are frequent reasons for consultations in primary care or breast clinics. Breast pain, breast lumps, and nipple discharge are the most common complaints. Less common symptoms such as skin changes and axillary abnormalities also require specific diagnostic approaches. Imaging the symptomatic breast should be performed by appropriately trained breast radiologists following the best practice guidelines and quality standards. Full-field digital mammography (FFDM), digital breast tomosynthesis (DBT), a…

Rank110.0
Systematic review or meta-analysis

Sensitive Period Analysis of Adulthood BMI and Cancer Risk: An Individual Participant Data Meta-Analysis of Over 720,000 Participants in the ABACus 2 Consortium.

International journal of cancer · 2026 · PMID 41952250

At least 13 cancers are linked to obesity. We analyse time-to-event data using Sensitive Period Analysis to explore whether associations between body mass index (BMI) and cancer incidence vary throughout adulthood to inform cancer prevention strategies, policy and weight management trials of optimal intervention ages. Using the European Prospective Investigation into Cancer and Nutrition cohort, Atherosclerosis Risk in Communities study, Women's Health Initiative, Prostate, Lung, Colorectal, Ovarian Cancer Screenin…

Rank110.0
Clinical guideline or consensus statement

Italian guidelines for age range and test interval in breast cancer screening programmes: GRADE-ADOLOPMENT of the European guidelines.

La Radiologia medica · 2024 · PMID 39460891

A guideline panel formulated a set of recommendations for breast cancer screening and diagnosis to implement clinical activities in Italy in alignment with the European Breast Cancer Guidelines on Screening and Diagnosis (European Commission Initiative on Breast Cancer-ECIBC). The panel issued national recommendations through adopting, adapting, and/or developing recommendations from the European guidelines (ADOLOPMENT approach). This process utilizes the Grading of Recommendations Assessment, Development, and Eval…

Rank107.6
Systematic review or meta-analysis

Prognosis and therapeutic choices for occult breast cancer in female patients: a systematic review and meta-analysis.

BMC surgery · 2026 · PMID 42958221

BACKGROUND: Occult breast cancer (OBC) is a rare subtype characterized by axillary lymph node (LN) metastasis without an identifiable primary breast lesion. Owing to its rarity, optimal management remains controversial. We performed a systematic review and meta-analysis to comprehensively evaluate the clinicopathological characteristics, prognosis, and treatment outcomes of female patients with OBC. METHODS: A systematic review and meta-analysis were conducted using PubMed/MEDLINE, Embase, and the Cochrane Library …

Rank107.6
Systematic review or meta-analysis

Association between hair cortisol concentration and cancer-related outcomes in adult patients: A systematic review.

Psychoneuroendocrinology · 2026 · PMID 42784920

BACKGROUND: Chronic stress, through sustained hypothalamic-pituitary-adrenal (HPA) axis activation, has been implicated in cancer progression. Hair cortisol concentration (HCC) offers a unique retrospective window into cumulative cortisol exposure, yet its relationship with cancer outcomes has never been systematically examined. OBJECTIVE: To critically appraise the evidence linking HCC to cancer-related outcomes in adults and to identify the methodological gaps that currently limit this emerging field. METHODS: Fo…

Rank106.0
Systematic review or meta-analysis

Physical prehabilitation in patients with breast cancer: a systematic review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025 · PMID 39757306

INTRODUCTION: In 2023, 35,000 new cases of breast cancer were diagnosed, becoming the first type of tumour diagnosed in Spain. This tumour and its treatments generate important changes in the patient's quality of life. Alterations in the range of motion, pain and both physical and psychological disability are some of the effects that breast cancer generates in patients. Physical prehabilitation could be an opportunity to prevent some of these adverse effects. OBJECTIVE: The objective of this review was to analyse t…

Rank100.0
Systematic review or meta-analysis

Instruments for measuring body image in breast cancer patients: a systematic review of measurement properties.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026 · PMID 42701946

PURPOSE: To evaluate the psychometric properties of PROMs for measuring body image in breast cancer patients. METHODS: In December 2024, a psychometric systematic review was performed in the nine databases. The COSMIN checklist was employed to evaluate the methodological quality and psychometric properties of the included body image measures. The level of evidence was assessed using the GRADE framework, and final recommendations were formulated for the scale. RESULTS: Thirty-eight articles evaluating fifteen PROMs …

Rank100.0
Systematic review or meta-analysis

Association of peritumoral region features assessed on breast MRI and prognosis of breast cancer: a systematic review and meta-analysis.

European radiology · 2024 · PMID 38334760

BACKGROUND: Increasing attention has been given to the peritumoral region. However, conflicting findings have been reported regarding the relationship between peritumoral region features on MRI and the prognosis of breast cancer. PURPOSE: To evaluate the relationship between peritumoral region features on MRI and prognosis of breast cancer. MATERIALS AND METHODS: A retrospective meta-analysis of observational studies comparing either qualitative or quantitative assessments of peritumoral MRI features on breast canc…

Rank99.8
Randomized controlled trial

Real-Time Electronic Patient-Reported Outcome Monitoring With Digital Triage and Care-Team Integration in Early Breast Cancer: ENABLE Randomized Controlled Trial.

Journal of medical Internet research · 2026 · PMID 42954133

BACKGROUND: Electronic patient-reported outcomes (ePROs) can support patient-centered oncology care, but in early breast cancer, it is unclear whether real-time ePRO-triggered triage adds benefit beyond lower-intensity app-based support and scheduled ePRO collection. OBJECTIVE: We tested whether adding weekly ePRO screening, rule-based triage, and care-team escalation to app-based support improves health-related quality of life (HRQoL) during systemic therapy for early breast cancer. METHODS: ENABLE was a multicent…

Rank99.7
Systematic review or meta-analysis

Organizational impact of systemic implementation of digital breast tomosynthesis as a primary test for breast cancer screening in Italy.

La Radiologia medica · 2024 · PMID 39042203

PURPOSE: We present a comprehensive investigation into the organizational, social, and ethical impact of implementing digital breast tomosynthesis (DBT) as a primary test for breast cancer screening in Italy. The analyses aimed to assess the feasibility of DBT specifically for all women aged 45-74, women aged 45-49 only, or those with dense breasts only. METHODS: Questions were framed according to the European Network of Health Technology Assessment (EuNetHTA) Screening Core Model to produce evidence for the resour…

Rank99.0
Systematic review or meta-analysis

Isoliquiritigenin in breast cancer therapy: from mechanistic insights to advanced nano-enabled delivery strategies.

Biochemical pharmacology · 2026 · PMID 42913800

Isoliquiritigenin (ISL), a chalcone from Glycyrrhiza species, exhibits multi-target anti-breast cancer activity but faces pharmacokinetic limitations. This review synthesizes evidence for ISL's molecular targets and mechanisms and evaluates nano-delivery strategies. In preclinical models, ISL inhibits proliferation via miR-374a/PTEN/Akt, reverses EMT through miR-200c/C-JUN/β-catenin, targets cancer stem cells via GRP78 inhibition and WIF1 reactivation, suppresses aromatase and COX-2, modulates osteoclast activity, …

Rank98.4
Randomized controlled trial

Acceptability of de-intensified screening for women at low risk of breast cancer: a randomised online experimental survey.

BMC cancer · 2024 · PMID 39243000

BACKGROUND: Risk-stratified approaches to breast screening show promise for increasing benefits and reducing harms. But the successful implementation of such an approach will rely on public acceptability. To date, research suggests that while increased screening for women at high risk will be acceptable, any de-intensification of screening for low-risk groups may be met with less enthusiasm. We report findings from a population-based survey of women in England, approaching the age of eligibility for breast screenin…

Rank98.1
Randomized controlled trialCorrection flagged

Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.

JAMA · 2026 · PMID 41385349

IMPORTANCE: Individual breast cancer risk can guide screening initiation, frequency, use of supplemental imaging, and preventive measures to improve breast cancer screening by shifting resources from low-risk women to high-risk women. OBJECTIVE: To determine whether risk-based breast cancer screening is a feasible alternative to annual mammography. DESIGN, SETTING, AND PARTICIPANTS: Parallel-group, pragmatic, multicenter randomized clinical trial comparing risk-based (n = 14 212) with annual (n = 14 160) breast can…

Rank97.6
Randomized controlled trial

Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical Trial.

JAMA internal medicine · 2026 · PMID 41385723

IMPORTANCE: The prevalence of pathogenic or likely pathogenic variants (PVs) in breast cancer susceptibility genes in the US population-regardless of family history risk factors-remains largely unknown because population-based genetic screening is not routinely performed. OBJECTIVE: To identify the prevalence of PVs in a large cohort of women offered criteria-independent genetic testing and to evaluate the relationship of test positivity to family history and other patient characteristics. DESIGN, SETTING, AND PART…

Rank97.2
Randomized controlled trial

"Getting Out of a Dark Place": a qualitative exploration of the impact, current coping, and what people with breast cancer hope to gain by participating in a fear of recurrence clinical trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39508951

PURPOSE: Many people with breast cancer (PwBC) experience psychological distress, including fear of cancer recurrence (FCR). Clinical levels of FCR can negatively impact quality of life. While the FCR trajectory may vary according to age, stage at diagnosis, and imminent exams, FCR levels tend to remain relatively stable over time without intervention. Understanding FCR's impact and how PwBC cope with FCR can improve care. This study aimed to explore the nature of FCR and coping mechanisms by analyzing responses to…

Rank97.2
Randomized controlled trialResult signal: null

Correlation of CTCAE and patient-reported breast radiation dermatitis symptom scores.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39556198

BACKGROUND AND PURPOSE: Clinicians use the CTCAE scale to grade radiation dermatitis (RD) based on edema, erythema, and desquamation. The purpose of this study was to correlate the CTCAE scores with the severity of patient-reported symptoms using a skin symptom assessment (SSA) and the Radiation-Induced Skin Reaction Assessment Scale (RISRAS). MATERIALS AND METHODS: This is a secondary analysis of a randomized controlled trial involving 376 patients receiving Mepitel Film or standard-of-care for RD prophylaxis. The…

Rank96.0
Systematic review or meta-analysis

GlycoRNA-related cellular program scoring identifies Siglec- and myeloid-associated tumor microenvironments for glycoRNA validation.

Frontiers in immunology · 2026 · PMID 42947688

BACKGROUND: Glycosylated RNAs (glycoRNAs) represent a recently recognized connection between RNA biology and cell-surface glycobiology. However, whether glycoRNA-related processes are relevant to human tumors remains unclear, partly because direct glycoRNA measurements are not yet available across large cancer cohorts. We therefore used transcriptomic data to identify tumor settings in which glycoRNA-related programs may be most suitable for further experimental validation. METHODS: We curated a glycoRNA-focused li…

Rank96.0
Systematic review or meta-analysis

Survival After Risk-Reducing Mastectomy in Patients With Pathogenic Variants in BRCA1 and BRCA2: A Network Meta-Analysis.

JAMA network open · 2026 · PMID 42961418

IMPORTANCE: The independent survival benefit of risk-reducing mastectomy (RRM), separate from risk-reducing salpingo-oophorectomy (RRSO), remains uncertain among patients with pathogenic variants (PVs) in BRCA1 and BRCA2 genes. OBJECTIVE: To evaluate the association of RRM, magnetic resonance imaging (MRI)-based screening, and mammography alone with all-cause and breast cancer-specific mortality using RRSO-adjusted estimates. DATA SOURCES: MEDLINE, Embase, and Web of Science were searched from January 1, 1990, to M…

Rank95.5
Randomized controlled trial

Exploring the effect of exercise training on breast cancer's pathologic response and tumor immune microenvironment after neoadjuvant chemotherapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39432116

BACKGROUND: Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) and the percentage of tumor-infiltrating lymphocytes (TILs) are established prognostic biomarkers in early breast cancer (BC). While exercise training is effective as supportive care throughout the BC journey, its impact on the efficacy of NAC is unknown. This study aims to investigate the influence of a supervised exercise training program (SETP) on pCR and TILs in BC women undergoing NAC. METHODS: Retrospective exploratory analy…

Rank94.3
Randomized clinical study

WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design.

NPJ breast cancer · 2026 · PMID 42177197

The Women Informed to Screen Depending on Measures of risk (WISDOM) Study (clinicaltrials.gov NCT02620852, 2016-08-31) is pragmatic randomized controlled trial evaluating risk assessment to inform the age to start, frequency and modality of breast cancer screening and risk reduction. The WISDOM Study uses a preference-tolerant design, enabling women who decline randomization to self-select their screening arm. The risk-based arm included comprehensive breast cancer risk assessment using the Breast Cancer Surveillan…

Rank92.2
Randomized clinical study

Breast cancer screening based on clinical breast examination performed by community health workers: study protocol for a randomized clinical trial - ITABERAÍ Project.

Contemporary clinical trials · 2026 · PMID 42838324

OBJECTIVE: The ITABERAÍ project evaluates whether breast cancer screening based on clinical breast examination (CBE) performed by community health workers (CHWs) can reduce advanced breast cancer and mortality. METHODS: This prospective, phase III, cluster-randomized controlled trial includes women aged ≥40 years using Brazil's public health system. Primary healthcare units and their Family Health Teams were randomized to a control group (CG) or intervention grop (IG). CHWs in the CG received standard breast cancer…

Rank92.0
Randomized controlled trial

Combined pharmacologic and lifestyle intervention for breast cancer prevention: Results of the randomized phase II TOLERANT trial in high-risk women.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42892237

BACKGROUND: Breast cancer (BC) prevention strategies include lifestyle modification and preventive agents such as selective estrogen receptor modulators and aromatase inhibitors. Sex hormone-binding globulin (SHBG) is a breast cancer risk-associated biomarker; however, it is not a validated surrogate endpoint for breast cancer risk reduction. METHODS: Population: women with hereditary BC risk, a ≥ 5% 10-year BC risk, or a history of intraepithelial neoplasia were enrolled. TRIAL DESIGN: a four-arm randomized phase …

Rank92.0
Randomized controlled trial

Subclinical cardiac damage monitoring in breast cancer patients treated with an anthracycline-based chemotherapy receiving left-sided breast radiation therapy: subgroup analysis from a phase 3 trial.

La Radiologia medica · 2024 · PMID 39436588

OBJECTIVE: This study, derived from the phase 3 SAFE trial (ClinicalTrials.gov identifier: NCT2236806), explores subclinical cardiac damage in breast cancer patients receiving anthracycline-based chemotherapy and left-sided breast radiation therapy (RT). MATERIALS AND METHODS: Eligible patients were randomized to a cardioprotective pharmacological therapy (bisoprolol, ramipril, or both) or placebo, with cardiac surveillance at multiple time-point using standard and 3-dimensional echocardiography. Dosimetric paramet…

Evidence Syntheses194 records
Rank113.0
Systematic review or meta-analysisResult signal: benefit

Beyond predictive performance: A systematic review and critical methodological appraisal of AI/ML and conventional modelling strategies in breast, colorectal, and pancreatic Cancer.

Artificial intelligence in medicine · 2026 · PMID 42641254

BACKGROUND: Predictive modelling for cancer risk, treatment-related complications, and survival is central to precision oncology. Conventional logistic regression (LR) and Cox proportional hazards (CoxPH) regression remain widely used but are limited when modelling nonlinear interactions, high-dimensional imaging features, and multimodal clinical-metabolic predictors. Artificial intelligence (AI) and machine learning (ML) methods offer expanded capability through automated feature extraction, ensemble learning, and…

Rank112.8
Systematic review or meta-analysis

Artificial Intelligence in Breast Cancer Diagnosis, Treatment, and Perioperative Management: A Systematic Review of Current Applications and Future Perspectives.

La Clinica terapeutica · 2026 · PMID 42922241

BACKGROUND: Breast cancer is the most frequently diagnosed malignancy in women globally, accounting for approximately 2.30 million new cases and 666,103 deaths in 2022. Artificial intelligence technologies including machine learning, deep learning, radiomics, and natural language processing have been widely applied across the breast cancer care continuum. However, no systematic review restricted to primary studies with patient-level or image-level data has synthesized evidence spanning all clinical domains simultan…

Rank112.0
Clinical guideline or consensus statement

CAR Practice Guidelines on Breast Imaging and Interventions: Contrast-Enhanced Mammography.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42198829

This guideline presents Part II of the Canadian Association of Radiologists (CAR) Practice Guidelines on Breast Imaging and Intervention and addresses the clinical application of contrast-enhanced mammography (CEM). Reflecting the expanding evidence base and increasing clinical adoption of CEM since 2016, this guideline provides updated recommendations on indications, examination technique, contrast administration, image interpretation, reporting standards, quality control, and patient safety. Particular emphasis i…

Rank110.0
Systematic review or meta-analysis

Preoperative CA15-3 as a predictor of axillary lymph node metastasis and prognosis in women with breast cancer: a GRADE-assessed systematic review and meta-analysis.

Breast cancer (Tokyo, Japan) · 2026 · PMID 42831963

BACKGROUND: Breast cancer (BC) is the leading cause of cancer-related death among women. Axillary lymph node metastasis (ALNM) is a key prognostic factor, yet its assessment relies on invasive procedures. The prognostic value of preoperative CA15-3 remains controversial. We aimed to evaluate the association between preoperative CA15-3 levels and overall survival (OS), disease-free survival (DFS), and ALNM in breast cancer patients. METHODS: We systematically searched PubMed, Scopus, Web of Science, Embase, and Coch…

Rank110.0
Clinical guideline or consensus statement

CAR Practice Guidelines on Breast Imaging and Interventions: Mammography and Digital Breast Tomosynthesis.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42198822

This guideline presents Part I of the Canadian Association of Radiologists (CAR) Practice Guidelines on Breast Imaging and Intervention and focuses on mammography and digital breast tomosynthesis (DBT). Developed by the CAR Breast Imaging Working Group, this guideline provides updated, evidence-based recommendations for screening and diagnostic mammography, reflecting advances in digital imaging, tomosynthesis, artificial intelligence, and quality assurance since the previous consolidated guidelines published in 20…

Rank110.0
Clinical guideline or consensus statement

CAR Practice Guidelines on Breast Imaging and Interventions: Breast Ultrasound.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42198835

This guideline presents Part III of the Canadian Association of Radiologists (CAR) Practice Guidelines on Breast Imaging and Intervention and focuses on breast ultrasound. Recommendations address the diagnostic, supplemental screening, and interventional roles of ultrasound in contemporary breast imaging practice. Topics include clinical indications, equipment and technical performance, axillary assessment, documentation, structured reporting using BI-RADS®, quality assurance, and personnel qualifications, with att…

Rank110.0
Clinical guideline or consensus statement

Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42462191

UNLABELLED: ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the https://www.asco.org/practice-patients/guidelines/guideline-methodology. ASCO Guidelines follow the https://www.asco.org/about-asco/legal/conflict-interest-coi.Clinical Practice Guidelines and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options. It is inten…

Rank110.0
Clinical guideline or consensus statement

CAR/BRC Recommendations for Management of Axillary Lymphadenopathy Following COVID-19 Vaccination.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42175918

Axillary lymphadenopathy following vaccination has long been recognized as a benign, self-limited immune response, but its increased frequency during the COVID 19 vaccination campaign created diagnostic uncertainty and contributed to delays in breast imaging and unnecessary follow-up. Early conservative guidance, issued in the context of limited evidence, led to postponed screening examinations and increased patient anxiety. Since then, robust prospective and longitudinal data have demonstrated an extremely low, ne…

Rank110.0
Systematic review or meta-analysis

No evidence for a genetic causal effect of breast cancer on venous thromboembolism: a mendelian randomization study.

Journal of thrombosis and thrombolysis · 2024 · PMID 37615800

Active cancer is known to contribute to venous thromboembolism (VTE), but the cause-and-effect association of breast cancer on VTE is not yet clear. In order to investigate the possible causal relationships, we used a Mendelian randomization analysis. Data for generically predicted breast cancer were identified based on the BCAC consortium. A meta-analysis of genome-wide association study (GWAS) comprising 1,500,861 participants for VTE as well as data from the FinnGen study for VTE, DVT and PE was used for the cau…

Rank110.0
Clinical guideline or consensus statement

CAR Practice Guidelines on Breast Imaging and Interventions: Breast Magnetic Resonance Imaging.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42198826

This guideline presents Part IV of the Canadian Association of Radiologists (CAR) Practice Guidelines on Breast Imaging and Intervention and addresses breast magnetic resonance imaging (MRI). As the most sensitive imaging modality for breast cancer detection, MRI plays an established and expanding role in screening, staging, problem-solving, and treatment monitoring. This guideline provides updated recommendations on indications, technical requirements, contrast administration, reporting standards, quality assuranc…

Rank110.0
Clinical guideline or consensus statement

CAR Practice Guidelines on Breast Imaging and Interventions: Breast Intervention and Biopsy Procedures.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42198851

This guideline presents Part V of the Canadian Association of Radiologists (CAR) Practice Guidelines on Breast Imaging and Intervention and addresses image-guided breast intervention and biopsy procedures. This guideline provides comprehensive recommendations for stereotactic-, tomosynthesis-, ultrasound-, and MRI-guided biopsy, as well as preoperative localization and post-procedural management. Key areas include indications and contraindications, biopsy device and needle selection, tissue marker placement, docume…

Rank110.0
Systematic review or meta-analysis

The associations between household food insecurity and cancer: A comprehensive systematic review and meta-analysis of observational studies among adults.

Social science & medicine (1982) · 2026 · PMID 42685390

BACKGROUND: Household food insecurity (HFI) is a critical social determinant of health that can adversely influence cancer prevention, treatment, and survivorship, while a cancer diagnosis with its financial and functional consequences may also increase the risk of HFI. This study aimed to examine the associations between HFI and cancer-related outcomes. METHODS: A systematic search was done in PubMed, Embase, Scopus, Web of Science, and Cochrane Library until July 29, 2025. Eligible studies were observational in a…

Rank110.0
Clinical guideline or consensus statement

Italian guidelines for age range and test interval in breast cancer screening programmes: GRADE-ADOLOPMENT of the European guidelines.

La Radiologia medica · 2024 · PMID 39460891

A guideline panel formulated a set of recommendations for breast cancer screening and diagnosis to implement clinical activities in Italy in alignment with the European Breast Cancer Guidelines on Screening and Diagnosis (European Commission Initiative on Breast Cancer-ECIBC). The panel issued national recommendations through adopting, adapting, and/or developing recommendations from the European guidelines (ADOLOPMENT approach). This process utilizes the Grading of Recommendations Assessment, Development, and Eval…

Rank110.0
Systematic review or meta-analysis

Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.

Journal of endocrinological investigation · 2024 · PMID 38530620

BACKGROUND: The effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cancer has yet to be fully elucidated. OBJECTIVE: This systematic review and meta-analysis investigated the effects of SGLT2 inhibitors on cancer. METHODS: We searched the PubMed and ClinicalTrials.gov databases up to July 15, 2023, to identify eligible randomized, double-blind, placebo-controlled trials that lasted at least ≥24 weeks. The primary outcome was the overall cancer incidence, and the secondary outcomes were the incidences of…

Rank110.0
Systematic review or meta-analysis

Sensitive Period Analysis of Adulthood BMI and Cancer Risk: An Individual Participant Data Meta-Analysis of Over 720,000 Participants in the ABACus 2 Consortium.

International journal of cancer · 2026 · PMID 41952250

At least 13 cancers are linked to obesity. We analyse time-to-event data using Sensitive Period Analysis to explore whether associations between body mass index (BMI) and cancer incidence vary throughout adulthood to inform cancer prevention strategies, policy and weight management trials of optimal intervention ages. Using the European Prospective Investigation into Cancer and Nutrition cohort, Atherosclerosis Risk in Communities study, Women's Health Initiative, Prostate, Lung, Colorectal, Ovarian Cancer Screenin…

Rank110.0
Systematic review or meta-analysis

Clinicopathological response and survival outcomes of HER2-low versus HER2-zero early breast Cancer: A systematic review and Meta-analysis.

Clinica chimica acta; international journal of clinical chemistry · 2027 · PMID 42248318

BACKGROUND: Breast cancer is the most common malignant tumor in women. Human epidermal growth factor receptor 2 (HER2) is a key biomarker for classification and treatment. A subgroup with HER2-low expression has been identified, but existing evidence is heterogeneous. This systematic review and meta-analysis compared pathological response and survival outcomes between HER2-low and HER2-zero early-stage breast cancer to clarify prognostic features. METHODS: This study followed PRISMA guidelines and was registered in…

Rank110.0
Systematic review or meta-analysis

The effect of BMI on survival outcome of breast cancer patients: a systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025 · PMID 39012453

OBJECTIVE: The main goal of the present research is to explore the potential link of body mass index (BMI) with different survival metrics in breast cancer patients. Our aim is to offer the latest and most thorough meta-analysis, assessing the strength and reliability of the connection that BMI has with prognostic indicators in this disease. PATIENTS AND METHODS: As of January 2024, we conducted a systematic literature search across PubMed, Embase, Web of Science, and the Cochrane Library databases. Our search aime…

Rank110.0
Clinical guideline or consensus statement

ESR Essentials: diagnostic work-up in patients with symptomatic breast disease-practice recommendations by the European Society of Breast Imaging.

European radiology · 2025 · PMID 39085641

Breast complaints are frequent reasons for consultations in primary care or breast clinics. Breast pain, breast lumps, and nipple discharge are the most common complaints. Less common symptoms such as skin changes and axillary abnormalities also require specific diagnostic approaches. Imaging the symptomatic breast should be performed by appropriately trained breast radiologists following the best practice guidelines and quality standards. Full-field digital mammography (FFDM), digital breast tomosynthesis (DBT), a…

Rank109.7
Systematic review or meta-analysisResult signal: benefit

Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies.

Targeted oncology · 2025 · PMID 39656361

BACKGROUND: The efficacy and safety of cyclin-dependent kinase (CDK)4/6 inhibitors in patients with breast cancer have been investigated by large-scale trials sponsored by drug companies. A lack of real-world evidence may lead to biases. OBJECTIVE: We systematically reviewed the large-scale clinical trials and real-world data to investigate the efficacy and safety of CDK4/6 inhibitors in patients with breast cancer. PATIENTS AND METHODS: We searched PubMed, Embase, and Cochrane Library from the inception of each da…

Rank109.2
Systematic review or meta-analysis

Increasing Uptake Of Screening For Women's Cancers: A Systematic Review Of Interventions To Increase Attendance At First Invitation.

Journal of health psychology · 2026 · PMID 41881813

Low uptake of cancer screening in those becoming newly eligible is evident across all UK cancer screening programmes. To establish the evidence base around strategies to increase uptake of cancer screening for women at first invitation, the published literature was reviewed. Papers reporting on invitations to breast and/or cervical screening, specified first-time invitee, used quantitative or qualitative methodologies and research conducted in the UK were included. The search identified 6713 articles, with 99 full-…

Rank108.3
Systematic review or meta-analysis

Abbreviated versus full diagnostic protocol MRI for breast cancer detection: a diagnostic test accuracy systematic review and meta-analysis.

European journal of radiology · 2026 · PMID 42574771

BACKGROUND: To systematically compare the diagnostic accuracy of abbreviated breast MRI (AB-MRI) and full diagnostic protocol MRI (FDP-MRI) for breast cancer detection. METHODS: Ovid-MEDLINE, Embase, Cochrane Library, and Web of Science were searched up to December 1, 2025. Risk of bias was assessed using the modified Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. RESULTS: Forty studies (14,266 patients) were included. In screening settings, the first postcontrast subtracted (FAST) protocol achi…

Rank108.0
Systematic review or meta-analysis

Prevalence and clinical implications of sarcopenia in breast cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38702479

PURPOSE: The impact of sarcopenia in oncology is increasingly recognized, yet little is known about its clinical implications in breast cancer. This systematic review and meta-analysis estimates the overall prevalence of sarcopenia in breast cancer, quantifies skeletal muscle index (SMI), and comprehensively evaluates sarcopenia's impact on clinical outcomes. METHODS: We systematically searched primary original research published before June 2023 in four databases: the Cochrane Library via Wiley, CINAHL Plus with F…

Rank107.8
Systematic review or meta-analysis

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer.

European journal of clinical pharmacology · 2024 · PMID 38900307

PURPOSE: The aim of this study was to quantitatively compare the efficacy and safety of CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors for ER+/HER2- metastatic breast cancer. METHODS: A parametric survival function was used to analyze the time course of overall survival (OS) and progression-free survival (PFS). The objective response rate (ORR) and the incidence of any grade and grade 3-4 adverse events were summarized using the random-effects model of a single-arm meta-analysis. RESULTS: This study included 44 arm…

Rank107.7
Systematic review or meta-analysis

Risk of locoregional recurrence after breast cancer surgery by molecular subtype-a systematic review and network meta-analysis.

Irish journal of medical science · 2024 · PMID 39331262

BACKGROUND: The prevention of locoregional recurrence (LRR) is crucial in breast cancer, as it translates directly into reduced breast cancer-related death. Breast cancer is subclassified into distinct intrinsic biological subtypes with varying clinical outcomes. AIMS: To perform a systematic review and network meta-analysis (NMA) to determine the rate of LRR by breast cancer molecular subtype. METHODS: A NMA was performed as per PRISMA-NMA guidelines. Molecular subtypes were classified by St Gallen expert consensu…

Rank107.6
Systematic review or meta-analysis

Prognosis and therapeutic choices for occult breast cancer in female patients: a systematic review and meta-analysis.

BMC surgery · 2026 · PMID 42958221

BACKGROUND: Occult breast cancer (OBC) is a rare subtype characterized by axillary lymph node (LN) metastasis without an identifiable primary breast lesion. Owing to its rarity, optimal management remains controversial. We performed a systematic review and meta-analysis to comprehensively evaluate the clinicopathological characteristics, prognosis, and treatment outcomes of female patients with OBC. METHODS: A systematic review and meta-analysis were conducted using PubMed/MEDLINE, Embase, and the Cochrane Library …

Landmark Evidence241 records
Rank110.0
Clinical guideline or consensus statement

ESR Essentials: diagnostic work-up in patients with symptomatic breast disease-practice recommendations by the European Society of Breast Imaging.

European radiology · 2025 · PMID 39085641

Breast complaints are frequent reasons for consultations in primary care or breast clinics. Breast pain, breast lumps, and nipple discharge are the most common complaints. Less common symptoms such as skin changes and axillary abnormalities also require specific diagnostic approaches. Imaging the symptomatic breast should be performed by appropriately trained breast radiologists following the best practice guidelines and quality standards. Full-field digital mammography (FFDM), digital breast tomosynthesis (DBT), a…

Rank110.0
Clinical guideline or consensus statement

Italian guidelines for age range and test interval in breast cancer screening programmes: GRADE-ADOLOPMENT of the European guidelines.

La Radiologia medica · 2024 · PMID 39460891

A guideline panel formulated a set of recommendations for breast cancer screening and diagnosis to implement clinical activities in Italy in alignment with the European Breast Cancer Guidelines on Screening and Diagnosis (European Commission Initiative on Breast Cancer-ECIBC). The panel issued national recommendations through adopting, adapting, and/or developing recommendations from the European guidelines (ADOLOPMENT approach). This process utilizes the Grading of Recommendations Assessment, Development, and Eval…

Rank110.0
Systematic review or meta-analysis

No evidence for a genetic causal effect of breast cancer on venous thromboembolism: a mendelian randomization study.

Journal of thrombosis and thrombolysis · 2024 · PMID 37615800

Active cancer is known to contribute to venous thromboembolism (VTE), but the cause-and-effect association of breast cancer on VTE is not yet clear. In order to investigate the possible causal relationships, we used a Mendelian randomization analysis. Data for generically predicted breast cancer were identified based on the BCAC consortium. A meta-analysis of genome-wide association study (GWAS) comprising 1,500,861 participants for VTE as well as data from the FinnGen study for VTE, DVT and PE was used for the cau…

Rank110.0
Systematic review or meta-analysis

Sensitive Period Analysis of Adulthood BMI and Cancer Risk: An Individual Participant Data Meta-Analysis of Over 720,000 Participants in the ABACus 2 Consortium.

International journal of cancer · 2026 · PMID 41952250

At least 13 cancers are linked to obesity. We analyse time-to-event data using Sensitive Period Analysis to explore whether associations between body mass index (BMI) and cancer incidence vary throughout adulthood to inform cancer prevention strategies, policy and weight management trials of optimal intervention ages. Using the European Prospective Investigation into Cancer and Nutrition cohort, Atherosclerosis Risk in Communities study, Women's Health Initiative, Prostate, Lung, Colorectal, Ovarian Cancer Screenin…

Rank110.0
Systematic review or meta-analysis

Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.

Journal of endocrinological investigation · 2024 · PMID 38530620

BACKGROUND: The effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cancer has yet to be fully elucidated. OBJECTIVE: This systematic review and meta-analysis investigated the effects of SGLT2 inhibitors on cancer. METHODS: We searched the PubMed and ClinicalTrials.gov databases up to July 15, 2023, to identify eligible randomized, double-blind, placebo-controlled trials that lasted at least ≥24 weeks. The primary outcome was the overall cancer incidence, and the secondary outcomes were the incidences of…

Rank110.0
Systematic review or meta-analysis

The effect of BMI on survival outcome of breast cancer patients: a systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025 · PMID 39012453

OBJECTIVE: The main goal of the present research is to explore the potential link of body mass index (BMI) with different survival metrics in breast cancer patients. Our aim is to offer the latest and most thorough meta-analysis, assessing the strength and reliability of the connection that BMI has with prognostic indicators in this disease. PATIENTS AND METHODS: As of January 2024, we conducted a systematic literature search across PubMed, Embase, Web of Science, and the Cochrane Library databases. Our search aime…

Rank109.7
Systematic review or meta-analysisResult signal: benefit

Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies.

Targeted oncology · 2025 · PMID 39656361

BACKGROUND: The efficacy and safety of cyclin-dependent kinase (CDK)4/6 inhibitors in patients with breast cancer have been investigated by large-scale trials sponsored by drug companies. A lack of real-world evidence may lead to biases. OBJECTIVE: We systematically reviewed the large-scale clinical trials and real-world data to investigate the efficacy and safety of CDK4/6 inhibitors in patients with breast cancer. PATIENTS AND METHODS: We searched PubMed, Embase, and Cochrane Library from the inception of each da…

Rank109.6
Systematic review or meta-analysisResult signal: harm

Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks.

American journal of obstetrics and gynecology · 2025 · PMID 39521301

OBJECTIVE: To assess the risk of breast cancer recurrence, breast cancer-specific mortality, and overall mortality for breast cancer survivors receiving vaginal estrogen therapy for genitourinary syndrome of menopause. DATA SOURCES: From the inception of each database to April 6th, 2024, a systematic literature search was conducted in Google Scholar, PubMed, EMBASE, CINAHL, NCBI, and Science Direct. A secondary search was conducted on September 26th, 2024 utilizing Google Scholar, PubMed, EMBASE, CINAHL, and Scienc…

Rank109.4
Systematic review or meta-analysis

Atypical ductal or lobular hyperplasia, lobular carcinoma in-situ, flat epithelial atypia, and future risk of developing breast cancer: Systematic review and meta-analysis.

Breast (Edinburgh, Scotland) · 2024 · PMID 39270543

BACKGROUND: Biopsy-proven breast lesions such as atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS) and flat epithelial atypia (FEA) increase subsequent risk of breast cancer (BC), but long-term risk has not been synthesized. A systematic review was conducted to quantify future risk of breast cancer accounting for time since diagnosis of these high-risk lesions. METHODS: A systematic search of literature from 2000 was performed to identify studies reporting BC …

Rank108.0
Systematic review or meta-analysis

Prevalence and clinical implications of sarcopenia in breast cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38702479

PURPOSE: The impact of sarcopenia in oncology is increasingly recognized, yet little is known about its clinical implications in breast cancer. This systematic review and meta-analysis estimates the overall prevalence of sarcopenia in breast cancer, quantifies skeletal muscle index (SMI), and comprehensively evaluates sarcopenia's impact on clinical outcomes. METHODS: We systematically searched primary original research published before June 2023 in four databases: the Cochrane Library via Wiley, CINAHL Plus with F…

Rank107.8
Systematic review or meta-analysis

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer.

European journal of clinical pharmacology · 2024 · PMID 38900307

PURPOSE: The aim of this study was to quantitatively compare the efficacy and safety of CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors for ER+/HER2- metastatic breast cancer. METHODS: A parametric survival function was used to analyze the time course of overall survival (OS) and progression-free survival (PFS). The objective response rate (ORR) and the incidence of any grade and grade 3-4 adverse events were summarized using the random-effects model of a single-arm meta-analysis. RESULTS: This study included 44 arm…

Rank107.7
Systematic review or meta-analysis

Risk of locoregional recurrence after breast cancer surgery by molecular subtype-a systematic review and network meta-analysis.

Irish journal of medical science · 2024 · PMID 39331262

BACKGROUND: The prevention of locoregional recurrence (LRR) is crucial in breast cancer, as it translates directly into reduced breast cancer-related death. Breast cancer is subclassified into distinct intrinsic biological subtypes with varying clinical outcomes. AIMS: To perform a systematic review and network meta-analysis (NMA) to determine the rate of LRR by breast cancer molecular subtype. METHODS: A NMA was performed as per PRISMA-NMA guidelines. Molecular subtypes were classified by St Gallen expert consensu…

Rank107.6
Systematic review or meta-analysis

Prognosis and therapeutic choices for occult breast cancer in female patients: a systematic review and meta-analysis.

BMC surgery · 2026 · PMID 42958221

BACKGROUND: Occult breast cancer (OBC) is a rare subtype characterized by axillary lymph node (LN) metastasis without an identifiable primary breast lesion. Owing to its rarity, optimal management remains controversial. We performed a systematic review and meta-analysis to comprehensively evaluate the clinicopathological characteristics, prognosis, and treatment outcomes of female patients with OBC. METHODS: A systematic review and meta-analysis were conducted using PubMed/MEDLINE, Embase, and the Cochrane Library …

Rank107.2
Systematic review or meta-analysis

Updated findings of skin flap thickness and residual breast tissue after mastectomy for breast cancer: a systematic review of the literature.

Updates in surgery · 2024 · PMID 37864625

BACKGROUND: There is limited evidence on the ideal retention thickness of skin flap in mastectomy. Residual breast tissue (RBT) after mastectomy still represents an unknown risk for local recurrence or new breast cancer lesions. We made this systematic review to identify the optimal flap after mastectomy with minimal complications and better oncological safety. METHODS: A systematic review was performed using MEDLINE search in PubMed, Embase, and Cochrane Library with the search terms relevant to skin flap thicknes…

Rank107.0
Systematic review or meta-analysis

Migraine and Risk of Breast Cancer: A Systematic Review and Meta-analysis.

Clinical breast cancer · 2023 · PMID 36624014

Migraine and breast cancer are 2 prevalent diseases with high morbidity and mortality rates world-wide. There have been inconsistent reports regarding the association between migraine and risk of breast cancer. This systematic review and meta-analysis aimed to assess the risk of breast cancer in patients with migraine. By December, 1, 2022, we searched PubMed, Web of Science, Scopus, and Cochrane Library databases. Odds ratio (OR), hazard ratio (HR), and 95% confidence intervals (CIs) were extracted or assessed to …

Rank107.0
Clinical guideline or consensus statementResult signal: harm

Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.

BJOG : an international journal of obstetrics and gynaecology · 2022 · PMID 34672090

This paper deals with the use of hormone replacement therapy (HRT) after the removal of fallopian tubes and ovaries to prevent ovarian cancer in premenopausal high risk women. Some women have an alteration in their genetic code, which makes them more likely to develop ovarian cancer. Two well-known genes which can carry an alteration are the BRCA1 and BRCA2 genes. Examples of other genes associated with an increased risk of ovarian cancer include RAD51C, RAD51D, BRIP1, PALB2 and Lynch syndrome genes. Women with a s…

Rank107.0
Systematic review or meta-analysisResult signal: null

Efficacy and safety of a combination treatment of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 38587602

PURPOSE: Immune checkpoint inhibitors (ICIs) in combination with chemotherapy have showed its benefits in clinical studies, and here we conducted a further evaluation on the safety and efficacy of this treatment strategy. METHODS: A systematic literature review was conducted in PubMed, Embase and Cochrane Library to identify clinical studies on ICIs and chemotherapy for metastatic breast cancer. The primary efficacy endpoints were progression-free survival (PFS) and overall survival (OS), and adverse events (AEs) w…

Rank106.9
Systematic review or meta-analysis

Diagnostic performance of MRI for assessing axillary lymph node status after neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.

European radiology · 2024 · PMID 37615764

OBJECTIVE: This systematic review examined the diagnostic performance of magnetic resonance imaging (MRI) for assessing axillary lymph node status (ALNS) after neoadjuvant chemotherapy (NAC) in breast cancer patients. METHODS: We searched PubMed, Embase, Cochrane Library, and Web of Science to identify relevant studies and used the QUADAS-2 tool to assess methodological quality of eligible studies. We used STATA version 12.0 to perform data pooling, heterogeneity testing, subgroup analysis, and sensitivity analysis…

Rank106.9
Systematic review or meta-analysisResult signal: benefit

Reducing rates of chronic breast cancer-related lymphedema with screening and early intervention: an update of recent data.

Journal of cancer survivorship : research and practice · 2024 · PMID 35947288

PURPOSE: Breast cancer-related lymphedema (BCRL) represents a dreaded complication of breast cancer treatment that can lead to morbidity, diminished quality of life, and psychosocial harm and is associated with increased costs of care. Increasingly, data has supported the concept of prospective BCRL surveillance coupled with early intervention to mitigate these effects. METHODS: We performed a systematic review of the literature searching for published randomized and prospective data evaluating prospective BCRL sur…

Rank106.7
Systematic review or meta-analysisResult signal: benefit

Acupuncture for Symptoms Characteristic of the Fatigue-Sleep Disturbance-Depression Symptom Cluster (FSDSC) in Breast Cancer: A Systematic Review and Meta-Analysis.

Integrative cancer therapies · 2026 · PMID 42960607

BackgroundThis study aimed to evaluate the effects of acupuncture or acupressure on fatigue, sleep disturbance/insomnia, and depression, the three component symptoms within the fatigue-sleep disturbance-depression symptom-cluster (FSDSC) conceptual framework in patients with breast cancer.MethodsA systematic review was conducted according to PRISMA guidelines. Seven databases (Embase, MEDLINE [Ovid], Cochrane Library [Trials], Scopus, Web of Science Core Collection, CNKI, and Wanfang Data) were searched from incept…

Rank106.7
Systematic review or meta-analysis

Postoperative outcomes of minimally invasive versus conventional nipple-sparing mastectomy with prosthesis breast reconstruction in breast cancer: a meta-analysis.

Journal of robotic surgery · 2024 · PMID 38951387

Breast cancer is the most common malignant tumor worldwide, and mastectomy remains the primary strategy for treating early stage breast cancer. However, the complication rates, surgical variables, and oncologic safety of minimally invasive nipple-sparing mastectomy (MINSM) have not been fully addressed. We systematically searched PubMed, Web of Science, Embase, and the Cochrane Library for randomized-controlled trials (RCTs) and non-RCTs that compared MINSM with conventional nipple-sparing mastectomy (CNSM), both f…

Rank106.5
Systematic review or meta-analysisResult signal: benefit

Effect of telehealth interventions on adherence to endocrine therapy among patients with breast cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38332357

PURPOSE: To evaluate the effect of telehealth interventions on adherence to endocrine therapy among patients with breast cancer. METHODS: A systematic search of five English databases (PubMed, Web of Science, Embase, the American Psychological Association PsycNet, and the Cochrane Library) and four Chinese databases (Chinese National Knowledge Infrastructure, SinoMed, WanFang Data, and WeiPu Data) was performed from inception to March 31, 2023. Two investigators independently screened the available studies for elig…

Rank106.5
Systematic review or meta-analysis

[Effects of phytoestrogens on prognosis and hormonal markers of breast cancer: A systematic review of randomized controlled trials].

Bulletin du cancer · 2026 · PMID 42823214

INTRODUCTION: Estrogen exposure is a known risk factor for breast cancer. Phytoestrogens, plant-derived compounds found in the diet, have a structure similar to estradiol. Observational studies suggest that they are associated with a reduced risk of breast cancer recurrence. The objective of this systematic review is to evaluate, based on data from randomized controlled trials, the effect of phytoestrogens on breast cancer prognosis and hormonal markers. METHODS: MEDLINE, EMBASE, CENTRAL, and ClinicalTrials.gov wer…

Rank106.4
Systematic review or meta-analysis

Impact of resistance training on fatigue among breast cancer patients undergoing chemotherapy: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39392491

PURPOSE: The effects of aerobic exercise interventions for reducing fatigue after cancer treatment are well-established, and the effect of resistance training remains uncertain. Therefore, this systematic review and meta-analysis aim to analyze the effect of resistance training and combined resistance and endurance training on cancer-related fatigue (CRF) in breast cancer patients. METHODS: A systematic search for randomized controlled trials (RCTs) was conducted on the PubMed, SPORTDiscus, Embase, and Cochrane dat…

Rank106.4
Systematic review or meta-analysisResult signal: null

Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials.

European journal of clinical pharmacology · 2024 · PMID 38888626

INTRODUCTION: Incorporation of AKT inhibitors into adjuvant therapy for advanced or metastatic breast cancer has improved clinical outcomes. However, the safety of AKT inhibitors should be better evaluated, given the possibility of prolonging survival and impacting patient quality of life. Our aim was to assess how the addition of AKT inhibitors to adjuvant therapy affects treatment-related adverse events. METHODS: We evaluated binary outcomes with risk ratios (RRs), with 95% confidence intervals (CIs). We used Der…

Most Effective Evidence Supported Treatments243 records
Rank113.0
Systematic review or meta-analysisResult signal: benefit

Beyond predictive performance: A systematic review and critical methodological appraisal of AI/ML and conventional modelling strategies in breast, colorectal, and pancreatic Cancer.

Artificial intelligence in medicine · 2026 · PMID 42641254

BACKGROUND: Predictive modelling for cancer risk, treatment-related complications, and survival is central to precision oncology. Conventional logistic regression (LR) and Cox proportional hazards (CoxPH) regression remain widely used but are limited when modelling nonlinear interactions, high-dimensional imaging features, and multimodal clinical-metabolic predictors. Artificial intelligence (AI) and machine learning (ML) methods offer expanded capability through automated feature extraction, ensemble learning, and…

Rank112.8
Systematic review or meta-analysis

Artificial Intelligence in Breast Cancer Diagnosis, Treatment, and Perioperative Management: A Systematic Review of Current Applications and Future Perspectives.

La Clinica terapeutica · 2026 · PMID 42922241

BACKGROUND: Breast cancer is the most frequently diagnosed malignancy in women globally, accounting for approximately 2.30 million new cases and 666,103 deaths in 2022. Artificial intelligence technologies including machine learning, deep learning, radiomics, and natural language processing have been widely applied across the breast cancer care continuum. However, no systematic review restricted to primary studies with patient-level or image-level data has synthesized evidence spanning all clinical domains simultan…

Rank110.0
Clinical guideline or consensus statement

CAR/BRC Recommendations for Management of Axillary Lymphadenopathy Following COVID-19 Vaccination.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42175918

Axillary lymphadenopathy following vaccination has long been recognized as a benign, self-limited immune response, but its increased frequency during the COVID 19 vaccination campaign created diagnostic uncertainty and contributed to delays in breast imaging and unnecessary follow-up. Early conservative guidance, issued in the context of limited evidence, led to postponed screening examinations and increased patient anxiety. Since then, robust prospective and longitudinal data have demonstrated an extremely low, ne…

Rank110.0
Systematic review or meta-analysis

Preoperative CA15-3 as a predictor of axillary lymph node metastasis and prognosis in women with breast cancer: a GRADE-assessed systematic review and meta-analysis.

Breast cancer (Tokyo, Japan) · 2026 · PMID 42831963

BACKGROUND: Breast cancer (BC) is the leading cause of cancer-related death among women. Axillary lymph node metastasis (ALNM) is a key prognostic factor, yet its assessment relies on invasive procedures. The prognostic value of preoperative CA15-3 remains controversial. We aimed to evaluate the association between preoperative CA15-3 levels and overall survival (OS), disease-free survival (DFS), and ALNM in breast cancer patients. METHODS: We systematically searched PubMed, Scopus, Web of Science, Embase, and Coch…

Rank110.0
Clinical guideline or consensus statement

CAR Practice Guidelines on Breast Imaging and Interventions: Breast Magnetic Resonance Imaging.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2026 · PMID 42198826

This guideline presents Part IV of the Canadian Association of Radiologists (CAR) Practice Guidelines on Breast Imaging and Intervention and addresses breast magnetic resonance imaging (MRI). As the most sensitive imaging modality for breast cancer detection, MRI plays an established and expanding role in screening, staging, problem-solving, and treatment monitoring. This guideline provides updated recommendations on indications, technical requirements, contrast administration, reporting standards, quality assuranc…

Rank110.0
Systematic review or meta-analysis

Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.

Journal of endocrinological investigation · 2024 · PMID 38530620

BACKGROUND: The effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cancer has yet to be fully elucidated. OBJECTIVE: This systematic review and meta-analysis investigated the effects of SGLT2 inhibitors on cancer. METHODS: We searched the PubMed and ClinicalTrials.gov databases up to July 15, 2023, to identify eligible randomized, double-blind, placebo-controlled trials that lasted at least ≥24 weeks. The primary outcome was the overall cancer incidence, and the secondary outcomes were the incidences of…

Rank110.0
Systematic review or meta-analysis

The effect of BMI on survival outcome of breast cancer patients: a systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025 · PMID 39012453

OBJECTIVE: The main goal of the present research is to explore the potential link of body mass index (BMI) with different survival metrics in breast cancer patients. Our aim is to offer the latest and most thorough meta-analysis, assessing the strength and reliability of the connection that BMI has with prognostic indicators in this disease. PATIENTS AND METHODS: As of January 2024, we conducted a systematic literature search across PubMed, Embase, Web of Science, and the Cochrane Library databases. Our search aime…

Rank110.0
Systematic review or meta-analysis

The associations between household food insecurity and cancer: A comprehensive systematic review and meta-analysis of observational studies among adults.

Social science & medicine (1982) · 2026 · PMID 42685390

BACKGROUND: Household food insecurity (HFI) is a critical social determinant of health that can adversely influence cancer prevention, treatment, and survivorship, while a cancer diagnosis with its financial and functional consequences may also increase the risk of HFI. This study aimed to examine the associations between HFI and cancer-related outcomes. METHODS: A systematic search was done in PubMed, Embase, Scopus, Web of Science, and Cochrane Library until July 29, 2025. Eligible studies were observational in a…

Rank110.0
Systematic review or meta-analysis

Clinicopathological response and survival outcomes of HER2-low versus HER2-zero early breast Cancer: A systematic review and Meta-analysis.

Clinica chimica acta; international journal of clinical chemistry · 2027 · PMID 42248318

BACKGROUND: Breast cancer is the most common malignant tumor in women. Human epidermal growth factor receptor 2 (HER2) is a key biomarker for classification and treatment. A subgroup with HER2-low expression has been identified, but existing evidence is heterogeneous. This systematic review and meta-analysis compared pathological response and survival outcomes between HER2-low and HER2-zero early-stage breast cancer to clarify prognostic features. METHODS: This study followed PRISMA guidelines and was registered in…

Rank109.7
Systematic review or meta-analysisResult signal: benefit

Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies.

Targeted oncology · 2025 · PMID 39656361

BACKGROUND: The efficacy and safety of cyclin-dependent kinase (CDK)4/6 inhibitors in patients with breast cancer have been investigated by large-scale trials sponsored by drug companies. A lack of real-world evidence may lead to biases. OBJECTIVE: We systematically reviewed the large-scale clinical trials and real-world data to investigate the efficacy and safety of CDK4/6 inhibitors in patients with breast cancer. PATIENTS AND METHODS: We searched PubMed, Embase, and Cochrane Library from the inception of each da…

Rank108.0
Systematic review or meta-analysis

Prevalence and clinical implications of sarcopenia in breast cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38702479

PURPOSE: The impact of sarcopenia in oncology is increasingly recognized, yet little is known about its clinical implications in breast cancer. This systematic review and meta-analysis estimates the overall prevalence of sarcopenia in breast cancer, quantifies skeletal muscle index (SMI), and comprehensively evaluates sarcopenia's impact on clinical outcomes. METHODS: We systematically searched primary original research published before June 2023 in four databases: the Cochrane Library via Wiley, CINAHL Plus with F…

Rank107.8
Systematic review or meta-analysis

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer.

European journal of clinical pharmacology · 2024 · PMID 38900307

PURPOSE: The aim of this study was to quantitatively compare the efficacy and safety of CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors for ER+/HER2- metastatic breast cancer. METHODS: A parametric survival function was used to analyze the time course of overall survival (OS) and progression-free survival (PFS). The objective response rate (ORR) and the incidence of any grade and grade 3-4 adverse events were summarized using the random-effects model of a single-arm meta-analysis. RESULTS: This study included 44 arm…

Rank107.7
Systematic review or meta-analysis

Risk of locoregional recurrence after breast cancer surgery by molecular subtype-a systematic review and network meta-analysis.

Irish journal of medical science · 2024 · PMID 39331262

BACKGROUND: The prevention of locoregional recurrence (LRR) is crucial in breast cancer, as it translates directly into reduced breast cancer-related death. Breast cancer is subclassified into distinct intrinsic biological subtypes with varying clinical outcomes. AIMS: To perform a systematic review and network meta-analysis (NMA) to determine the rate of LRR by breast cancer molecular subtype. METHODS: A NMA was performed as per PRISMA-NMA guidelines. Molecular subtypes were classified by St Gallen expert consensu…

Rank107.6
Systematic review or meta-analysis

Prognosis and therapeutic choices for occult breast cancer in female patients: a systematic review and meta-analysis.

BMC surgery · 2026 · PMID 42958221

BACKGROUND: Occult breast cancer (OBC) is a rare subtype characterized by axillary lymph node (LN) metastasis without an identifiable primary breast lesion. Owing to its rarity, optimal management remains controversial. We performed a systematic review and meta-analysis to comprehensively evaluate the clinicopathological characteristics, prognosis, and treatment outcomes of female patients with OBC. METHODS: A systematic review and meta-analysis were conducted using PubMed/MEDLINE, Embase, and the Cochrane Library …

Rank107.6
Systematic review or meta-analysis

Association between hair cortisol concentration and cancer-related outcomes in adult patients: A systematic review.

Psychoneuroendocrinology · 2026 · PMID 42784920

BACKGROUND: Chronic stress, through sustained hypothalamic-pituitary-adrenal (HPA) axis activation, has been implicated in cancer progression. Hair cortisol concentration (HCC) offers a unique retrospective window into cumulative cortisol exposure, yet its relationship with cancer outcomes has never been systematically examined. OBJECTIVE: To critically appraise the evidence linking HCC to cancer-related outcomes in adults and to identify the methodological gaps that currently limit this emerging field. METHODS: Fo…

Rank107.2
Systematic review or meta-analysis

Margin positivity and re-excision after breast-conserving surgery following neoadjuvant chemotherapy: A systematic review and meta-analysis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42790237

Neoadjuvant chemotherapy (NACT) is increasingly used to facilitate breast-conserving surgery (BCS) in patients with early-stage and locally advanced breast cancer. However, tumour response to NACT is heterogeneous, and comparative studies have reported higher rates of margin involvement and re-excision compared with primary surgery. Despite its clinical significance, the incidence of positive margins and rates of re-excision remain incompletely defined. A systematic review and meta-analysis was conducted in accorda…

Rank107.2
Systematic review or meta-analysis

Updated findings of skin flap thickness and residual breast tissue after mastectomy for breast cancer: a systematic review of the literature.

Updates in surgery · 2024 · PMID 37864625

BACKGROUND: There is limited evidence on the ideal retention thickness of skin flap in mastectomy. Residual breast tissue (RBT) after mastectomy still represents an unknown risk for local recurrence or new breast cancer lesions. We made this systematic review to identify the optimal flap after mastectomy with minimal complications and better oncological safety. METHODS: A systematic review was performed using MEDLINE search in PubMed, Embase, and Cochrane Library with the search terms relevant to skin flap thicknes…

Rank107.0
Systematic review or meta-analysisResult signal: null

Efficacy and safety of a combination treatment of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 38587602

PURPOSE: Immune checkpoint inhibitors (ICIs) in combination with chemotherapy have showed its benefits in clinical studies, and here we conducted a further evaluation on the safety and efficacy of this treatment strategy. METHODS: A systematic literature review was conducted in PubMed, Embase and Cochrane Library to identify clinical studies on ICIs and chemotherapy for metastatic breast cancer. The primary efficacy endpoints were progression-free survival (PFS) and overall survival (OS), and adverse events (AEs) w…

Rank107.0
Clinical guideline or consensus statementResult signal: harm

Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.

BJOG : an international journal of obstetrics and gynaecology · 2022 · PMID 34672090

This paper deals with the use of hormone replacement therapy (HRT) after the removal of fallopian tubes and ovaries to prevent ovarian cancer in premenopausal high risk women. Some women have an alteration in their genetic code, which makes them more likely to develop ovarian cancer. Two well-known genes which can carry an alteration are the BRCA1 and BRCA2 genes. Examples of other genes associated with an increased risk of ovarian cancer include RAD51C, RAD51D, BRIP1, PALB2 and Lynch syndrome genes. Women with a s…

Rank106.9
Systematic review or meta-analysis

Diagnostic performance of MRI for assessing axillary lymph node status after neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.

European radiology · 2024 · PMID 37615764

OBJECTIVE: This systematic review examined the diagnostic performance of magnetic resonance imaging (MRI) for assessing axillary lymph node status (ALNS) after neoadjuvant chemotherapy (NAC) in breast cancer patients. METHODS: We searched PubMed, Embase, Cochrane Library, and Web of Science to identify relevant studies and used the QUADAS-2 tool to assess methodological quality of eligible studies. We used STATA version 12.0 to perform data pooling, heterogeneity testing, subgroup analysis, and sensitivity analysis…

Rank106.9
Systematic review or meta-analysisResult signal: benefit

Reducing rates of chronic breast cancer-related lymphedema with screening and early intervention: an update of recent data.

Journal of cancer survivorship : research and practice · 2024 · PMID 35947288

PURPOSE: Breast cancer-related lymphedema (BCRL) represents a dreaded complication of breast cancer treatment that can lead to morbidity, diminished quality of life, and psychosocial harm and is associated with increased costs of care. Increasingly, data has supported the concept of prospective BCRL surveillance coupled with early intervention to mitigate these effects. METHODS: We performed a systematic review of the literature searching for published randomized and prospective data evaluating prospective BCRL sur…

Rank106.8
Systematic review or meta-analysisResult signal: benefit

Efficacy and safety of trastuzumab deruxtecan in HER2-high and HER2-low breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Journal of chemotherapy (Florence, Italy) · 2026 · PMID 41345476

Breast cancer is the most common malignancy, with approximately ∼20% of cases involving HER2 overexpression. Trastuzumab deruxtecan (T-DXd), an HER2-targeted antibody-drug conjugate, is approved for HER2-high and HER2-low disease. This meta-analysis assessed four randomized controlled trials (DESTINY-Breast02, -03, -04, and -06; 2555 patients) from PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. A random-effects model revealed that T-DXd significantly improved progression-free survival (hazard ratio [HR] …

Rank106.7
Systematic review or meta-analysis

Neoadjuvant antibody-drug conjugates for early-stage breast cancer: A systematic review and meta-analysis.

Critical reviews in oncology/hematology · 2026 · PMID 42772656

BACKGROUND: Pathologic complete response (pCR) is a key endpoint of neoadjuvant therapy in early-stage breast cancer (EBC), associated with improved survival, particularly in triple-negative and human epidermal growth factor receptor 2 (HER2)-positive disease. More recently, antibody-drug conjugates (ADCs), established in metastatic disease, are being evaluated in the neoadjuvant setting. DESIGN: We systematically searched for studies of EBC patients treated with neoadjuvant ADCs, alone or in combination. Meta-anal…

Rank106.7
Systematic review or meta-analysisResult signal: benefit

Acupuncture for Symptoms Characteristic of the Fatigue-Sleep Disturbance-Depression Symptom Cluster (FSDSC) in Breast Cancer: A Systematic Review and Meta-Analysis.

Integrative cancer therapies · 2026 · PMID 42960607

BackgroundThis study aimed to evaluate the effects of acupuncture or acupressure on fatigue, sleep disturbance/insomnia, and depression, the three component symptoms within the fatigue-sleep disturbance-depression symptom-cluster (FSDSC) conceptual framework in patients with breast cancer.MethodsA systematic review was conducted according to PRISMA guidelines. Seven databases (Embase, MEDLINE [Ovid], Cochrane Library [Trials], Scopus, Web of Science Core Collection, CNKI, and Wanfang Data) were searched from incept…

Rank106.7
Systematic review or meta-analysis

Postoperative outcomes of minimally invasive versus conventional nipple-sparing mastectomy with prosthesis breast reconstruction in breast cancer: a meta-analysis.

Journal of robotic surgery · 2024 · PMID 38951387

Breast cancer is the most common malignant tumor worldwide, and mastectomy remains the primary strategy for treating early stage breast cancer. However, the complication rates, surgical variables, and oncologic safety of minimally invasive nipple-sparing mastectomy (MINSM) have not been fully addressed. We systematically searched PubMed, Web of Science, Embase, and the Cochrane Library for randomized-controlled trials (RCTs) and non-RCTs that compared MINSM with conventional nipple-sparing mastectomy (CNSM), both f…

New Research Last 24 Months305 records
Rank110.4
Systematic review or meta-analysis

Prevalence of anxiety and depression in breast cancer patients: a meta-analysis.

Frontiers in psychology · 2026 · PMID 42952549

INTRODUCTION: Depression and anxiety are frequently reported among women with breast cancer, but prevalence estimates vary substantially across settings and assessment instruments. This meta-analysis synthesized recent international evidence and examined overall, severity-stratified, and instrument-specific prevalence estimates. METHODS: We searched PubMed, Web of Science, Embase, the Cochrane Library, APA PsycINFO, and Scopus for observational studies published from January 2015 through September 10, 2026. Proport…

Rank106.5
Systematic review or meta-analysis

[Effects of phytoestrogens on prognosis and hormonal markers of breast cancer: A systematic review of randomized controlled trials].

Bulletin du cancer · 2026 · PMID 42823214

INTRODUCTION: Estrogen exposure is a known risk factor for breast cancer. Phytoestrogens, plant-derived compounds found in the diet, have a structure similar to estradiol. Observational studies suggest that they are associated with a reduced risk of breast cancer recurrence. The objective of this systematic review is to evaluate, based on data from randomized controlled trials, the effect of phytoestrogens on breast cancer prognosis and hormonal markers. METHODS: MEDLINE, EMBASE, CENTRAL, and ClinicalTrials.gov wer…

Rank105.1
Systematic review or meta-analysis

Physical activity interventions for women with metastatic breast cancer: a systematic review of published and ongoing randomised controlled trials.

Journal of cancer survivorship : research and practice · 2026 · PMID 41214274

PURPOSE: We systematically reviewed published and ongoing physical activity (PA) trials in women with metastatic breast cancer (MBC). We examined (i) the effectiveness of PA interventions and identified (ii) the type of interventions being evaluated, (iii) how they are delivered and (iv) their theoretical basis. METHODS: Seven databases and two trial registries were searched in August 2024 for randomised controlled trials, testing any PA intervention in people with MBC, reporting a PA outcome. The Joanna Briggs Ins…

Rank102.1
Systematic review or meta-analysisResult signal: mixed

The effect of different telerehabilitation technologies on the management of cardiovascular disease in oncology survivors: systematic review.

Journal of cancer survivorship : research and practice · 2026 · PMID 41354726

PURPOSE: With advancements in early detection and treatment improving cancer survival rates, cancer survivors face an increased risk of cardiovascular-specific morbidity and mortality. Cardiovascular telerehabilitation has been a notable tool to enhance the quality of life and manage cardiovascular disease in cancer survivors. This systematic review aims to evaluate the effectiveness of different telerehabilitation technologies in improving cardiovascular fitness in cancer survivors. METHODS: This review was regist…

Rank102.0
Systematic review or meta-analysis

Metabolic Bariatric Surgery for Cancer Prevention and Risk Reduction in Patients with Obesity: A GRADE-Based International Federation for the Surgery and Other Therapies for Obesity (IFSO) Position Statement.

Obesity surgery · 2026 · PMID 42834256

BACKGROUND: Obesity is a major increasing driver of cancer burden worldwide, and intentional weight loss has emerged as a potential strategy for cancer risk reduction. Metabolic bariatric surgery (MBS) achieves sustained weight loss, but its role in cancer prevention remains uncertain. This GRADE-based International Federation for the Surgery and Other Therapies for Obesity (IFSO) position statement aimed to synthesize contemporary evidence on MBS and cancer outcomes and translate it into clinically actionable reco…

Rank101.6
Systematic review or meta-analysis

Tumor lysis syndrome in breast cancer: a systematic review of the literature.

Frontiers in oncology · 2026 · PMID 42952660

BACKGROUND: Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency well-characterized in hematologic malignancies but considered rare in solid tumors. In breast cancer, TLS has been documented only in sporadic case reports, and the evolving treatment landscape-including CDK4/6 inhibitors, PI3K inhibitors, novel endocrine agents, and antibody-drug conjugates-may introduce previously unrecognized TLS risks. The only prior review on this topic was published in 2021 and has been superseded by numerous new…

Rank100.0
Systematic review or meta-analysis

Impact of age and treatment-related adverse events on financial toxicity among patients with breast cancer: a systematic review.

Journal of cancer survivorship : research and practice · 2026 · PMID 40884698

PURPOSE: Increasing incidence of breast cancer among young adults (YA), defined by the National Comprehensive Cancer Network (NCCN) as age < 40 years, has amplified concerns over financial toxicity (FT) in this demographic. This systematic review sought to clarify the association between YA status and FT. METHODS: We queried bibliographic databases for full-text English language publications between 2010 and 2024 reporting FT using validated patient-reported outcome metrics among patients with stage I-III breast ca…

Rank100.0
Systematic review or meta-analysis

Venlafaxine in oncology: supportive-care evidence and emerging preclinical anticancer signals: a systematic review.

Frontiers in pharmacology · 2026 · PMID 42964294

BACKGROUND: Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, has been investigated in oncology for several supportive care indications and, more recently, for potential anticancer activity. However, the available evidence remains fragmented across clinical and preclinical studies. OBJECTIVE: This systematic review aimed to synthesize the available evidence regarding the role of venlafaxine in oncology, including established supportive care applications and emerging anticancer potential. METHODS: A system…

Rank99.8
Randomized controlled trial

Real-Time Electronic Patient-Reported Outcome Monitoring With Digital Triage and Care-Team Integration in Early Breast Cancer: ENABLE Randomized Controlled Trial.

Journal of medical Internet research · 2026 · PMID 42954133

BACKGROUND: Electronic patient-reported outcomes (ePROs) can support patient-centered oncology care, but in early breast cancer, it is unclear whether real-time ePRO-triggered triage adds benefit beyond lower-intensity app-based support and scheduled ePRO collection. OBJECTIVE: We tested whether adding weekly ePRO screening, rule-based triage, and care-team escalation to app-based support improves health-related quality of life (HRQoL) during systemic therapy for early breast cancer. METHODS: ENABLE was a multicent…

Rank99.4
Randomized controlled trial

Recurrence Score gene group components and outcomes in the RxPONDER trial (SWOG S1007).

Journal of the National Cancer Institute · 2026 · PMID 42458791

BACKGROUND: The RxPONDER trial has guided adjuvant chemotherapy use in node-positive HR+/HER2- breast cancer; however, prior analyses showed poorer outcomes among non-Hispanic Black (NHB) women compared with non-Hispanic White (NHW) women despite similar 21-gene Recurrence Score (RS) results. This suggests contributors to disparities may not be captured by the composite RS. We evaluated RS gene group components-proliferation, estrogen receptor (ER), HER2 (GRB7), and invasion-by ethnicity, body mass index, and menop…

Rank99.0
Systematic review or meta-analysis

Isoliquiritigenin in breast cancer therapy: from mechanistic insights to advanced nano-enabled delivery strategies.

Biochemical pharmacology · 2026 · PMID 42913800

Isoliquiritigenin (ISL), a chalcone from Glycyrrhiza species, exhibits multi-target anti-breast cancer activity but faces pharmacokinetic limitations. This review synthesizes evidence for ISL's molecular targets and mechanisms and evaluates nano-delivery strategies. In preclinical models, ISL inhibits proliferation via miR-374a/PTEN/Akt, reverses EMT through miR-200c/C-JUN/β-catenin, targets cancer stem cells via GRP78 inhibition and WIF1 reactivation, suppresses aromatase and COX-2, modulates osteoclast activity, …

Rank97.0
Randomized controlled trial

Perceived discrimination, patient-provider communication, and quality of life among breast cancer survivors: a mediation analysis.

Journal of cancer survivorship : research and practice · 2026 · PMID 40875141

PURPOSE: Breast cancer is common among women in the US and can impact survivors' quality of life (QoL). Perceived discrimination, defined as unfair treatment based on group membership, is often associated with poorer QoL, while effective patient-provider communication is often linked to better QoL. However, whether communication can mitigate the negative effects of discrimination remains unclear. This study investigates the relationship between perceived discrimination and QoL among women with early-stage breast ca…

Rank96.0
Systematic review or meta-analysis

GlycoRNA-related cellular program scoring identifies Siglec- and myeloid-associated tumor microenvironments for glycoRNA validation.

Frontiers in immunology · 2026 · PMID 42947688

BACKGROUND: Glycosylated RNAs (glycoRNAs) represent a recently recognized connection between RNA biology and cell-surface glycobiology. However, whether glycoRNA-related processes are relevant to human tumors remains unclear, partly because direct glycoRNA measurements are not yet available across large cancer cohorts. We therefore used transcriptomic data to identify tumor settings in which glycoRNA-related programs may be most suitable for further experimental validation. METHODS: We curated a glycoRNA-focused li…

Rank96.0
Systematic review or meta-analysis

The preventive strategies for chronic persistent postsurgical pain following breast cancer surgery: A systematic review and meta-analysis.

Saudi journal of anaesthesia · 2026 · PMID 42960323

INTRODUCTION: Breast cancer is the most common malignant disease among women worldwide. With improved treatment, 5-year survival has increased leading to increasing number of survivors reporting chronic persistent post-surgical pain (CPPP). Hence this systematic review and meta-analysis was conducted to analyse preventive strategies in chronic persistent postsurgical pain following breast cancer surgery. METHODS: Electronic databases were searched for randomized controlled trials that allocated patients undergoing …

Rank96.0
Systematic review or meta-analysis

Survival After Risk-Reducing Mastectomy in Patients With Pathogenic Variants in BRCA1 and BRCA2: A Network Meta-Analysis.

JAMA network open · 2026 · PMID 42961418

IMPORTANCE: The independent survival benefit of risk-reducing mastectomy (RRM), separate from risk-reducing salpingo-oophorectomy (RRSO), remains uncertain among patients with pathogenic variants (PVs) in BRCA1 and BRCA2 genes. OBJECTIVE: To evaluate the association of RRM, magnetic resonance imaging (MRI)-based screening, and mammography alone with all-cause and breast cancer-specific mortality using RRSO-adjusted estimates. DATA SOURCES: MEDLINE, Embase, and Web of Science were searched from January 1, 1990, to M…

Rank96.0
Systematic review or meta-analysis

Time to treatment initiation for breast cancer: A systematic review and meta-analysis of studies from 21 countries.

Cancer epidemiology · 2026 · PMID 42962385

BACKGROUND: Breast cancer is the most common cancer among women globally, accounting for one in four cancer cases and one in six cancer deaths. Timely initiation of treatment after diagnosis is critical to improving survival outcomes. However, delays in treatment initiation remain widespread, influenced by health system constraints, socio-demographic factors, and the COVID-19 pandemic. Despite growing recognition of this issue, no prior study has comprehensively quantified global evidence on diagnosis-to-treatment …

Rank96.0
Systematic review or meta-analysis

Temporal Eating Patterns Show Inconsistent Associations With Cancer Incidence and Mortality: Systematic Review of Prospective Studies.

The Journal of nutrition · 2026 · PMID 42966568

BACKGROUND: Temporal eating patterns, such as eating time, frequency, and regularity, may be associated with cancer outcomes through circadian and metabolic pathways, but evidence remains limited. OBJECTIVES: We aimed to systematically review prospective studies examining associations between temporal eating patterns and cancer incidence or mortality. METHODS: Following PRISMA guidelines, PubMed and Embase were searched from inception to September 2, 2026. Eligible studies included prospective cohorts of adults ass…

Rank93.6
Randomized clinical study

Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort.

Clinical and translational radiation oncology · 2027 · PMID 42935767

PURPOSE: The international REQUITE study and its follow-up studies (RADprecise/REQUITEplus) prospectively collected longitudinal data from patients undergoing radiotherapy for breast, prostate, or lung cancer. We present data from 2057 women with breast cancer, describing patient-reported outcomes and acute and late adverse effects. METHODS: Patients were recruited between April 2014 and October 2016. Eligible patients received external-beam photon radiotherapy after breast-conserving surgery, had no metastasis at …

Rank92.2
Randomized clinical study

Breast cancer screening based on clinical breast examination performed by community health workers: study protocol for a randomized clinical trial - ITABERAÍ Project.

Contemporary clinical trials · 2026 · PMID 42838324

OBJECTIVE: The ITABERAÍ project evaluates whether breast cancer screening based on clinical breast examination (CBE) performed by community health workers (CHWs) can reduce advanced breast cancer and mortality. METHODS: This prospective, phase III, cluster-randomized controlled trial includes women aged ≥40 years using Brazil's public health system. Primary healthcare units and their Family Health Teams were randomized to a control group (CG) or intervention grop (IG). CHWs in the CG received standard breast cancer…

Rank92.0
Randomized controlled trial

Combined pharmacologic and lifestyle intervention for breast cancer prevention: Results of the randomized phase II TOLERANT trial in high-risk women.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42892237

BACKGROUND: Breast cancer (BC) prevention strategies include lifestyle modification and preventive agents such as selective estrogen receptor modulators and aromatase inhibitors. Sex hormone-binding globulin (SHBG) is a breast cancer risk-associated biomarker; however, it is not a validated surrogate endpoint for breast cancer risk reduction. METHODS: Population: women with hereditary BC risk, a ≥ 5% 10-year BC risk, or a history of intraepithelial neoplasia were enrolled. TRIAL DESIGN: a four-arm randomized phase …

Rank92.0
Randomized controlled trial

Breaking the Silence: A Mixed Methods Analysis Unveiling Barriers to Mental Health Service Use in Breast Cancer Survivors With Clinically Significant Distress.

Psycho-oncology · 2026 · PMID 42947255

BACKGROUND: Breast cancer survivors are at elevated risk for psychological distress, including depression, anxiety, and post-traumatic stress (PTS), compared to healthy controls. Fear of cancer recurrence (FCR) is particularly prevalent, with approximately 50% of breast cancer survivors reporting clinically significant FCR. AIMS: This mixed methods study examined associations among psychological distress, mental health service (MHS) use, and barriers to MHS use among breast cancer survivors. METHODS: Using a sequen…

Rank89.9
Randomized clinical study

Efficacy of cryotherapy in preventing taxane-induced neuropathy: the CryoPac randomised controlled trial.

Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42838271

BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating adverse effect of taxane chemotherapy. Currently, there is no established strategy for prevention or treatment. Smaller studies have suggested that cryotherapy may prevent CIPN. PATIENTS AND METHODS: We conducted a randomised controlled trial comparing usual care with cryotherapy using frozen gloves and socks during each taxane treatment. Participants were stratified by site and chemotherapy regiment and randomly assigned 1 :…

Rank89.9
Randomized clinical study

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial.

Nature medicine · 2026 · PMID 42957778

PHERGain was a randomized, non-comparative phase 2 trial evaluating a positron 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET)-guided, pathological complete response (pCR)-adapted strategy to omit chemotherapy in HER2-positive early breast cancer. Female patients with HER2-positive stages I-IIIA operable breast cancer (tumor size ≥ 1.5 cm) were randomized to receive chemotherapy plus trastuzumab and pertuzumab (HP; group A) or HP ± endocrine therapy (group B). In group B, treatment was adapted acc…

Rank89.3
Randomized clinical studyResult signal: benefit

Hormone receptor-positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression.

The oncologist · 2026 · PMID 42898011

BACKGROUND: The management of oligometastatic breast cancer (OMBC) remains controversial, particularly regarding selection for local ablative treatment (LAT). In HR+/HER2- OMBC, where prolonged survival is often the case, improved stratification and characterization of progression may guide treatment. We aimed to define prognostic subsets, assess the contribution of Modern-Imaging-Methods (MIMs; 18F-FDG-PET/CT or WB-MRI) to LAT selection, and describe progression after first-line therapy in these subgroups of patie…

Rank85.0
Randomized clinical study

Persistent chemotherapy-induced alopecia: a scoping review.

Current opinion in supportive and palliative care · 2026 · PMID 42888908

PURPOSE OF REVIEW: Persistent chemotherapy-induced alopecia (pCIA) is defined as incomplete hair growth ≥6 months after chemotherapy completion. This scoping review aimed to identify gaps for future research by mapping pCIA's incidence, risk factors, quality-of-life (QoL) impacts, presentation, prevention, and management. RECENT FINDINGS: Thirty-nine articles were included. The most common study type was case reports (12/39, 30.8%). Only 2/39 (5.1%) were randomized controlled trials (RCTs). Most studies (27/39, 69.…

Preclinical Research304 records
Rank100.0
Systematic review or meta-analysis

Venlafaxine in oncology: supportive-care evidence and emerging preclinical anticancer signals: a systematic review.

Frontiers in pharmacology · 2026 · PMID 42964294

BACKGROUND: Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, has been investigated in oncology for several supportive care indications and, more recently, for potential anticancer activity. However, the available evidence remains fragmented across clinical and preclinical studies. OBJECTIVE: This systematic review aimed to synthesize the available evidence regarding the role of venlafaxine in oncology, including established supportive care applications and emerging anticancer potential. METHODS: A system…

Rank100.0
Systematic review or meta-analysis

Re-evaluating the α/β ratio in 2026: A systematic review and quantitative reappraisal in the era of molecular radiobiology.

Medical dosimetry : official journal of the American Association of Medical Dosimetrists · 2026 · PMID 42731947

The linear-quadratic (LQ) model and its derived ratio, α/β, have served as the cornerstone of radiotherapy dose-fractionation decisions. The period from 2015 to 2026 has witnessed a substantial re-evaluation of this paradigm, driven by the clinical success of hypofractionation in prostate and breast cancer, stereotactic body radiation therapy (SBRT), and radiogenomics. A systematic review with narrative synthesis was conducted to evaluate quantitative estimates of α/β derived from clinical and preclinical studies o…

Rank100.0
Systematic review or meta-analysis

Preclinical evidence for mifepristone in breast cancer: A systematic review and meta-analysis of animal studies.

European journal of pharmacology · 2026 · PMID 42854814

Mifepristone (MIF), an antagonist of the progesterone receptor (PR) and glucocorticoid receptor (GR), has shown antitumor activity in experimental breast cancer, but the consistency and certainty of the preclinical evidence remain unclear. We systematically searched PubMed, Embase, Web of Science, and the China National Knowledge Infrastructure through May 5, 2026, for animal studies evaluating MIF alone or in combination with other anticancer treatments. Random-effects meta-analyses were performed using Hedges' g …

Rank99.2
Systematic review or meta-analysis

Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies.

Current oncology reports · 2023 · PMID 36995535

PURPOSE OF REVIEW: Patients seek clinical guidance on mushroom supplements that can be given alongside conventional treatments, but most research on such fungi has been preclinical. The current systematic review focused on clinical studies of mushrooms in cancer care conducted in the past 10 years. We searched Medline (Ovid), Embase (Ovid), Scopus (Wiley), and Cochrane Library to identify all mushroom studies conducted in humans published from January 2010 through December 2020. Two authors independently assessed p…

Rank99.0
Systematic review or meta-analysis

Isoliquiritigenin in breast cancer therapy: from mechanistic insights to advanced nano-enabled delivery strategies.

Biochemical pharmacology · 2026 · PMID 42913800

Isoliquiritigenin (ISL), a chalcone from Glycyrrhiza species, exhibits multi-target anti-breast cancer activity but faces pharmacokinetic limitations. This review synthesizes evidence for ISL's molecular targets and mechanisms and evaluates nano-delivery strategies. In preclinical models, ISL inhibits proliferation via miR-374a/PTEN/Akt, reverses EMT through miR-200c/C-JUN/β-catenin, targets cancer stem cells via GRP78 inhibition and WIF1 reactivation, suppresses aromatase and COX-2, modulates osteoclast activity, …

Rank92.0
Randomized controlled trial

A Co-clinical Trial of Exercise Therapy in Breast Cancer Prevention.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2025 · PMID 40184238

PURPOSE: We conducted a mouse-human co-clinical trial to evaluate the biological efficacy of exercise therapy in breast cancer prevention. PATIENTS AND METHODS: In a phase I randomized trial, 75 nonexercising women at high risk of breast cancer were allocated to receive (1:1 ratio) usual care or one of three exercise therapy dose regimens: 75, 150, or 300 minutes/week for 24 consecutive weeks. Biological efficacy was evaluated by changes in breast epithelial cell proliferation (Ki67). Correlative proteomic analysis…

Rank85.0
Randomized clinical study

Liraglutide and denatonium benzoate attenuate T2DM-induced metabolic, neurological, and testicular changes in rats: Targeting oxidative stress, inflammation, and BCRP transporter.

Journal of molecular histology · 2025 · PMID 39881033

Type 2 diabetes mellitus (T2DM) adversely affects various organs, including the brain and its blood barrier. In addition to the brain, hyperglycemia damages the testes. The testes possess blood-tissue barriers that share common characteristics and proteins with the blood-brain barrier (BBB), including breast cancer-resistant protein (BCRP). This study aimed to investigate the impact of uncontrolled DM on the brain and testes, with a specific focus on BCRP. Moreover, it examined the effects of liraglutide (Lira) and…

Rank85.0
Randomized clinical study

Optimizing near infrared laser irradiation and photosensitizer accumulation period for indocyanine green-mediated photodynamic therapy in breast cancer xenografts: a focus on treatment and characterization.

Lasers in medical science · 2024 · PMID 39382719

Photodynamic therapy (PDT) is a promising cancer treatment approach. Indocyanine green (ICG) is a water-soluble tricarbocyanine dye with a peak absorption wavelength of around 800 nm and possesses the capacity to produce reactive oxygen species. FTIR spectroscopy is rarely used and offers insights into molecular changes in cancer studies. MCF-7 cells were injected into Nude mouse. Once the tumor had grown to a size of 3-4 mm, mice were randomized into the 12 PDT groups. After each mouse received 5 mg/kg of ICG, the…

Rank82.0
Randomized clinical study

Elacestrant: a new FDA-approved SERD for the treatment of breast cancer.

Medical oncology (Northwood, London, England) · 2023 · PMID 37191763

Elacestrant (RAD-1901), a selective estrogen receptor degrader, was approved by USFDA on January 27, 2023, for the treatment of breast cancer. It has been developed by Menarini Group under the brand name Orserdu®. Elacestrant showed anticancer activity both in vitro and in vivo in ER+ HER2-positive breast cancer models. The present review delebrates the development stages of Elacestrant, with its medicinal chemistry, synthesis, mechanism of action, and pharmacokinetic studies. Clinical data and safety profile has a…

Rank48.1
Other PubMed-indexed publication

Clinicopathological characteristics and clinical outcomes of multiple histological subtypes in feline mammary carcinomas.

Veterinary pathology · 2026 · PMID 42439398

Feline mammary carcinomas (FMCs) are heterogeneous neoplasms often comprising multiple histological patterns within a single case. The current practice of focusing on a prominent subtype hinders prognostic accuracy and potentially produces suboptimal therapeutic decisions. This retrospective study proposed criteria for grouping these mixed patterns and evaluated their prognostic significance in FMCs. The criteria were based on the tubular carcinoma composition and adopted from those of human breast cancer. Eighty-s…

Rank47.0
Other PubMed-indexed publication

15th Annual ENBDC Meeting: How do Cellular Potency, Microenvironment and Natural Rhythms Influence Mammary Gland Biology and Breast Cancer?

Journal of mammary gland biology and neoplasia · 2024 · PMID 39585439

Following previous editions, the fifteenth annual workshop of the European Network for Breast Development and Cancer (ENBDC) on Methods in Mammary Gland Biology and Breast Cancer was held from the 2nd to the 4th of May in Weggis, Switzerland. Over the course of this meeting, participants followed and discussed presentations from a roster of internationally renowned invited speakers and selected abstracts, complemented with two poster sessions covering exciting unpublished results. The sessions covered projects on n…

Rank45.0
Other PubMed-indexed publication

ATAD2B governs epigenetic silencing of the epithelial program to fuel cancer metastasis and neuronal migration.

The EMBO journal · 2026 · PMID 42963391

Epithelial-to-mesenchymal transition (EMT) is a pivotal developmental program that is frequently co-opted to drive cancer aggressiveness and metastasis. While the dynamic remodelling of histone H3 lysine 27 acetylation (H3K27ac) landscapes is a hallmark of EMT, the specific chromatin readers decoding these epigenetic signals remain largely unknown. Here, we identify ATAD2B as a novel H3K27ac reader essential for cell migration in both cancer metastasis and brain development. Multi-omics profiling revealed that, at …

Rank45.0
Other PubMed-indexed publication

High-fat, low-carb diet reduces tumor growth and induces liver metabolism remodeling in a breast cancer mouse model.

American journal of physiology. Cell physiology · 2026 · PMID 42302718

Cancer cells require large quantities of glucose to ensure sufficient ATP production through glycolysis, and the liver may facilitate this glucose supply. A high-fat low-carbohydrate ketogenic diet (KD) could represent a strategy to reduce tumor growth. However, the molecular effects of carbohydrate restriction mediated by the KD and its hepatic impact remain poorly understood. To address this question, 6-wk-old FVB/N-Tg(MMTV-PyVT)634Mul/J mice, which develop spontaneous mammary tumors, were fed a standard chow die…

Rank45.0
Other PubMed-indexed publication

Depression promotes breast cancer progression by regulating amino acid neurotransmitter metabolism and gut microbial disturbance.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 38194019

INTRODUCTION: Breast cancer (BC) is the most prevalent type of cancer and has the highest mortality among women worldwide. BC patients have a high risk of depression, which has been recognized as an independent factor in the progression of BC. However, the potential mechanism has not been clearly demonstrated. METHODS: To explore the correlation and mechanism between depression and BC progression, we induced depression and tumor in BC mouse models. Depression was induced via chronic unpredictable mild stress (CUMS)…

Rank45.0
Other PubMed-indexed publication

Well-known polypeptides of deer antler velvet with key actives: modern pharmacological advances.

Naunyn-Schmiedeberg's archives of pharmacology · 2024 · PMID 37555852

Deer antler velvet, with kidney tonifying, promoting the production of essence and blood, strengthening tendons and bones, not only has a thousand-year medicinal history but also its modern pharmacology mainly focuses on its active polypeptides on motor, nerve, and immune systems. The purpose of this report is to fill the gap in the comprehensive, systematic, and detailed review of polypeptides during the recent 30 years (1992-2023). The research method was to review 53 pharmacological articles from the Public Medi…

Rank45.0
Other PubMed-indexed publication

Magnetic Particle Imaging Reveals Heterogeneous Retention, Leakage, and Redistribution of Nanoparticles Following Intratumoral Injection.

Nano letters · 2026 · PMID 42915354

Intratumoral (i.t.) delivery of nanoparticles (NPs) is widely used to achieve high local NP concentrations. However, the temporal and spatial fate of i.t.-injected NPs remains poorly understood. We present a quantitative approach using whole-body in vivo magnetic particle imaging (MPI) to track magnetic NPs (MNPs) following i.t. injection. Using fiducial-calibrated imaging, we quantified MNP mass over time in subcutaneous 4T1 breast tumors. Longitudinal imaging revealed progressive loss of i.t. MNP content and hete…

Rank45.0
Other PubMed-indexed publication

Physicochemical and molecular determinants of lipid migration through multicellular assemblies.

Journal of controlled release : official journal of the Controlled Release Society · 2026 · PMID 42685979

Efficient movement of lipid molecules across multiple cell layers is a fundamental requirement for lipid-based drug delivery, but the physicochemical and molecular properties that enable this process remain poorly understood. To address this question, we generated a library of lipids with the fluorescent cyanine 3 and cyanine 5 dye headgroups, different tail lengths, and headgroup-tail linkers. We used multicellular 3D breast cancer spheroids to study the lipid penetration into the core (core/periphery ratio) with …

Rank45.0
Other PubMed-indexed publication

Wnt3a/GSK3β/β-catenin Signalling Modulates Doxorubicin-associated Memory Deficits in Breast Cancer.

Molecular neurobiology · 2024 · PMID 38198045

BACKGROUND: Chemobrain is widespread in breast cancer patients receiving chemotherapy. However, the exact mechanism, especially the associated signalling pathway, is not currently clear. This study was to evaluate the behavioural changes in breast cancer mice after chemotherapy and to further explore the role of Wnt3a/glycogen synthase kinase (GSK3β)/β-catenin signalling in chemobrain. METHODS: MMTV-PyMT(+) breast cancer mice were injected intraperitoneally with doxorubicin (4 mg/kg) once a week for three weeks to …

Rank45.0
Other PubMed-indexed publication

Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing.

Current oncology reports · 2025 · PMID 39786525

PURPOSE OF REVIEW: In this review, we discuss evidence supporting the use of antibody-drug conjugates (ADCs) in breast cancer treatment, describe novel ADCs and combination regimens under development, and examine our current understanding of resistance mechanisms and biomarkers to guide ADC selection and sequencing. RECENT FINDINGS: Three ADCs have proven benefit in patients with metastatic breast cancer: trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan (SG). There are over t…

Rank45.0
Other PubMed-indexed publication

Sanhuang Xiexin Decoction Ameliorates TNBC By Modulating JAK2-STAT3 and Lipid Metabolism.

Chinese journal of integrative medicine · 2024 · PMID 37930511

OBJECTIVE: To investigate the therapeutic effect of Sanhuang Xiexin Decoction (SXD) on triple-negative breast cancer (TNBC) in mice and its underlying mechanism. METHODS: The high-performance liquid chromatography (HPLC) was used to quantitate and qualify SXD. A total of 15 female BALB/c mice were inoculated subcutaneously on the right hypogastrium with 3×105 of 4T1-Luc cells to establish TNBC mouse model. All mice were divided randomly into 3 groups, including phosphate buffered solution (PBS), SXD and doxorubicin…

Rank45.0
Other PubMed-indexed publication

Organoid models of breast cancer in precision medicine and translational research.

Molecular biology reports · 2024 · PMID 39570495

One of the most famous and heterogeneous cancers worldwide is breast cancer (BC). Owing to differences in the gene expression profiles and clinical features of distinct BC subtypes, different treatments are prescribed for patients. However, even with more thorough pathological evaluations of tumors than in the past, available treatments do not perform equally well for all individuals. Precision medicine is a new approach that considers the effects of patients' genes, lifestyle, and environment to choose the right t…

Rank45.0
Other PubMed-indexed publication

Addressing radiotherapy-induced fibrosis: the potential of platelet-rich plasma and infliximab for improved breast cancer management.

Histochemistry and cell biology · 2024 · PMID 38282055

Breast cancer treatment encompasses various therapeutic modalities, including surgery, radiotherapy, and chemotherapy. Breast-conserving surgery has been an integral part of breast cancer management. However, radiotherapy, an important component of breast cancer management, can lead to complications, particularly fibrosis, affecting reconstructive surgery outcomes. We conducted an in vivo study using 48 female Wistar Albino rats, employing segmental mastectomy and radiotherapy to simulate post-mastectomy conditions…

Rank45.0
Other PubMed-indexed publication

Lentinula edodes Cultured Extract Intake at Puberty Mitigates Inflammatory Signals at the Mammary Glands by the Involvement of Epigenetic Mechanisms in BALB/c Mice.

The breast journal · 2026 · PMID 41915463

Exposure to immune stress or lipopolysaccharide (LPS) during critical developmental stages like puberty may lead to gut microbiome dysbiosis and epigenetic dysregulation in mammary glands, affecting gene expression and potentially elevating breast cancer susceptibility in adulthood. Although LPS's adverse impacts on intestinal and brain functions are well-documented, its effects on mammary glands remain underexplored. Using an immunocompetent BALB/c mouse model, we administered an acute LPS dose (1.5 mg/kg body wei…

Rank45.0
Other PubMed-indexed publication

Ligand-modulated redox, DNA-binding, and cytotoxic properties of novel Palladium(II) oxime complexes.

Journal of inorganic biochemistry · 2027 · PMID 42837948

Three novel Pd(II) complexes, [Pd(L1)Cl₂], K[Pd(L2)Cl₂], and [Pd(L3)Cl₂] (L1 = 2-acetylpyridine oxime, L2 = 2-acetylpyrrole oxime, L3 = 2-acetylthiophene oxime), were synthesized and comprehensively investigated in terms of their DNA-binding and electrochemical and anticancer properties. DNA interaction studies, including UV-Vis absorption titration, thermal denaturation, fluorescence quenching, and viscosity measurements, indicated that the complexes interact with DNA predominantly through non-covalent modes, such…

Rank43.6
Other PubMed-indexed publication

Epirubicin Treatment Induces Neurobehavioral, Oxido-Inflammatory and Neurohistology Alterations in Rats: Protective Effect of the Endogenous Metabolite of Tryptophan - 3-Indolepropionic Acid.

Neurochemical research · 2023 · PMID 37097396

Epirubicin's (EPI) efficacy as a chemotherapeutic agent against breast cancer is limited by EPI's neurotoxicity associated with increased oxidative and inflammatory stressors. 3-Indolepropionic acid (3-IPA) derived from in vivo metabolism of tryptophan is reported to possess antioxidative properties devoid of pro-oxidant activity. In this regard, we investigated the effect of 3-IPA on EPI-mediated neurotoxicity in forty female rats (180-200 g; five cohorts (n = 6) treated as follows: Untreated control; EPI alone (2…

Promising Experimental Therapies108 records
Rank100.0
Systematic review or meta-analysis

Preclinical evidence for mifepristone in breast cancer: A systematic review and meta-analysis of animal studies.

European journal of pharmacology · 2026 · PMID 42854814

Mifepristone (MIF), an antagonist of the progesterone receptor (PR) and glucocorticoid receptor (GR), has shown antitumor activity in experimental breast cancer, but the consistency and certainty of the preclinical evidence remain unclear. We systematically searched PubMed, Embase, Web of Science, and the China National Knowledge Infrastructure through May 5, 2026, for animal studies evaluating MIF alone or in combination with other anticancer treatments. Random-effects meta-analyses were performed using Hedges' g …

Rank98.4
Randomized controlled trial

Acceptability of de-intensified screening for women at low risk of breast cancer: a randomised online experimental survey.

BMC cancer · 2024 · PMID 39243000

BACKGROUND: Risk-stratified approaches to breast screening show promise for increasing benefits and reducing harms. But the successful implementation of such an approach will rely on public acceptability. To date, research suggests that while increased screening for women at high risk will be acceptable, any de-intensification of screening for low-risk groups may be met with less enthusiasm. We report findings from a population-based survey of women in England, approaching the age of eligibility for breast screenin…

Rank97.2
Randomized controlled trial

AI Health message intervention: The role of message customization and message source in breast cancer screening among women of color.

Patient education and counseling · 2026 · PMID 42537382

OBJECTIVES: To examine the effectiveness of breast cancer screening messages with varying levels of customization (generic, targeted, and tailored) and to compare AI-generated versus human-generated messages. METHODS: A between-subjects experimental design with a control condition was employed. Message content followed a standardized structure and varied by level of customization: generic, targeted (demographic-based), and tailored (perceived susceptibility- and barrier-based). Messages were developed by either the…

Rank97.1
Randomized controlled trial

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.

Nature medicine · 2024 · PMID 38191615

The combination of immune-checkpoint blockade with chemotherapy for the first-line treatment of advanced triple-negative breast cancer (TNBC) has generated mixed results. TORCHLIGHT is a randomized, double-blinded phase 3 trial evaluating the efficacy and safety of first-line toripalimab and nab-paclitaxel (nab-P) (n = 353; experimental arm) versus placebo and nab-P (n = 178; control arm) for the treatment of women with metastatic or recurrent TNBC. The primary end point was progression-free survival (PFS) assessed…

Rank97.0
Systematic review or meta-analysis

Effects of the appearance care on psychosocial outcomes for breast cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022 · PMID 35835903

PURPOSE: To synthesize the evidence for the immediate and short-term effects of appearance care on psychosocial outcomes in breast cancer patients in order to inform the design of future research and clinical practice. METHODS: A search of four databases (PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web of Science). The JBI Critical Appraisal Checklists were used by two reviewers to assess methodology quality. Subgroup analysis was conducted for the different time points measured after interv…

Rank96.6
Randomized controlled trial

Impact of remote management using patient-reported outcomes on pain and anxiety after breast biopsy: the BIO-PSY randomized controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42911430

PURPOSE: Although breast biopsy is a routine procedure, it often triggers significant pain and anxiety. Pre-procedural distress has been associated with increased pain and discomfort, and persistent post-biopsy distress may affect psychological and treatment-related outcomes. However, post-biopsy care still lacks standardized follow-up. This study evaluated whether remote monitoring using patient-reported outcomes (PROs) triggering targeted interventions could improve pain and anxiety management after breast biopsy…

Rank96.5
Randomized controlled trial

Primed to feel, not to flare: Early life adversity and psychological sensitivity to interleukin-6 in a randomized trial among middle-aged female breast cancer survivors.

Brain, behavior, and immunity · 2026 · PMID 42526663

BACKGROUND: There have been recent calls to investigate potential moderators of inflammation's psychological effects in humans. In a small observational study, Kuhlman et al. (2020b) found that individuals with higher early life adversity (ELA) showed heightened psychological sensitivity (i.e., more depressed mood and poorer cognition but not decreased social connection) in response to influenza vaccine-induced increases in interleukin-6 (IL-6). In a larger cohort with a placebo-controlled experimental design, we e…

Rank96.0
Systematic review or meta-analysis

GlycoRNA-related cellular program scoring identifies Siglec- and myeloid-associated tumor microenvironments for glycoRNA validation.

Frontiers in immunology · 2026 · PMID 42947688

BACKGROUND: Glycosylated RNAs (glycoRNAs) represent a recently recognized connection between RNA biology and cell-surface glycobiology. However, whether glycoRNA-related processes are relevant to human tumors remains unclear, partly because direct glycoRNA measurements are not yet available across large cancer cohorts. We therefore used transcriptomic data to identify tumor settings in which glycoRNA-related programs may be most suitable for further experimental validation. METHODS: We curated a glycoRNA-focused li…

Rank96.0
Randomized controlled trialResult signal: benefit

Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.

Nature medicine · 2024 · PMID 38969879

It remains unclear whether metronomic chemotherapy is superior to conventional chemotherapy when combined with immune checkpoint blockade. Here we performed a phase 2 clinical trial of metronomic chemotherapy combined with PD-1 blockade to compare the efficacy of combined conventional chemotherapy and PD-1 blockade using Bayesian adaptive randomization and efficacy monitoring. Eligible patients had metastatic HER2-negative breast cancer and had not received more than one prior line of standard chemotherapy. Patient…

Rank93.0
Randomized controlled trialResult signal: null

A novel, multi-active emollient for the prevention of acute radiation dermatitis in breast cancer patients: a randomized clinical trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023 · PMID 37819539

PURPOSE: To investigate the efficacy of a novel, multi-active emollient in preventing and managing acute radiation dermatitis (ARD) in breast cancer patients undergoing moderate hypofractionated (HF) radiotherapy (RT) compared to standard of care. METHODSA: A monocentric, open-label, randomized clinical trial (RCT) with breast cancer patients receiving moderate HF (dose: 40.05-55.86 Gy, fractions: 15-21) was conducted between January 2022 and May 2023. The experimental group received the novel emollient, while the …

Rank92.0
Randomized controlled trial

Postprandial glycaemic response and pain sensitivity in breast cancer survivors suffering from chronic pain: a double-blind, randomised controlled cross-over pilot experiment.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025 · PMID 39820733

INTRODUCTION: The study's primary goal is to investigate differences in postprandial glycaemic response (PPGR) to beverages with varying glycaemic index (i.e. low and medium) between breast cancer survivors (BCS) with chronic pain and healthy pain-free controls (HC). The secondary goal of the study is to investigate the potential link between PPGR and pain-related outcomes in BCS with chronic pain. METHODS: In this study, 15 BCS and 15 HC were included. After 12 h of fasting, subjects were randomised between drinki…

Rank92.0
Randomized controlled trial

A Co-clinical Trial of Exercise Therapy in Breast Cancer Prevention.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2025 · PMID 40184238

PURPOSE: We conducted a mouse-human co-clinical trial to evaluate the biological efficacy of exercise therapy in breast cancer prevention. PATIENTS AND METHODS: In a phase I randomized trial, 75 nonexercising women at high risk of breast cancer were allocated to receive (1:1 ratio) usual care or one of three exercise therapy dose regimens: 75, 150, or 300 minutes/week for 24 consecutive weeks. Biological efficacy was evaluated by changes in breast epithelial cell proliferation (Ki67). Correlative proteomic analysis…

Rank92.0
Randomized controlled trial

Combined pharmacologic and lifestyle intervention for breast cancer prevention: Results of the randomized phase II TOLERANT trial in high-risk women.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42892237

BACKGROUND: Breast cancer (BC) prevention strategies include lifestyle modification and preventive agents such as selective estrogen receptor modulators and aromatase inhibitors. Sex hormone-binding globulin (SHBG) is a breast cancer risk-associated biomarker; however, it is not a validated surrogate endpoint for breast cancer risk reduction. METHODS: Population: women with hereditary BC risk, a ≥ 5% 10-year BC risk, or a history of intraepithelial neoplasia were enrolled. TRIAL DESIGN: a four-arm randomized phase …

Rank88.0
Randomized clinical study

Anesthetics and cancer biology: Translational evidence from perioperative modulation to drug repurposing (Review).

International journal of molecular medicine · 2026 · PMID 42852614

Perioperative anesthesia is delivered during a brief but biologically dynamic interval in which surgical stress, inflammation, immune perturbation and tissue repair may alter the environment encountered by residual or disseminated tumor cells. Experimental studies indicate that anesthetic‑related agents can modify proliferation, apoptosis, epithelial‑mesenchymal transition, angiogenesis, immune surveillance and the tumor microenvironment. Translation to clinical benefit, however, has been inconsistent, in part beca…

Rank85.0
Randomized clinical study

Precision immuno-oncology in triple-negative breast cancer: from PD-L1 to multimodal biomarkers, ADC-ICI combinations, and global real-world integration.

Frontiers in immunology · 2026 · PMID 42936250

Immune checkpoint blockade improves outcomes in defined settings of triple-negative breast cancer (TNBC), but treatment failure does not identify a single biological mechanism or an interchangeable set of remedies. This focused narrative review examines how biomarkers can distinguish established treatment eligibility from investigational strategies intended to address immune exclusion and resistance. Randomized TNBC trials provide the clinical reference, while translational studies and trials in other malignancies …

Rank85.0
Randomized clinical study

Robust Prediction-Reliability Assessment in Biomedical Sensing and Classification Under Data Scarcity Using Conformal Prediction and Statistical Randomization.

Sensors (Basel, Switzerland) · 2026 · PMID 42944376

Reliable assessment of prediction reliability is important in biomedical sensing and measurement applications, where machine learning models increasingly transform imaging, physiological, chemical, and molecular measurements into clinically relevant predictions. Such applications often operate under limited labeled data because sensor acquisition, experimental measurement, and expert annotation can be costly, while biological and measurement variability can further challenge model development. Under these condition…

Rank81.9
Phase II clinical trial

Long-term outcome after partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy: Results from a Phase II prospective study with extended follow-up.

Brachytherapy · 2026 · PMID 42800727

OBJECTIVE: To assess late toxicities, cosmesis, and oncological outcomes in patients treated with Partial Breast Irradiation (PBI) using interstitial multi-catheter high dose-rate brachytherapy. METHODS: From 2003 to 2023, 292 patients were enrolled in a prospective observational study (follow-up up to 20 years). INCLUSION CRITERIA: age ≥40 years; ECOG 0-2; ductal carcinoma in situ; invasive non lobular carcinoma; tumor size ≤2.5 cm; negative axillary lymph nodes; surgical margins ≥2 mm. PBI dose was 32 Gy in 8 fra…

Rank81.7
Phase II clinical trialCorrection flagged

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42623567

PURPOSE: EA1181 (ClinicalTrials.gov identifier: NCT04266249) is a single-arm trial evaluating neoadjuvant taxane, trastuzumab, and pertuzumab (THP) in patients with clinical stage II/IIIa human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This report focuses on the secondary end points of pathologic complete response (pCR) rates and associated factors. The primary end point-3-year recurrence-free survival among patients achieving a pCR (ypT0/Tis, ypN0)-will be reported when data mature. METHODS…

Rank80.5
Phase II clinical trial

Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42550849

PURPOSE: Behavioral weight loss (BWL) interventions consisting of remote coaching and self-monitoring have limited effectiveness in breast cancer survivors. We conducted a single-arm phase II study evaluating the addition of Contrave for <5% weight loss (%WL) after 2 months of BWL. PATIENTS AND METHODS: Women with prior stage 0 to III breast cancer and a body mass index ≥27 kg/m2 were eligible and initiated BWL. We collected weight, patient-reported outcomes, and labs at baseline, 2 months, and 6 months. At 2 month…

Rank79.1
Phase II clinical trial

Five-year outcomes of partial breast proton beam therapy without lumpectomy for early-stage breast cancer: an interventional prospective study.

Breast cancer (Tokyo, Japan) · 2026 · PMID 42762384

BACKGROUND: We report on our initial clinical experience with partial breast proton beam therapy (PB-PBT) without tumor resection as an alternative to partial mastectomy for low-risk early-stage breast cancer. METHODS: This trial commenced in 2015, and eligibility criteria included women with cT1N0M0 invasive ductal carcinoma, estrogen receptor positivity, human epidermal growth factor receptor type-2 negativity, age of 40-70 years, and a performance status of 0 or 1. In Phase I, PB-PBT was administered at 62.4 Gy …

Rank79.1
Phase II clinical trial

Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.

Nature communications · 2026 · PMID 42773107

Strategies are needed to avoid chemotherapy in early stage HER2-positive (HER2 + ) breast cancer (BC). We conducted a neoadjuvant therapy trial with zanidatamab, a dual HER2-directed bispecific antibody, in patients with 1-3 cm, node-negative HER2 + BC. Primary endpoint was pathologic complete response (pCR). Secondary endpoints were radiographic response by ultrasound and magnetic resonance imaging. US and MRI, pathologic response by residual cancer burden (RCB), rate of adverse events, feasibility of accrual and …

Rank68.7
Phase I clinical trial

A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018).

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42810148

BACKGROUND: This first-in-human, phase I study (NCT05174637) assessed F0024 (FDA018), a TROP2-directed ADC, in advanced solid tumors, including a dose-expansion cohort in triple-negative breast cancer (TNBC). METHODS: Participants were intravenously administered F0024 (2.5-15 mg/kg) in the dose-escalation phase to determine the safety and tolerability. Dose-expansion cohorts of patients with heavily pretreated TNBC received doses of 10 or 12 mg/kg to further assess the efficacy and safety. RESULTS: 67 participants …

Rank65.0
Phase I clinical trial

Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42777289

PURPOSE: Patients with metastatic castration-resistant prostate cancer (mCRPC) and advanced breast cancer (aBC) have poor outcomes with standard treatments. We report phase 1 results from the STESIDES (NCT03878823) study of ODM-209, an oral selective CYP11A1 inhibitor that blocks all synthesis of steroid hormones. METHODS: STESIDES was a dose-finding study (3 +3 design) in adults with progressive mCRPC, with or without activating androgen receptor ligand-binding domain (AR-LBD) mutations, who received ≥ 1 prior AR …

Rank48.0
Other PubMed-indexed publication

3-Indolepropionic acid mitigates sub-acute toxicity in the cardiomyocytes of epirubicin-treated female rats.

Naunyn-Schmiedeberg's archives of pharmacology · 2024 · PMID 37477660

Epirubicin (EPI) is an effective chemotherapeutic against breast cancer, though EPI-related cardiotoxicity limits its usage. Endogenously derived 3-indolepropionic acid (3-IPA) from tryptophan metabolism is of interest due to its antioxidant capabilities which may have cardioprotective effects. Supplementation with 3-IPA may abate EPI's cardiotoxicity, and herein we studied the possibility of lessening EPI-induced cardiotoxicity in Wistar rats. Experimental rats (n = 30; BW 180-200 g) were randomly distributed in f…

Rank47.5
Other PubMed-indexed publication

Clinical evaluation of deep learning-based automatic clinical target volume segmentation: a single-institution multi-site tumor experience.

La Radiologia medica · 2023 · PMID 37597126

PURPOSE: The large variability in tumor appearance and shape makes manual delineation of the clinical target volume (CTV) time-consuming, and the results depend on the oncologists' experience. Whereas deep learning techniques have allowed oncologists to automate the CTV delineation, multi-site tumor analysis is often lacking in the literature. This study aimed to evaluate the deep learning models that automatically contour CTVs of tumors at various sites on computed tomography (CT) images from objective and subject…

Prospective Cohort Studies140 records
Rank110.0
Systematic review or meta-analysis

Sensitive Period Analysis of Adulthood BMI and Cancer Risk: An Individual Participant Data Meta-Analysis of Over 720,000 Participants in the ABACus 2 Consortium.

International journal of cancer · 2026 · PMID 41952250

At least 13 cancers are linked to obesity. We analyse time-to-event data using Sensitive Period Analysis to explore whether associations between body mass index (BMI) and cancer incidence vary throughout adulthood to inform cancer prevention strategies, policy and weight management trials of optimal intervention ages. Using the European Prospective Investigation into Cancer and Nutrition cohort, Atherosclerosis Risk in Communities study, Women's Health Initiative, Prostate, Lung, Colorectal, Ovarian Cancer Screenin…

Rank106.9
Systematic review or meta-analysisResult signal: benefit

Reducing rates of chronic breast cancer-related lymphedema with screening and early intervention: an update of recent data.

Journal of cancer survivorship : research and practice · 2024 · PMID 35947288

PURPOSE: Breast cancer-related lymphedema (BCRL) represents a dreaded complication of breast cancer treatment that can lead to morbidity, diminished quality of life, and psychosocial harm and is associated with increased costs of care. Increasingly, data has supported the concept of prospective BCRL surveillance coupled with early intervention to mitigate these effects. METHODS: We performed a systematic review of the literature searching for published randomized and prospective data evaluating prospective BCRL sur…

Rank105.0
Systematic review or meta-analysis

Effect of Post-diagnosis Physical Activity on Breast Cancer Recurrence: a Systematic Review and Meta-analysis.

Current oncology reports · 2022 · PMID 35947284

PURPOSE OF REVIEW: Breast cancer (BC) recurrence dramatically decreases 5-year survival, which causes a fear of BC recurrence among a majority of BC survivors. Evidence is currently inconsistent on whether post-diagnosis recreational physical activity (rPA) can prevent BC recurrence due to the small number of included studies, as well as methodological heterogeneity among the studies. This systematic review aimed to clarify the association between post-diagnosis rPA and the risk of BC recurrence, by conducting a me…

Rank104.3
Systematic review or meta-analysis

Menopausal Estrogen Therapy and Risk of Breast Cancer.

Obstetrics and gynecology · 2026 · PMID 42594383

Recent evidence suggests that use of menopausal estrogen-only therapy in patients who have undergone hysterectomy reduces breast cancer risk among patients at population risk for breast cancer as well as in those with pathogenic high-risk BRCA variants. A meta-analysis of 10 randomized trials of estrogen therapy compared with placebo among 14,282 participants at population risk noted that 3.6% those randomized to estrogen alone were diagnosed with breast cancer, compared with 4.7% of those randomized to placebo (re…

Rank103.3
Systematic review or meta-analysis

Artificial intelligence-supported double reading in European population breast cancer screening: A systematic review and meta-analysis of prospective programs.

Clinical imaging · 2026 · PMID 42617468

BACKGROUND: Most European population mammography screening programs rely on double reading with arbitration, a model that delivers mortality benefit but is increasingly challenged by radiologist workload, variable specificity, and interval cancers. Artificial intelligence (AI) is being evaluated to support or optimize these established European screening pathways. PURPOSE: To synthesize prospective or program-embedded evaluations of AI conducted within European-style population screening programs and to estimate ex…

Rank102.5
Systematic review or meta-analysisResult signal: benefit

Management of genitourinary symptoms in patients with breast cancer: an updated systematic review of available evidence from randomized trials.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023 · PMID 36695978

PURPOSE: The purpose of this systematic review update is to synthesize available data on management of genitourinary symptoms (GUS) in breast cancer patients, a common and challenging clinical scenario. METHODS: EMBASE, Ovid Medline, and the Cochrane Library were searched from September 2014 to December 2021 for randomized controlled trials which examined various interventions for GUS in breast cancer patients. Outcomes of interest included improvements in vaginal symptoms (e.g., dryness, pain, dyspareunia, itching…

Rank100.0
Systematic review or meta-analysis

Cancer risk among individuals with mental illness - a systematic review and meta-analysis of nordic register-based prospective studies.

Translational psychiatry · 2026 · PMID 42957628

Although cancer patients have a high burden of mental illness, it is less clear whether patients with mental illness experience a higher-than-expected cancer risk. This systematic review investigated the associations between a wide range of types of mental illness and subsequent cancer risk. Five electronic databases were searched for articles published from database initiation to October 24, 2024. Studies using nationwide Nordic register data to conduct a prospective analysis of the association between mental illn…

Rank99.5
Randomized controlled trial

Multicenter randomized effectiveness/implementation trial of a digital self-management support tool to improve the quality of life during adjuvant hormonal therapy for patients with early breast cancer: The HOPE trial.

Contemporary clinical trials · 2026 · PMID 42501860

BACKGROUND: For patients with hormone receptor (HR) positive early breast cancer (BC), adjuvant endocrine therapy (ET) represents the cornerstone of treatment. However, 75% of patients experience ET-related symptoms that negatively affect their quality of life (QOL). Despite their high prevalence, these symptoms are often underestimated and under-addressed during consultations. As a result, non-adherence to ET is common and remains a major barrier for optimal disease and survival outcomes. METHODS: National, prospe…

Rank98.7
Randomized controlled trial

A Prospective, Multicenter Randomized Controlled Trial (RCT) of the da Vinci SP® Surgical System versus Open Surgery in Nipple-Sparing Mastectomy (NSM) Procedures for Patients with Breast Cancer.

Annals of surgical oncology · 2026 · PMID 42463607

BACKGROUND: This prospective randomized trial evaluated the safety and effectiveness of robotic-assisted nipple-sparing mastectomy (rNSM) using the da Vinci Single Port (SP)® compared with open NSM in women with early stage breast cancer. PATIENTS AND METHODS: This Food and Drug Administration (FDA) investigational device exemption (IDE)-approved, two-arm, multicenter randomized controlled trial (RCT) randomized eligible women (clinical Tis-T2, N0) 1:1 to rNSM or open NSM with immediate implant-based reconstruction…

Rank97.6
Randomized controlled trialResult signal: harm

Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial.

Breast (Edinburgh, Scotland) · 2026 · PMID 42632205

BACKGROUND: Hormone receptor-positive, HER2-negative (HR+/HER2-) early breast cancer (EBC) is characterized by a persistent risk of late recurrences up to 15 years from diagnosis. Phase III randomized IDEAL (Investigation on the Duration of Extended Adjuvant Letrozole) trial was conducted to optimize the duration of extended endocrine therapy (EET). This blinded prospective-retrospective study investigates the potential of CanAssist Breast (CAB) to predict late recurrences and identify patients who may benefit from…

Rank97.0
Systematic review or meta-analysisResult signal: null

A systematic review of robotic breast surgery versus open surgery.

Journal of robotic surgery · 2023 · PMID 37624486

Robotic-assisted breast surgery (RABS) is controversial. We systematically reviewed the evidence about RABS, comparing it to open conventional breast surgery (CBS). Following prospective registration (osf.io/97ewt), a search was performed in January 2023, without time or language restrictions, through bibliographic databases (PubMed, Web of Science, EMBASE, Scopus, Trip database and CDSR) and grey literature. Quality was assessed in duplicate using Qualsyst criteria (score range 0.0-1.0); reviewer agreement was 98%…

Rank97.0
Systematic review or meta-analysis

Impact of obstructive sleep apnea on cancer risk: a systematic review and meta-analysis.

Sleep & breathing = Schlaf & Atmung · 2023 · PMID 36129602

PURPOSE: We aimed to study the effect of obstructive sleep apnea (OSA) on cancer risk. METHODS: We searched PubMed, Embase, and Cochrane databases for relevant studies. The qualities of included studies were assessed using Newcastle-Ottawa Scale (NOS). Unadjusted and adjusted analyses were performed. We also conducted subgroup analyses stratified by gender, severity of OSA, study design, and cancer type. RESULTS: After literatures search, 18 studies were included in the present study. In the unadjusted analysis, we…

Rank96.6
Randomized controlled trial

Pooled analysis of NeoCARH and NeoCART trials: patient-reported outcomes in patients with early-stage breast cancer receiving platinum-based or anthracycline-based neoadjuvant chemotherapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38829506

PURPOSE: Anthracycline-based or platinum-based neoadjuvant chemotherapy belongs to the standard treatment for early-stage breast cancer (EBC) that is either triple-negative or human epidermal growth factor receptor 2 positive (HER2 +). Currently, there is a paucity of data comparing their impact on health-related quality of life (HRQoL). METHODS: Triple-negative or HER2 + EBC from our two prospective randomized controlled trials, neoCARH and neoCART, were divided into two groups based on the neoadjuvant chemotherap…

Rank96.4
Randomized controlled trial

Acute Radiation Side Effects of Proton Versus Photon Therapy Following Surgery for Early Breast Cancer, a Substudy of the Randomized Controlled Danish Breast Cancer Group Proton Trial.

International journal of radiation oncology, biology, physics · 2026 · PMID 42600707

PURPOSE: Proton therapy (PT) is associated with favorable dosimetric characteristics compared with photon radiation therapy (γRT) in invasive breast cancer; however, clinical evidence on acute toxicity remains limited. This study aimed to compare acute treatment-related side effects between moderately hypofractionated PT and γRT in breast cancer. METHODS AND MATERIALS: The Danish Breast Cancer Group Proton trial-acute side effects was a preplanned substudy of the national, phase 3 randomized trial, the Danish Breas…

Rank96.2
Randomized controlled trial

Low dose of dexamethasone combined with netupitant and palonosetron in preventing nausea and vomiting in breast cancer patients induced by anthracycline drugs.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025 · PMID 39002066

BACKGROUND: To study the effects of various courses of dexamethasone (DEX) combined with 5-HT3 receptor antagonists (RA) and NK-1 RA in suppressing high-grade nausea and vomiting (CINV) caused by anthracycline and cyclophosphamide chemotherapy regimens (AC or EC) in breast cancer (BC) patients. PATIENTS AND METHODS: A prospective study was performed with 252 BC patients who received AC between January, 2019 and June, 2022 in our hospital. Patients were randomly separated into control Group (N = 130) who received DE…

Rank94.3
Randomized controlled trial

Does the patient-assisted compression mode affect the mammography quality? A within-woman randomized controlled trial.

European radiology · 2022 · PMID 35536391

OBJECTIVES: Evaluate the image quality of a mammography screening device using the patient-assisted compression (PAC) compared with the standard compression (SC) mode. METHODS: This prospective within-woman, randomized controlled trial was conducted between September 2017 and December 2019. Participants were asymptomatic women aged 50 to 69 years attending their second or subsequent screening mammography round. By random assignment, one breast underwent the SC and the other breast, the PAC. Image quality was evalua…

Rank94.3
Randomized controlled trial

Comparison of technical parameters and women's experience between self-compression and standard compression modes in mammography screening: a single-blind randomized clinical trial.

European radiology · 2022 · PMID 35536390

OBJECTIVES: We compared the compression force, breast thickness, and glandular dose, as well as the severity of discomfort and women's experience between the patient-assisted compression (PAC) and standard compression (SC) modes. MATERIALS AND METHODS: We conducted a prospective randomized controlled study at Hospital del Mar in Barcelona, Spain. We included 448 asymptomatic women aged 50 to 69 years old, attending their screening round from December 2017 to December 2019. Mammograms included the two bilateral view…

Rank93.0
Randomized controlled trial

Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022 · PMID 36574052

PURPOSE: The most appropriate criteria and timing for palliative care referral remain a critical issue, especially in patients with metastatic breast cancer for whom long-term chemosensibility and survival are observed. We aimed to compare the impact of early palliative care including formal concertation with oncologists on decision for an additional line of chemotherapy compared with usual oncology care. METHODS: This randomized prospective study enrolled adult women with metastatic breast cancer and visceral meta…

Rank92.2
Randomized clinical study

Breast cancer screening based on clinical breast examination performed by community health workers: study protocol for a randomized clinical trial - ITABERAÍ Project.

Contemporary clinical trials · 2026 · PMID 42838324

OBJECTIVE: The ITABERAÍ project evaluates whether breast cancer screening based on clinical breast examination (CBE) performed by community health workers (CHWs) can reduce advanced breast cancer and mortality. METHODS: This prospective, phase III, cluster-randomized controlled trial includes women aged ≥40 years using Brazil's public health system. Primary healthcare units and their Family Health Teams were randomized to a control group (CG) or intervention grop (IG). CHWs in the CG received standard breast cancer…

Rank89.8
Randomized clinical study

Seroma incidence and risk factors in women undergoing mastectomies as surgical breast cancer treatment.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39322817

INTRODUCTION: Seroma is the most common early complication following surgical breast cancer treatment. Its development is associated with pain, scar complications, adjuvant therapy delays, the need for outpatient visits, and increased care costs. OBJECTIVE: Assess seroma incidence and risk factors in women undergoing mastectomies. METHOD: This study comprises a prospective cohort encompassing women aged 18 or over undergoing mastectomies as a breast cancer treatment. Patients underwent physiotherapy on the 1st, 7th…

Rank87.3
Randomized clinical study

The impact of the COVID-19 pandemic on breast cancer survivorship: a scoping review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42850372

INTRODUCTION: The COVID-19 pandemic has affected how cancer care is delivered globally. This scoping review aimed to evaluate the impact of COVID-19 on breast cancer survivors (BCS), specifically regarding their quality of life (QoL), follow-up care, and interventions to address their supportive care needs. METHODS: This review was prepared following PRISMA guidelines. Embase, MEDLINE, CINAHL, and Web of Science were searched from January 2020 to February 2025. Primary studies in English that specifically commented…

Rank86.9
Randomized clinical study

Safety and Efficacy of Mitoxantrone Hydrochloride Injection for Identification of Axillary Sentinel Lymph Nodes in Patients with Primary Breast Cancer.

World journal of surgery · 2023 · PMID 37085640

BACKGROUND: The dual technique using blue dye in combination with a radioisotope is considered the gold standard for identifying sentinel lymph nodes (SLNs) in patients with breast cancer. Unfortunately, not all cancer centres have access to radioactive material, which jeopardizes the SLN identification rate and patient safety. AIM: We aimed to assess the safety and efficacy of mitoxantrone hydrochloride injection (MHI) for identifying axillary SLNs in patients with primary breast cancer. PATIENTS AND METHODS: We h…

Rank82.0
Randomized clinical study

Current Diagnostic Tools for Breast Cancer-Related Lymphedema.

Current oncology reports · 2023 · PMID 36696076

PURPOSE OF REVIEW: Breast cancer-related lymphedema (BCRL) can have a significant impact on breast cancer survivors quality of life. The purpose of this review is to evaluate diagnostic tools for the assessment of BCRL. RECENT FINDINGS: Multiple BCRL diagnostic tools are available, though older diagnostic tools have low sensitivity, limiting the ability for sub-clinical BCRL diagnosis while BIS and perometry have increased sensitivity and the ability to diagnose BCRL sub-clinically. Prospective studies have demonst…

Rank81.9
Phase II clinical trial

Long-term outcome after partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy: Results from a Phase II prospective study with extended follow-up.

Brachytherapy · 2026 · PMID 42800727

OBJECTIVE: To assess late toxicities, cosmesis, and oncological outcomes in patients treated with Partial Breast Irradiation (PBI) using interstitial multi-catheter high dose-rate brachytherapy. METHODS: From 2003 to 2023, 292 patients were enrolled in a prospective observational study (follow-up up to 20 years). INCLUSION CRITERIA: age ≥40 years; ECOG 0-2; ductal carcinoma in situ; invasive non lobular carcinoma; tumor size ≤2.5 cm; negative axillary lymph nodes; surgical margins ≥2 mm. PBI dose was 32 Gy in 8 fra…

Rank79.1
Phase II clinical trial

Five-year outcomes of partial breast proton beam therapy without lumpectomy for early-stage breast cancer: an interventional prospective study.

Breast cancer (Tokyo, Japan) · 2026 · PMID 42762384

BACKGROUND: We report on our initial clinical experience with partial breast proton beam therapy (PB-PBT) without tumor resection as an alternative to partial mastectomy for low-risk early-stage breast cancer. METHODS: This trial commenced in 2015, and eligibility criteria included women with cT1N0M0 invasive ductal carcinoma, estrogen receptor positivity, human epidermal growth factor receptor type-2 negativity, age of 40-70 years, and a performance status of 0 or 1. In Phase I, PB-PBT was administered at 62.4 Gy …

Quality Of Life225 records
Rank110.0
Systematic review or meta-analysis

The associations between household food insecurity and cancer: A comprehensive systematic review and meta-analysis of observational studies among adults.

Social science & medicine (1982) · 2026 · PMID 42685390

BACKGROUND: Household food insecurity (HFI) is a critical social determinant of health that can adversely influence cancer prevention, treatment, and survivorship, while a cancer diagnosis with its financial and functional consequences may also increase the risk of HFI. This study aimed to examine the associations between HFI and cancer-related outcomes. METHODS: A systematic search was done in PubMed, Embase, Scopus, Web of Science, and Cochrane Library until July 29, 2025. Eligible studies were observational in a…

Rank106.9
Systematic review or meta-analysisResult signal: benefit

Reducing rates of chronic breast cancer-related lymphedema with screening and early intervention: an update of recent data.

Journal of cancer survivorship : research and practice · 2024 · PMID 35947288

PURPOSE: Breast cancer-related lymphedema (BCRL) represents a dreaded complication of breast cancer treatment that can lead to morbidity, diminished quality of life, and psychosocial harm and is associated with increased costs of care. Increasingly, data has supported the concept of prospective BCRL surveillance coupled with early intervention to mitigate these effects. METHODS: We performed a systematic review of the literature searching for published randomized and prospective data evaluating prospective BCRL sur…

Rank106.7
Systematic review or meta-analysisResult signal: benefit

Acupuncture for Symptoms Characteristic of the Fatigue-Sleep Disturbance-Depression Symptom Cluster (FSDSC) in Breast Cancer: A Systematic Review and Meta-Analysis.

Integrative cancer therapies · 2026 · PMID 42960607

BackgroundThis study aimed to evaluate the effects of acupuncture or acupressure on fatigue, sleep disturbance/insomnia, and depression, the three component symptoms within the fatigue-sleep disturbance-depression symptom-cluster (FSDSC) conceptual framework in patients with breast cancer.MethodsA systematic review was conducted according to PRISMA guidelines. Seven databases (Embase, MEDLINE [Ovid], Cochrane Library [Trials], Scopus, Web of Science Core Collection, CNKI, and Wanfang Data) were searched from incept…

Rank106.4
Systematic review or meta-analysisResult signal: null

Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials.

European journal of clinical pharmacology · 2024 · PMID 38888626

INTRODUCTION: Incorporation of AKT inhibitors into adjuvant therapy for advanced or metastatic breast cancer has improved clinical outcomes. However, the safety of AKT inhibitors should be better evaluated, given the possibility of prolonging survival and impacting patient quality of life. Our aim was to assess how the addition of AKT inhibitors to adjuvant therapy affects treatment-related adverse events. METHODS: We evaluated binary outcomes with risk ratios (RRs), with 95% confidence intervals (CIs). We used Der…

Rank106.3
Systematic review or meta-analysis

Cognitive behavioural therapy for insomnia in people with cancer.

The Cochrane database of systematic reviews · 2025 · PMID 41170811

BACKGROUND: Insomnia is a prevalent and distressing issue for individuals with cancer, negatively impacting their overall well-being. While cognitive behavioural therapy for insomnia (CBT-I) is the recommended first-line treatment for insomnia in the general population, its effects on cancer populations warrant rigorous, ongoing evaluation. Previous meta-analyses assessing CBT-I against specific comparators in people with cancer have often exhibited methodological limitations. Furthermore, with a recent increase in…

Rank106.1
Systematic review or meta-analysis

Safety and efficacy of Meridian sinew tuina (MST) for post-surgical upper limb lymphedema: a systematic review and meta-analysis.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026 · PMID 42703097

BACKGROUND: Complex Decongestive Therapy (CDT) is the non-operative standard for breast cancer-related lymphedema (BCRL), but many patients experience persistent subcutaneous stiffness, pain, and restricted mobility. This study systematically reviews the safety and clinical efficacy of Meridian Sinew Tuina (MST) protocols for BCRL. METHODS: Global and regional databases (PubMed, Cochrane Library, Embase, Web of Science, CNKI, Wanfang, VIP) were searched from inception to January 15, 2026, with alerts monitored thro…

Rank106.0
Systematic review or meta-analysis

Physical prehabilitation in patients with breast cancer: a systematic review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025 · PMID 39757306

INTRODUCTION: In 2023, 35,000 new cases of breast cancer were diagnosed, becoming the first type of tumour diagnosed in Spain. This tumour and its treatments generate important changes in the patient's quality of life. Alterations in the range of motion, pain and both physical and psychological disability are some of the effects that breast cancer generates in patients. Physical prehabilitation could be an opportunity to prevent some of these adverse effects. OBJECTIVE: The objective of this review was to analyse t…

Rank106.0
Systematic review or meta-analysisResult signal: harm

Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis.

American journal of obstetrics and gynecology · 2023 · PMID 37059410

OBJECTIVE: This study aimed to assess the impact of risk-reducing surgery for breast cancer and ovarian cancer prevention on quality of life. We considered risk-reducing mastectomy, risk-reducing salpingo-oophorectomy, and risk-reducing early salpingectomy and delayed oophorectomy. DATA SOURCES: We followed a prospective protocol (International Prospective Register of Systematic Reviews: CRD42022319782) and searched MEDLINE, Embase, PubMed, and Cochrane Library from inception to February 2023. STUDY ELIGIBILITY CRI…

Rank105.9
Systematic review or meta-analysis

Effectiveness of dance movement therapy and dance movement interventions on cancer patients' health-related outcomes: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38502260

OBJECTIVES: This review examined the effectiveness of using dance movement therapy (DMT) and dance movement interventions (DMIs) with cancer and palliative care patients. METHODS: A systematic review and meta-analysis were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Six databases were searched from inception to July 9, 2022, without limits on year or age. Searching was updated on July 10, 2023. The risk of bias was assessed by the Cochrane (RoB 2) and RO…

Rank105.1
Systematic review or meta-analysis

Physical activity interventions for women with metastatic breast cancer: a systematic review of published and ongoing randomised controlled trials.

Journal of cancer survivorship : research and practice · 2026 · PMID 41214274

PURPOSE: We systematically reviewed published and ongoing physical activity (PA) trials in women with metastatic breast cancer (MBC). We examined (i) the effectiveness of PA interventions and identified (ii) the type of interventions being evaluated, (iii) how they are delivered and (iv) their theoretical basis. METHODS: Seven databases and two trial registries were searched in August 2024 for randomised controlled trials, testing any PA intervention in people with MBC, reporting a PA outcome. The Joanna Briggs Ins…

Rank104.3
Systematic review or meta-analysis

Systematic review and meta-analysis of the effectiveness of expressive writing disclosure on cancer and palliative care patients' health-related outcomes.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023 · PMID 38157056

OBJECTIVES: This review aimed to synthesize the available evidence on the effectiveness of expressive writing (EW) on health outcomes of patients with cancer. METHODS: A systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Six databases were searched from 1986 to 9 July 2022. The searches were updated on 3 October 2023. Methodological quality was assessed using the Cochrane Risk of Bias tool for randomized controlled trials…

Rank104.2
Systematic review or meta-analysis

Correlates of stigma for patients with breast cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022 · PMID 36526859

OBJECTIVE: This study was conducted to examine the factors associated with stigma in breast cancer women. METHODS: PubMed, Embase, the Cochrane Library, Web of Science, and two Chinese electronic databases were electronically searched to identify eligible studies that reported the correlates of stigma for patients with breast cancer from inception to July 2022. Two researchers independently performed literature screening, data extraction, and risk of bias assessment. R4.1.1 software was used for statistical analysi…

Rank103.5
Systematic review or meta-analysis

Chest wall pain as a late effect following radiotherapy for breast cancer: A systematic review of prevalence and risk factors.

Technical innovations & patient support in radiation oncology · 2026 · PMID 42830996

BACKGROUND: Breast cancer is the most commonly diagnosed cancer in women with approximately 60% receiving adjuvant radiotherapy. Despite advances minimising radiation dose to normal tissues, many women report post treatment pain affecting quality of life. Limited evidence on pain location, severity and risk factors for occurrence impacts clinical management. This systematic review identified studies reporting the prevalence of chest wall pain after breast cancer radiotherapy and explored associated risk factors. ME…

Rank102.6
Systematic review or meta-analysis

Systematic review of aquatic therapeutic exercise efficacy in breast cancer survivors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022 · PMID 36525089

PURPOSE: The aim of this review is to establish the efficacy of aquatic therapeutic exercise in female breast cancer survivors for improving fatigue, pain, lymphedema, and quality of life. METHODS: A systematic literature review was conducted in PubMed, Web of Science, and Cochrane Library databases for articles published in the last 10 years. The review focuses on aquatic exercise-based rehabilitation in female breast cancer survivors, according to the PRISMA statement and using the PEDRO and Jadad scales. RESULTS…

Rank102.6
Systematic review or meta-analysis

Topical non-steroidal agents for the prevention of radiation dermatitis: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023 · PMID 36928164

PURPOSE: Radiation dermatitis (RD) is a common side effect of radiation therapy, affecting a majority of breast and head and neck cancer patients with a negative impact on quality of life. Currently, no consensus exists regarding the prevention of RD. METHODS: PubMed, Embase and Cochrane databases (1946 to December 2022) were searched using PRISMA guidelines to identify randomized controlled trials (RCTs) that investigated the use of topical non-steroidal agents in the prevention of RD in patients undergoing radiot…

Rank102.1
Systematic review or meta-analysisResult signal: mixed

The effect of different telerehabilitation technologies on the management of cardiovascular disease in oncology survivors: systematic review.

Journal of cancer survivorship : research and practice · 2026 · PMID 41354726

PURPOSE: With advancements in early detection and treatment improving cancer survival rates, cancer survivors face an increased risk of cardiovascular-specific morbidity and mortality. Cardiovascular telerehabilitation has been a notable tool to enhance the quality of life and manage cardiovascular disease in cancer survivors. This systematic review aims to evaluate the effectiveness of different telerehabilitation technologies in improving cardiovascular fitness in cancer survivors. METHODS: This review was regist…

Rank101.6
Systematic review or meta-analysis

StrataXRT for the prevention of acute radiation dermatitis in breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023 · PMID 37556002

PURPOSE: To evaluate the overall efficacy of StrataXRT, a topical gel dressing, in preventing acute radiation dermatitis (RD) in breast cancer patients undergoing radiotherapy (RT). METHODS: A systematic search was conducted on April 25, 2023 in Ovid MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. Randomized controlled trials (RCTs) assessing the effectiveness of StrataXRT in preventing acute RD in breast cancer patients undergoing adjuvant RT to the breast or chest wall with or without regiona…

Rank100.0
Systematic review or meta-analysis

Impact of age and treatment-related adverse events on financial toxicity among patients with breast cancer: a systematic review.

Journal of cancer survivorship : research and practice · 2026 · PMID 40884698

PURPOSE: Increasing incidence of breast cancer among young adults (YA), defined by the National Comprehensive Cancer Network (NCCN) as age < 40 years, has amplified concerns over financial toxicity (FT) in this demographic. This systematic review sought to clarify the association between YA status and FT. METHODS: We queried bibliographic databases for full-text English language publications between 2010 and 2024 reporting FT using validated patient-reported outcome metrics among patients with stage I-III breast ca…

Rank100.0
Systematic review or meta-analysis

Effect of exercise on fatigue and depression in breastcancer women undergoing chemotherapy: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39012405

This meta-analysis examined the effectiveness of exercise interventions in reducing fatigue and depression among women undergoing chemotherapy for breast cancer. The study followed PRISMA guidelines and analysed seven randomized controlled trials between 2016 and 2022. The results showed that exercise can substantially reduce fatigue levels (MD: -0.40, CI: -0.66, -0.14, P: 0.003), a common side effect of chemotherapy. Although depression did not significantly change (MD: -0.39, CI: -0.98, 0.20, P: 0.19), this study…

Rank100.0
Systematic review or meta-analysis

Instruments for measuring body image in breast cancer patients: a systematic review of measurement properties.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026 · PMID 42701946

PURPOSE: To evaluate the psychometric properties of PROMs for measuring body image in breast cancer patients. METHODS: In December 2024, a psychometric systematic review was performed in the nine databases. The COSMIN checklist was employed to evaluate the methodological quality and psychometric properties of the included body image measures. The level of evidence was assessed using the GRADE framework, and final recommendations were formulated for the scale. RESULTS: Thirty-eight articles evaluating fifteen PROMs …

Rank100.0
Systematic review or meta-analysis

Effect of yoga as a complementary therapy in prostate cancer survivors: a systematic review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39066831

PURPOSE: Currently, available evidence suggests a positive impact of yoga on physical and psychological well-being in patients across different types of cancer, especially breast cancer survivors. However, there are no available systematic reviews on the effects of yoga on male prostate cancer survivors. The objective of the current systematic review is to specifically examine the quality of life, feasibility, and other effects of yoga on prostate cancer survivors. METHODS: Bibliographic databases such as PubMed/Me…

Rank100.0
Systematic review or meta-analysis

Quality of life issues in patients with ductal carcinoma in situ: a systematic review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39352516

PURPOSE: Ductal carcinoma in situ (DCIS) of the breast is one of the most common pre-invasive cancers diagnosed in women. Quality of life (QoL) is extremely important to assess in studies including these patients due to the favorable prognosis of the disease. The primary objective of this systematic review was to compile a comprehensive list of QoL issues, all existing QoL assessment tools, and patient-reported outcome measures used to assess DCIS. METHODS: A search was conducted on Ovid MEDLINE, EMBASE, and Cochra…

Rank100.0
Systematic review or meta-analysis

Venlafaxine in oncology: supportive-care evidence and emerging preclinical anticancer signals: a systematic review.

Frontiers in pharmacology · 2026 · PMID 42964294

BACKGROUND: Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, has been investigated in oncology for several supportive care indications and, more recently, for potential anticancer activity. However, the available evidence remains fragmented across clinical and preclinical studies. OBJECTIVE: This systematic review aimed to synthesize the available evidence regarding the role of venlafaxine in oncology, including established supportive care applications and emerging anticancer potential. METHODS: A system…

Rank100.0
Systematic review or meta-analysis

Associations of frailty with symptoms, and HRQOL in older cancer survivors after cancer treatments: a systematic review and meta-analyses.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024 · PMID 37897643

PURPOSE: Frailty in older adult cancer survivors after cancer treatments is associated with various health outcomes. However, there is less agreement on how frailty affects symptoms and health-related quality of life (HRQOL). This systematic review and meta-analysis aimed to evaluate the current literature on frailty, symptoms, and HRQOL, as well as the associations of frailty with these factors in older adult cancer survivors with chemotherapy. METHODS: A review was conducted on peer-reviewed publications from 200…

Rank99.8
Randomized controlled trial

Real-Time Electronic Patient-Reported Outcome Monitoring With Digital Triage and Care-Team Integration in Early Breast Cancer: ENABLE Randomized Controlled Trial.

Journal of medical Internet research · 2026 · PMID 42954133

BACKGROUND: Electronic patient-reported outcomes (ePROs) can support patient-centered oncology care, but in early breast cancer, it is unclear whether real-time ePRO-triggered triage adds benefit beyond lower-intensity app-based support and scheduled ePRO collection. OBJECTIVE: We tested whether adding weekly ePRO screening, rule-based triage, and care-team escalation to app-based support improves health-related quality of life (HRQoL) during systemic therapy for early breast cancer. METHODS: ENABLE was a multicent…

Randomized Controlled Trials179 records
Rank112.8
Systematic review or meta-analysis

Artificial Intelligence in Breast Cancer Diagnosis, Treatment, and Perioperative Management: A Systematic Review of Current Applications and Future Perspectives.

La Clinica terapeutica · 2026 · PMID 42922241

BACKGROUND: Breast cancer is the most frequently diagnosed malignancy in women globally, accounting for approximately 2.30 million new cases and 666,103 deaths in 2022. Artificial intelligence technologies including machine learning, deep learning, radiomics, and natural language processing have been widely applied across the breast cancer care continuum. However, no systematic review restricted to primary studies with patient-level or image-level data has synthesized evidence spanning all clinical domains simultan…

Rank110.0
Clinical guideline or consensus statement

Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42462191

UNLABELLED: ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the https://www.asco.org/practice-patients/guidelines/guideline-methodology. ASCO Guidelines follow the https://www.asco.org/about-asco/legal/conflict-interest-coi.Clinical Practice Guidelines and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options. It is inten…

Rank110.0
Systematic review or meta-analysis

Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.

Journal of endocrinological investigation · 2024 · PMID 38530620

BACKGROUND: The effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cancer has yet to be fully elucidated. OBJECTIVE: This systematic review and meta-analysis investigated the effects of SGLT2 inhibitors on cancer. METHODS: We searched the PubMed and ClinicalTrials.gov databases up to July 15, 2023, to identify eligible randomized, double-blind, placebo-controlled trials that lasted at least ≥24 weeks. The primary outcome was the overall cancer incidence, and the secondary outcomes were the incidences of…

Rank109.7
Systematic review or meta-analysisResult signal: benefit

Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies.

Targeted oncology · 2025 · PMID 39656361

BACKGROUND: The efficacy and safety of cyclin-dependent kinase (CDK)4/6 inhibitors in patients with breast cancer have been investigated by large-scale trials sponsored by drug companies. A lack of real-world evidence may lead to biases. OBJECTIVE: We systematically reviewed the large-scale clinical trials and real-world data to investigate the efficacy and safety of CDK4/6 inhibitors in patients with breast cancer. PATIENTS AND METHODS: We searched PubMed, Embase, and Cochrane Library from the inception of each da…

Rank107.6
Systematic review or meta-analysis

Association between hair cortisol concentration and cancer-related outcomes in adult patients: A systematic review.

Psychoneuroendocrinology · 2026 · PMID 42784920

BACKGROUND: Chronic stress, through sustained hypothalamic-pituitary-adrenal (HPA) axis activation, has been implicated in cancer progression. Hair cortisol concentration (HCC) offers a unique retrospective window into cumulative cortisol exposure, yet its relationship with cancer outcomes has never been systematically examined. OBJECTIVE: To critically appraise the evidence linking HCC to cancer-related outcomes in adults and to identify the methodological gaps that currently limit this emerging field. METHODS: Fo…

Rank106.9
Systematic review or meta-analysisResult signal: benefit

Reducing rates of chronic breast cancer-related lymphedema with screening and early intervention: an update of recent data.

Journal of cancer survivorship : research and practice · 2024 · PMID 35947288

PURPOSE: Breast cancer-related lymphedema (BCRL) represents a dreaded complication of breast cancer treatment that can lead to morbidity, diminished quality of life, and psychosocial harm and is associated with increased costs of care. Increasingly, data has supported the concept of prospective BCRL surveillance coupled with early intervention to mitigate these effects. METHODS: We performed a systematic review of the literature searching for published randomized and prospective data evaluating prospective BCRL sur…

Rank106.8
Systematic review or meta-analysisResult signal: benefit

Efficacy and safety of trastuzumab deruxtecan in HER2-high and HER2-low breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Journal of chemotherapy (Florence, Italy) · 2026 · PMID 41345476

Breast cancer is the most common malignancy, with approximately ∼20% of cases involving HER2 overexpression. Trastuzumab deruxtecan (T-DXd), an HER2-targeted antibody-drug conjugate, is approved for HER2-high and HER2-low disease. This meta-analysis assessed four randomized controlled trials (DESTINY-Breast02, -03, -04, and -06; 2555 patients) from PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. A random-effects model revealed that T-DXd significantly improved progression-free survival (hazard ratio [HR] …

Rank106.7
Systematic review or meta-analysis

Postoperative outcomes of minimally invasive versus conventional nipple-sparing mastectomy with prosthesis breast reconstruction in breast cancer: a meta-analysis.

Journal of robotic surgery · 2024 · PMID 38951387

Breast cancer is the most common malignant tumor worldwide, and mastectomy remains the primary strategy for treating early stage breast cancer. However, the complication rates, surgical variables, and oncologic safety of minimally invasive nipple-sparing mastectomy (MINSM) have not been fully addressed. We systematically searched PubMed, Web of Science, Embase, and the Cochrane Library for randomized-controlled trials (RCTs) and non-RCTs that compared MINSM with conventional nipple-sparing mastectomy (CNSM), both f…

Rank106.7
Systematic review or meta-analysisResult signal: benefit

Acupuncture for Symptoms Characteristic of the Fatigue-Sleep Disturbance-Depression Symptom Cluster (FSDSC) in Breast Cancer: A Systematic Review and Meta-Analysis.

Integrative cancer therapies · 2026 · PMID 42960607

BackgroundThis study aimed to evaluate the effects of acupuncture or acupressure on fatigue, sleep disturbance/insomnia, and depression, the three component symptoms within the fatigue-sleep disturbance-depression symptom-cluster (FSDSC) conceptual framework in patients with breast cancer.MethodsA systematic review was conducted according to PRISMA guidelines. Seven databases (Embase, MEDLINE [Ovid], Cochrane Library [Trials], Scopus, Web of Science Core Collection, CNKI, and Wanfang Data) were searched from incept…

Rank106.5
Systematic review or meta-analysis

[Effects of phytoestrogens on prognosis and hormonal markers of breast cancer: A systematic review of randomized controlled trials].

Bulletin du cancer · 2026 · PMID 42823214

INTRODUCTION: Estrogen exposure is a known risk factor for breast cancer. Phytoestrogens, plant-derived compounds found in the diet, have a structure similar to estradiol. Observational studies suggest that they are associated with a reduced risk of breast cancer recurrence. The objective of this systematic review is to evaluate, based on data from randomized controlled trials, the effect of phytoestrogens on breast cancer prognosis and hormonal markers. METHODS: MEDLINE, EMBASE, CENTRAL, and ClinicalTrials.gov wer…

Rank106.5
Systematic review or meta-analysisResult signal: benefit

Effect of telehealth interventions on adherence to endocrine therapy among patients with breast cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38332357

PURPOSE: To evaluate the effect of telehealth interventions on adherence to endocrine therapy among patients with breast cancer. METHODS: A systematic search of five English databases (PubMed, Web of Science, Embase, the American Psychological Association PsycNet, and the Cochrane Library) and four Chinese databases (Chinese National Knowledge Infrastructure, SinoMed, WanFang Data, and WeiPu Data) was performed from inception to March 31, 2023. Two investigators independently screened the available studies for elig…

Rank106.4
Systematic review or meta-analysisResult signal: null

Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials.

European journal of clinical pharmacology · 2024 · PMID 38888626

INTRODUCTION: Incorporation of AKT inhibitors into adjuvant therapy for advanced or metastatic breast cancer has improved clinical outcomes. However, the safety of AKT inhibitors should be better evaluated, given the possibility of prolonging survival and impacting patient quality of life. Our aim was to assess how the addition of AKT inhibitors to adjuvant therapy affects treatment-related adverse events. METHODS: We evaluated binary outcomes with risk ratios (RRs), with 95% confidence intervals (CIs). We used Der…

Rank106.4
Systematic review or meta-analysis

Impact of resistance training on fatigue among breast cancer patients undergoing chemotherapy: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39392491

PURPOSE: The effects of aerobic exercise interventions for reducing fatigue after cancer treatment are well-established, and the effect of resistance training remains uncertain. Therefore, this systematic review and meta-analysis aim to analyze the effect of resistance training and combined resistance and endurance training on cancer-related fatigue (CRF) in breast cancer patients. METHODS: A systematic search for randomized controlled trials (RCTs) was conducted on the PubMed, SPORTDiscus, Embase, and Cochrane dat…

Rank106.3
Systematic review or meta-analysis

Cognitive behavioural therapy for insomnia in people with cancer.

The Cochrane database of systematic reviews · 2025 · PMID 41170811

BACKGROUND: Insomnia is a prevalent and distressing issue for individuals with cancer, negatively impacting their overall well-being. While cognitive behavioural therapy for insomnia (CBT-I) is the recommended first-line treatment for insomnia in the general population, its effects on cancer populations warrant rigorous, ongoing evaluation. Previous meta-analyses assessing CBT-I against specific comparators in people with cancer have often exhibited methodological limitations. Furthermore, with a recent increase in…

Rank106.1
Systematic review or meta-analysis

Safety and efficacy of Meridian sinew tuina (MST) for post-surgical upper limb lymphedema: a systematic review and meta-analysis.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026 · PMID 42703097

BACKGROUND: Complex Decongestive Therapy (CDT) is the non-operative standard for breast cancer-related lymphedema (BCRL), but many patients experience persistent subcutaneous stiffness, pain, and restricted mobility. This study systematically reviews the safety and clinical efficacy of Meridian Sinew Tuina (MST) protocols for BCRL. METHODS: Global and regional databases (PubMed, Cochrane Library, Embase, Web of Science, CNKI, Wanfang, VIP) were searched from inception to January 15, 2026, with alerts monitored thro…

Rank106.0
Systematic review or meta-analysisResult signal: harm

Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis.

American journal of obstetrics and gynecology · 2023 · PMID 37059410

OBJECTIVE: This study aimed to assess the impact of risk-reducing surgery for breast cancer and ovarian cancer prevention on quality of life. We considered risk-reducing mastectomy, risk-reducing salpingo-oophorectomy, and risk-reducing early salpingectomy and delayed oophorectomy. DATA SOURCES: We followed a prospective protocol (International Prospective Register of Systematic Reviews: CRD42022319782) and searched MEDLINE, Embase, PubMed, and Cochrane Library from inception to February 2023. STUDY ELIGIBILITY CRI…

Rank105.9
Systematic review or meta-analysis

Effectiveness of dance movement therapy and dance movement interventions on cancer patients' health-related outcomes: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38502260

OBJECTIVES: This review examined the effectiveness of using dance movement therapy (DMT) and dance movement interventions (DMIs) with cancer and palliative care patients. METHODS: A systematic review and meta-analysis were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Six databases were searched from inception to July 9, 2022, without limits on year or age. Searching was updated on July 10, 2023. The risk of bias was assessed by the Cochrane (RoB 2) and RO…

Rank105.8
Systematic review or meta-analysis

Decrease of radiation-induced skin reactions in breast cancer patients by preventive application of film dressings-a systematic review.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024 · PMID 37755486

PURPOSE: Radiation-induced skin reactions remain one of the most frequent side effects of adjuvant radiotherapy for breast cancer, which is the most common global malignancy. In individual cases, we observed a decrease in radiation dermatitis under film dressings used for skin marking purposes. Therefore, we decided to revise the available evidence regarding the prophylactic use of film dressings to reduce radiation dermatitis in breast cancer patients. METHODS: On 20 March 2023, we conducted a systematic review of…

Rank105.4
Systematic review or meta-analysis

Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

Journal of gastrointestinal cancer · 2024 · PMID 39160369

BACKGROUND AND OBJECTIVE: Metronomic capecitabine has been found to be useful in several types of cancers such as pancreatic cancer, breast cancer, gastrointestinal cancers, nasopharyngeal carcinoma, and metastatic colorectal cancer. This unique systematic literature review and meta-analysis was undertaken to assess the effectiveness and safety of metronomic capecitabine as a treatment regimen for hepatocellular carcinoma. METHOD: A systematic search of major databases was performed. Eight studies that dealt with t…

Rank105.1
Systematic review or meta-analysis

Physical activity interventions for women with metastatic breast cancer: a systematic review of published and ongoing randomised controlled trials.

Journal of cancer survivorship : research and practice · 2026 · PMID 41214274

PURPOSE: We systematically reviewed published and ongoing physical activity (PA) trials in women with metastatic breast cancer (MBC). We examined (i) the effectiveness of PA interventions and identified (ii) the type of interventions being evaluated, (iii) how they are delivered and (iv) their theoretical basis. METHODS: Seven databases and two trial registries were searched in August 2024 for randomised controlled trials, testing any PA intervention in people with MBC, reporting a PA outcome. The Joanna Briggs Ins…

Rank105.0
Systematic review or meta-analysis

Effect of Post-diagnosis Physical Activity on Breast Cancer Recurrence: a Systematic Review and Meta-analysis.

Current oncology reports · 2022 · PMID 35947284

PURPOSE OF REVIEW: Breast cancer (BC) recurrence dramatically decreases 5-year survival, which causes a fear of BC recurrence among a majority of BC survivors. Evidence is currently inconsistent on whether post-diagnosis recreational physical activity (rPA) can prevent BC recurrence due to the small number of included studies, as well as methodological heterogeneity among the studies. This systematic review aimed to clarify the association between post-diagnosis rPA and the risk of BC recurrence, by conducting a me…

Rank104.5
Systematic review or meta-analysis

Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis.

Annals of medicine · 2026 · PMID 41949990

BACKGROUND: Despite the availability of several chemotherapeutic regimens for early-stage breast cancer (BC), the ideal combination and dosing strategy remain to be defined. Thus, we conducted a network meta-analysis (NMA) comparing the current chemotherapeutic regimens used in the treatment of women with early-stage BC. METHODS: We searched public database from inception to May 2021 for Phase II and Phase III trials of adjuvant chemotherapy in patients with early-stage BC following PRISMA guidelines. The primary e…

Rank104.3
Systematic review or meta-analysis

Menopausal Estrogen Therapy and Risk of Breast Cancer.

Obstetrics and gynecology · 2026 · PMID 42594383

Recent evidence suggests that use of menopausal estrogen-only therapy in patients who have undergone hysterectomy reduces breast cancer risk among patients at population risk for breast cancer as well as in those with pathogenic high-risk BRCA variants. A meta-analysis of 10 randomized trials of estrogen therapy compared with placebo among 14,282 participants at population risk noted that 3.6% those randomized to estrogen alone were diagnosed with breast cancer, compared with 4.7% of those randomized to placebo (re…

Rank104.3
Systematic review or meta-analysis

Systematic review and meta-analysis of the effectiveness of expressive writing disclosure on cancer and palliative care patients' health-related outcomes.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023 · PMID 38157056

OBJECTIVES: This review aimed to synthesize the available evidence on the effectiveness of expressive writing (EW) on health outcomes of patients with cancer. METHODS: A systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Six databases were searched from 1986 to 9 July 2022. The searches were updated on 3 October 2023. Methodological quality was assessed using the Cochrane Risk of Bias tool for randomized controlled trials…

Rank103.9
Systematic review or meta-analysis

Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023 · PMID 36417083

BACKGROUND: We aimed to determine the effect of dual anti-HER2 blockade compared to monotherapy on clinically important outcomes. METHODS: We carried out a systematic review updated until July 2022. The outcomes included pathological complete response (pCR), clinical response, event-free survival, and overall survival. RESULTS: We identified eleven randomized clinical trials (2836 patients). When comparing paclitaxel plus dual treatment versus paclitaxel plus trastuzumab or lapatinib, dual treatment was associated …

Safety And Adverse Effects307 records
Rank110.0
Systematic review or meta-analysis

Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.

Journal of endocrinological investigation · 2024 · PMID 38530620

BACKGROUND: The effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cancer has yet to be fully elucidated. OBJECTIVE: This systematic review and meta-analysis investigated the effects of SGLT2 inhibitors on cancer. METHODS: We searched the PubMed and ClinicalTrials.gov databases up to July 15, 2023, to identify eligible randomized, double-blind, placebo-controlled trials that lasted at least ≥24 weeks. The primary outcome was the overall cancer incidence, and the secondary outcomes were the incidences of…

Rank109.7
Systematic review or meta-analysisResult signal: benefit

Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies.

Targeted oncology · 2025 · PMID 39656361

BACKGROUND: The efficacy and safety of cyclin-dependent kinase (CDK)4/6 inhibitors in patients with breast cancer have been investigated by large-scale trials sponsored by drug companies. A lack of real-world evidence may lead to biases. OBJECTIVE: We systematically reviewed the large-scale clinical trials and real-world data to investigate the efficacy and safety of CDK4/6 inhibitors in patients with breast cancer. PATIENTS AND METHODS: We searched PubMed, Embase, and Cochrane Library from the inception of each da…

Rank107.8
Systematic review or meta-analysis

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer.

European journal of clinical pharmacology · 2024 · PMID 38900307

PURPOSE: The aim of this study was to quantitatively compare the efficacy and safety of CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors for ER+/HER2- metastatic breast cancer. METHODS: A parametric survival function was used to analyze the time course of overall survival (OS) and progression-free survival (PFS). The objective response rate (ORR) and the incidence of any grade and grade 3-4 adverse events were summarized using the random-effects model of a single-arm meta-analysis. RESULTS: This study included 44 arm…

Rank107.2
Systematic review or meta-analysis

Updated findings of skin flap thickness and residual breast tissue after mastectomy for breast cancer: a systematic review of the literature.

Updates in surgery · 2024 · PMID 37864625

BACKGROUND: There is limited evidence on the ideal retention thickness of skin flap in mastectomy. Residual breast tissue (RBT) after mastectomy still represents an unknown risk for local recurrence or new breast cancer lesions. We made this systematic review to identify the optimal flap after mastectomy with minimal complications and better oncological safety. METHODS: A systematic review was performed using MEDLINE search in PubMed, Embase, and Cochrane Library with the search terms relevant to skin flap thicknes…

Rank107.0
Systematic review or meta-analysisResult signal: null

Efficacy and safety of a combination treatment of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 38587602

PURPOSE: Immune checkpoint inhibitors (ICIs) in combination with chemotherapy have showed its benefits in clinical studies, and here we conducted a further evaluation on the safety and efficacy of this treatment strategy. METHODS: A systematic literature review was conducted in PubMed, Embase and Cochrane Library to identify clinical studies on ICIs and chemotherapy for metastatic breast cancer. The primary efficacy endpoints were progression-free survival (PFS) and overall survival (OS), and adverse events (AEs) w…

Rank106.7
Systematic review or meta-analysis

Postoperative outcomes of minimally invasive versus conventional nipple-sparing mastectomy with prosthesis breast reconstruction in breast cancer: a meta-analysis.

Journal of robotic surgery · 2024 · PMID 38951387

Breast cancer is the most common malignant tumor worldwide, and mastectomy remains the primary strategy for treating early stage breast cancer. However, the complication rates, surgical variables, and oncologic safety of minimally invasive nipple-sparing mastectomy (MINSM) have not been fully addressed. We systematically searched PubMed, Web of Science, Embase, and the Cochrane Library for randomized-controlled trials (RCTs) and non-RCTs that compared MINSM with conventional nipple-sparing mastectomy (CNSM), both f…

Rank106.4
Systematic review or meta-analysisResult signal: null

Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials.

European journal of clinical pharmacology · 2024 · PMID 38888626

INTRODUCTION: Incorporation of AKT inhibitors into adjuvant therapy for advanced or metastatic breast cancer has improved clinical outcomes. However, the safety of AKT inhibitors should be better evaluated, given the possibility of prolonging survival and impacting patient quality of life. Our aim was to assess how the addition of AKT inhibitors to adjuvant therapy affects treatment-related adverse events. METHODS: We evaluated binary outcomes with risk ratios (RRs), with 95% confidence intervals (CIs). We used Der…

Rank106.4
Systematic review or meta-analysis

Impact of resistance training on fatigue among breast cancer patients undergoing chemotherapy: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39392491

PURPOSE: The effects of aerobic exercise interventions for reducing fatigue after cancer treatment are well-established, and the effect of resistance training remains uncertain. Therefore, this systematic review and meta-analysis aim to analyze the effect of resistance training and combined resistance and endurance training on cancer-related fatigue (CRF) in breast cancer patients. METHODS: A systematic search for randomized controlled trials (RCTs) was conducted on the PubMed, SPORTDiscus, Embase, and Cochrane dat…

Rank106.3
Systematic review or meta-analysis

Cognitive behavioural therapy for insomnia in people with cancer.

The Cochrane database of systematic reviews · 2025 · PMID 41170811

BACKGROUND: Insomnia is a prevalent and distressing issue for individuals with cancer, negatively impacting their overall well-being. While cognitive behavioural therapy for insomnia (CBT-I) is the recommended first-line treatment for insomnia in the general population, its effects on cancer populations warrant rigorous, ongoing evaluation. Previous meta-analyses assessing CBT-I against specific comparators in people with cancer have often exhibited methodological limitations. Furthermore, with a recent increase in…

Rank106.1
Systematic review or meta-analysis

Safety and efficacy of Meridian sinew tuina (MST) for post-surgical upper limb lymphedema: a systematic review and meta-analysis.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026 · PMID 42703097

BACKGROUND: Complex Decongestive Therapy (CDT) is the non-operative standard for breast cancer-related lymphedema (BCRL), but many patients experience persistent subcutaneous stiffness, pain, and restricted mobility. This study systematically reviews the safety and clinical efficacy of Meridian Sinew Tuina (MST) protocols for BCRL. METHODS: Global and regional databases (PubMed, Cochrane Library, Embase, Web of Science, CNKI, Wanfang, VIP) were searched from inception to January 15, 2026, with alerts monitored thro…

Rank105.8
Systematic review or meta-analysis

Decrease of radiation-induced skin reactions in breast cancer patients by preventive application of film dressings-a systematic review.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024 · PMID 37755486

PURPOSE: Radiation-induced skin reactions remain one of the most frequent side effects of adjuvant radiotherapy for breast cancer, which is the most common global malignancy. In individual cases, we observed a decrease in radiation dermatitis under film dressings used for skin marking purposes. Therefore, we decided to revise the available evidence regarding the prophylactic use of film dressings to reduce radiation dermatitis in breast cancer patients. METHODS: On 20 March 2023, we conducted a systematic review of…

Rank105.4
Systematic review or meta-analysis

Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

Journal of gastrointestinal cancer · 2024 · PMID 39160369

BACKGROUND AND OBJECTIVE: Metronomic capecitabine has been found to be useful in several types of cancers such as pancreatic cancer, breast cancer, gastrointestinal cancers, nasopharyngeal carcinoma, and metastatic colorectal cancer. This unique systematic literature review and meta-analysis was undertaken to assess the effectiveness and safety of metronomic capecitabine as a treatment regimen for hepatocellular carcinoma. METHOD: A systematic search of major databases was performed. Eight studies that dealt with t…

Rank105.1
Systematic review or meta-analysis

Physical activity interventions for women with metastatic breast cancer: a systematic review of published and ongoing randomised controlled trials.

Journal of cancer survivorship : research and practice · 2026 · PMID 41214274

PURPOSE: We systematically reviewed published and ongoing physical activity (PA) trials in women with metastatic breast cancer (MBC). We examined (i) the effectiveness of PA interventions and identified (ii) the type of interventions being evaluated, (iii) how they are delivered and (iv) their theoretical basis. METHODS: Seven databases and two trial registries were searched in August 2024 for randomised controlled trials, testing any PA intervention in people with MBC, reporting a PA outcome. The Joanna Briggs Ins…

Rank104.0
Systematic review or meta-analysis

Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.

Clinical and experimental medicine · 2023 · PMID 36422737

Although platinum-based chemotherapy can improve pathologic complete response (pCR) in patients with triple-negative breast cancer (TNBC), the impact on survival of platinum-based neoadjuvant and adjuvant chemotherapy is still controversial. Our meta-analysis aimed at analyzing survival with platinum-based neoadjuvant and adjuvant chemotherapy in patients with TNBC. We searched PubMed, EMBASE, MEDLINE, Cochrane databases, and several major conferences up to January 2021. Fixed and random models were used for our me…

Rank103.2
Systematic review or meta-analysis

Systemic Glucocorticoid Use and Risk of Site-Specific Cancers: A Methodologic Systematic Review of Observational Studies.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026 · PMID 41931525

Systemic glucocorticoids, widely prescribed for inflammatory and autoimmune diseases, have long been suspected of increasing cancer risk through immunosuppressive and metabolic effects. Randomized trials are often unethical and difficult to conduct, leaving observational studies the best option to determine whether the use of systemic glucocorticoids affects cancer development. However, these studies face significant methodologic issues that may compromise the validity of their findings. We systematically reviewed …

Rank103.0
Systematic review or meta-analysis

Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis.

Clinical and experimental medicine · 2023 · PMID 37120775

Anti-human epidermal growth factor receptor-2 (anti-HER2) therapy has shown excellent efficacy in patients with HER2 overexpression and amplification. Although HER2 mutations are rarely expressed in several cancers, when they occur, they can activate the HER2 signaling pathway. In recent years, studies have shown that anti-HER2 drugs have promising efficacy in patients with HER2 mutations. Based on keywords, we searched databases, such as PubMed, Embase, and Cochrane Library, and the main conference abstracts. We e…

Rank102.7
Systematic review or meta-analysis

Pharmacologic prevention of cardiotoxicity in breast cancer: a Bayesian network meta-analysis and meta-regression.

Cardio-oncology (London, England) · 2026 · PMID 42958440

BACKGROUND: Cancer therapy related cardiac dysfunction (CTRCD) is a major concern in breast cancer patients, often reducing left ventricular ejection fraction (LVEF) and causing symptomatic heart failure. This study assessed the comparative effectiveness and safety of cardioprotective drugs in preserving LVEF during chemotherapy. METHODS: Our database search, included Cochrane, PubMed, WOS, and SCOPUS, from inception to May 1st, 2024, to find randomized controlled trials (RCTs) that assessed the effectiveness and s…

Rank102.1
Systematic review or meta-analysisResult signal: mixed

The effect of different telerehabilitation technologies on the management of cardiovascular disease in oncology survivors: systematic review.

Journal of cancer survivorship : research and practice · 2026 · PMID 41354726

PURPOSE: With advancements in early detection and treatment improving cancer survival rates, cancer survivors face an increased risk of cardiovascular-specific morbidity and mortality. Cardiovascular telerehabilitation has been a notable tool to enhance the quality of life and manage cardiovascular disease in cancer survivors. This systematic review aims to evaluate the effectiveness of different telerehabilitation technologies in improving cardiovascular fitness in cancer survivors. METHODS: This review was regist…

Rank100.0
Systematic review or meta-analysis

Impact of age and treatment-related adverse events on financial toxicity among patients with breast cancer: a systematic review.

Journal of cancer survivorship : research and practice · 2026 · PMID 40884698

PURPOSE: Increasing incidence of breast cancer among young adults (YA), defined by the National Comprehensive Cancer Network (NCCN) as age < 40 years, has amplified concerns over financial toxicity (FT) in this demographic. This systematic review sought to clarify the association between YA status and FT. METHODS: We queried bibliographic databases for full-text English language publications between 2010 and 2024 reporting FT using validated patient-reported outcome metrics among patients with stage I-III breast ca…

Rank100.0
Systematic review or meta-analysis

Dose reduction and discontinuation due to the combination of CDK4/6 inhibitors and endocrine drugs: a systematic review and meta-analysis.

European journal of clinical pharmacology · 2024 · PMID 39271490

BACKGROUND: With the widespread use of CDK4/6 inhibitors, the number of discontinuations and reductions due to adverse events is increasing. Therefore, we examined the risk of dose reduction, discontinuation, and occurrence of serious adverse events and death due to adverse events when CDK4/6 inhibitors are combined with endocrine drugs. METHODS: We searched English-language articles published up to February 10, 2024, using RR values (risk ratio) to indicate the risk of discontinuation, dose reduction, death, and t…

Rank100.0
Systematic review or meta-analysis

Effect of exercise on fatigue and depression in breastcancer women undergoing chemotherapy: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39012405

This meta-analysis examined the effectiveness of exercise interventions in reducing fatigue and depression among women undergoing chemotherapy for breast cancer. The study followed PRISMA guidelines and analysed seven randomized controlled trials between 2016 and 2022. The results showed that exercise can substantially reduce fatigue levels (MD: -0.40, CI: -0.66, -0.14, P: 0.003), a common side effect of chemotherapy. Although depression did not significantly change (MD: -0.39, CI: -0.98, 0.20, P: 0.19), this study…

Rank100.0
Systematic review or meta-analysis

A critical review of randomized controlled trials on topical corticosteroids for the prevention of radiation dermatitis in breast cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025 · PMID 39903309

INTRODUCTION: Topical steroids have shown effectiveness in preventing radiation dermatitis (RD) in breast cancer patients in randomized controlled trials (RCTs). This review provides an in-depth analysis of the study methodology of these RCTs to review whether topical steroids should be employed in routine clinical practice. METHODS: A systematic literature search of MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials was conducted from database inception until May 31, 2024. RCTs comparing topic…

Rank100.0
Systematic review or meta-analysis

Efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy versus photothermal therapy alone for breast cancer xenograft tumors: a meta-analysis.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 42449201

OBJECTIVE: To systematically evaluate the efficacy of doxorubicin (DOX)-loaded graphene nanoplatform chemo-photothermal therapy (CPT) compared with photothermal therapy (PTT) alone on relative tumor volume (RTV) in breast cancer xenograft models and to summarize reported secondary safety and translational endpoints. METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched for animal studies published from January 2010 to December 2025 investigating DOX-loaded graphene nanomaterial-mediated CPT in…

Rank100.0
Systematic review or meta-analysis

Preclinical evidence for mifepristone in breast cancer: A systematic review and meta-analysis of animal studies.

European journal of pharmacology · 2026 · PMID 42854814

Mifepristone (MIF), an antagonist of the progesterone receptor (PR) and glucocorticoid receptor (GR), has shown antitumor activity in experimental breast cancer, but the consistency and certainty of the preclinical evidence remain unclear. We systematically searched PubMed, Embase, Web of Science, and the China National Knowledge Infrastructure through May 5, 2026, for animal studies evaluating MIF alone or in combination with other anticancer treatments. Random-effects meta-analyses were performed using Hedges' g …

Rank100.0
Systematic review or meta-analysis

Doxorubicin downregulates cell cycle regulatory hub genes in breast cancer cells.

Medical oncology (Northwood, London, England) · 2024 · PMID 39115587

Breast cancer (BC) is the leading commonly diagnosed cancer in the world, with complex mechanisms underlying its development. There is an urgent need to enlighten key genes as potential therapeutic targets crucial to advancing BC treatment. This study sought to investigate the influence of doxorubicin (DOX) on identified key genes consistent across numerous BC datasets obtained through bioinformatic analysis. To date, a meta-analysis of publicly available coding datasets for expression profiling by array from the G…

Treatments That Failed Clinical Trials87 records
Rank101.6
Randomized controlled trial

A Multicenter Non-Inferiority Randomized Controlled Trial of Sentinel Lymph Node Biopsy in Early Breast Cancer: Conventional Dual Tracer Versus Superparamagnetic Iron Oxide.

World journal of surgery · 2026 · PMID 42537885

BACKGROUND: The gold standard for detecting sentinel lymph node (SLN) in early breast cancer is combined use of radioisotope and blue dye. A newer agent, superparamagnetic iron oxide (SPIO), was developed to address the challenges faced with the traditional method. This study aims to compare the detection rate of SLN biopsy and show the non-inferiority of SPIO. METHODS: From March 2021 to April 2024, patients with clinically and radiologically node-negative breast cancer were randomized to receive SPIO-only injecti…

Rank101.0
Randomized controlled trial

Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer.

JAMA oncology · 2026 · PMID 42593771

IMPORTANCE: Molecular residual disease (MRD) detection has potential to transform the selection of adjuvant therapy. Most evidence is from tumor-informed assays. Tissue-free assays not requiring sequencing of the primary tumor may simplify workflows if they offer accuracy similar to that of tumor-informed assays. OBJECTIVE: To evaluate tissue-free circulating tumor DNA (ctDNA) analysis in patients with triple negative breast cancer (TNBC) and compare the tissue-free assay with tumor-informed assay results. DESIGN, …

Rank100.9
Randomized controlled trialResult signal: benefit

A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial.

Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42218963

BACKGROUND: Platinum agents have been shown to increase pathologic complete response (pCR) rates when added to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC). The PEARLY multicenter, randomized, phase III trial investigated the efficacy and safety of adding carboplatin to standard anthracycline-based and taxane chemotherapy for patients with early-stage TNBC in the neoadjuvant or adjuvant settings. PATIENTS AND METHODS: Patients with stage II or III TNBC were enrolled. Patients received either st…

Rank100.8
Randomized controlled trial

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.

Nature medicine · 2026 · PMID 42680950

Triple-negative breast cancer (TNBC) is an aggressive subtype with an activated tumor immune microenvironment. The multicenter, multinational, double-blinded NSABP B-59/GeparDouze trial evaluated the addition of atezolizumab (atezo) (773 patients randomized) or placebo (777 patients) to sequential taxane-carboplatin-anthracycline-based neoadjuvant chemotherapy in stage II-III TNBC. The addition of atezo did not significantly improve the primary endpoint of event-free survival (EFS) (HR, 0.80 (95% CI, 0.062-1.03); s…

Rank99.5
Randomized controlled trialResult signal: nullCorrection flagged

Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial.

Annals of surgical oncology · 2026 · PMID 42545411

BACKGROUND: Mastectomy rates in women with breast cancer are higher in younger women than in older women. The impact of this more extensive surgery on overall survival (OS) and locoregional recurrence in younger women is unknown, especially after neoadjuvant systemic therapy (NST). This study evaluated surgical management and outcomes of patients aged ≤ 45 versus > 45 years enrolled in multicenter NST clinical trial, I-SPY2.0 (NCT01042379, PMID 37325931). METHODS: We conducted a secondary data analysis comparing lo…

Rank99.2
Randomized controlled trial

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42229584

BACKGROUND: The Suppression of Ovarian Function Trial (SOFT) found adding ovarian function suppression (OFS) to tamoxifen (T) reduced breast cancer recurrence, and exemestane (E)+OFS further reduced recurrence. A combined analysis of SOFT and TEXT showed a significant reduction in distant recurrence with E+OFS versus T+OFS. We now report final 15-year outcomes. PATIENTS AND METHODS: Premenopausal women with hormone receptor-positive early breast cancer were enrolled, with 3047 in SOFT and 2660 in TEXT intention-to-…

Rank99.1
Randomized controlled trial

Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32.

JNCI cancer spectrum · 2026 · PMID 42360727

BACKGROUND: Circulating levels of cancer antigen (CA) 15-3 have been associated with distant breast cancer recurrence; data on breast cancer subtypes are sparse. We examined associations of CA 15-3 with outcomes across immunohistochemically defined breast cancer subtypes in MA.32. METHODS: A total of 3649 participants with T1-3, N0-1, M0 breast cancer were randomly assigned; 2740 (75.1%) provided blood at entry (mean = 278 days postdiagnosis) and 6 months later. Prognostic associations of baseline and 6-month chang…

Rank97.8
Randomized controlled trial

EORTC QLQ-C30 symptom components and their functional correlates during adjuvant chemotherapy for early breast cancer: a multivariate analysis. Data from GEICAM/2003-02 study.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026 · PMID 42859303

PURPOSE: Understanding how multiple symptoms jointly impact functioning is essential for interpreting patient-reported outcomes (PROs) in oncology. We aimed to characterize the main dimensions underlying change-from-baseline (CFB) in symptom scores during adjuvant chemotherapy for early breast cancer, and to examine their associations with functional outcomes. PATIENTS AND METHODS: We analyzed EORTC QLQ-C30 CFB scores from 820 patients enrolled in the GEICAM/2003-02 trial. Principal component analysis (PCA) was use…

Rank97.6
Randomized controlled trial

Use of indocyanine green fluorescence versus patent blue V dye for sentinel lymph node biopsy in early breast cancer, a randomized controlled trial.

Journal of the Egyptian National Cancer Institute · 2026 · PMID 42684555

BACKGROUND: Sentinel lymph node biopsy (SLNB) is standard for axillary staging in early breast cancer. While the combination of radioisotope and blue dye (e.g., patent blue V, PBV) remains the standard, it has limitations including logistics, variable identification rate (IR), and allergic potential. Indocyanine green (ICG) fluorescence is a promising alternative, but high-quality comparative evidence is needed. METHODS: This was a single-center, prospective, randomized controlled trial. Forty patients with early-s…

Rank97.6
Randomized controlled trialResult signal: harm

Biomarker-based risk stratification for predicting late recurrence and benefit of extended endocrine therapy: A secondary analysis of the IDEAL trial.

Breast (Edinburgh, Scotland) · 2026 · PMID 42632205

BACKGROUND: Hormone receptor-positive, HER2-negative (HR+/HER2-) early breast cancer (EBC) is characterized by a persistent risk of late recurrences up to 15 years from diagnosis. Phase III randomized IDEAL (Investigation on the Duration of Extended Adjuvant Letrozole) trial was conducted to optimize the duration of extended endocrine therapy (EET). This blinded prospective-retrospective study investigates the potential of CanAssist Breast (CAB) to predict late recurrences and identify patients who may benefit from…

Rank97.3
Randomized controlled trial

Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42467210

PURPOSE: We aimed to investigate the prognostic and predictive value of tumor-infiltrating lymphocytes (TIL) for adjuvant immunotherapy in high-risk early triple-negative breast cancer (TNBC). PATIENTS AND METHODS: The phase III A-BRAVE trial randomized 466 patients with high-risk early TNBC to adjuvant avelumab or observation after standard therapy. Inclusion criteria allowed 2 strata: stratum A (primary surgery followed by adjuvant chemotherapy, defined at high risk based on pathologic stage) and stratum B (neoad…

Rank97.3
Randomized controlled trial

Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial.

ESMO open · 2026 · PMID 42785163

BACKGROUND: The IMpassion050 (NCT03726879) primary analysis showed similar pathologic complete response (pCR) rates with/without the addition of neoadjuvant atezolizumab to pertuzumab, trastuzumab, and chemotherapy in high-risk human epidermal growth factor receptor 2-positive early breast cancer in the intention-to-treat and programmed death-ligand 1 (PD-L1)-positive populations. Safety was consistent with other atezolizumab combination studies. We report final analysis results. PATIENTS AND METHODS: Patients were…

Rank97.2
Randomized controlled trial

AI Health message intervention: The role of message customization and message source in breast cancer screening among women of color.

Patient education and counseling · 2026 · PMID 42537382

OBJECTIVES: To examine the effectiveness of breast cancer screening messages with varying levels of customization (generic, targeted, and tailored) and to compare AI-generated versus human-generated messages. METHODS: A between-subjects experimental design with a control condition was employed. Message content followed a standardized structure and varied by level of customization: generic, targeted (demographic-based), and tailored (perceived susceptibility- and barrier-based). Messages were developed by either the…

Rank97.2
Randomized controlled trialResult signal: null

Correlation of CTCAE and patient-reported breast radiation dermatitis symptom scores.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39556198

BACKGROUND AND PURPOSE: Clinicians use the CTCAE scale to grade radiation dermatitis (RD) based on edema, erythema, and desquamation. The purpose of this study was to correlate the CTCAE scores with the severity of patient-reported symptoms using a skin symptom assessment (SSA) and the Radiation-Induced Skin Reaction Assessment Scale (RISRAS). MATERIALS AND METHODS: This is a secondary analysis of a randomized controlled trial involving 376 patients receiving Mepitel Film or standard-of-care for RD prophylaxis. The…

Rank97.1
Randomized controlled trial

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.

JAMA oncology · 2026 · PMID 42530945

IMPORTANCE: Although adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves outcomes in high-risk early-stage breast cancer, opportunities remain to further enhance response. Dual checkpoint blockade offers a potential strategy to further enhance efficacy. OBJECTIVE: To evaluate the combination of anti-programmed cell death 1 protein (PD-1) cemiplimab and anti-lymphocyte activation gene 3 (LAG-3) added to neoadjuvant therapy in ERBB2-negative early-stage, high-risk breast cancer. DESIGN, SETTING, …

Rank97.1
Randomized controlled trial

Giredestrant plus Everolimus in Advanced Breast Cancer.

The New England journal of medicine · 2026 · PMID 42814929

BACKGROUND: Giredestrant and everolimus target the estrogen receptor (ER) pathway and the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) pathway, respectively, which are implicated in endocrine-therapy resistance. METHODS: In this phase 3, open-label, randomized trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who had disease progression or recurrence after receipt of …

Rank97.1
Randomized controlled trial

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.

Nature medicine · 2024 · PMID 38191615

The combination of immune-checkpoint blockade with chemotherapy for the first-line treatment of advanced triple-negative breast cancer (TNBC) has generated mixed results. TORCHLIGHT is a randomized, double-blinded phase 3 trial evaluating the efficacy and safety of first-line toripalimab and nab-paclitaxel (nab-P) (n = 353; experimental arm) versus placebo and nab-P (n = 178; control arm) for the treatment of women with metastatic or recurrent TNBC. The primary end point was progression-free survival (PFS) assessed…

Rank97.1
Randomized controlled trialResult signal: benefit

Entinostat plus exemestane for hormone receptor-positive advanced breast cancer: long-term overall survival results from the EOC103A3101 randomized controlled trial.

Signal transduction and targeted therapy · 2026 · PMID 42897132

The addition of entinostat, a histone deacetylase inhibitor, to exemestane has demonstrated improved progression-free survival (PFS) in hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) following endocrine therapy failure in the EOC103A3101 randomized trial (NCT03538171). This study reports long-term overall survival (OS) results. In this study, 354 patients with HR + /HER2- ABC that had recurred or progressed after endocrine therapy were rando…

Rank97.0
Randomized controlled trial

Perceived discrimination, patient-provider communication, and quality of life among breast cancer survivors: a mediation analysis.

Journal of cancer survivorship : research and practice · 2026 · PMID 40875141

PURPOSE: Breast cancer is common among women in the US and can impact survivors' quality of life (QoL). Perceived discrimination, defined as unfair treatment based on group membership, is often associated with poorer QoL, while effective patient-provider communication is often linked to better QoL. However, whether communication can mitigate the negative effects of discrimination remains unclear. This study investigates the relationship between perceived discrimination and QoL among women with early-stage breast ca…

Rank97.0
Randomized controlled trial

Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42308863

BACKGROUND: Phosphoinositide 3-kinase (PI3K) pathway, involved in obesity-related signalling, may influence efficacy and toxicity of PI3K inhibitors (PI3Ki). We explored associations between body mass index (BMI) and objective response rate (ORR), safety, molecular features, and breast density in the LORELEI trial. METHODS: LORELEI (NCT02273973) was a randomized trial evaluating neoadjuvant PI3Ki taselisib plus letrozole vs placebo plus letrozole in patients with estrogen receptor-positive/HER2-negative early breas…

Rank96.9
Randomized controlled trialCorrection flagged

Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial.

JAMA surgery · 2026 · PMID 42384406

IMPORTANCE: The NRG Oncology research organization and NSABP B-35 randomized clinical trial prospectively collected margin width data on postmenopausal women with hormone receptor (HR)-positive ductal carcinoma in situ (DCIS) who underwent lumpectomy, whole-breast irradiation (WBI), and randomly assigned adjuvant anastrozole or tamoxifen therapy. This permitted analysis of outcomes per margin width. OBJECTIVE: To analyze the effect of margin width on ipsilateral breast tumor recurrence (IBTR). DESIGN, SETTING, AND …

Rank96.9
Randomized controlled trial

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42162664

BACKGROUND: Triple-negative breast cancer (TNBC) is immunogenic, but only a subset of patients benefits from neoadjuvant immune checkpoint inhibitors combined with chemotherapy. Predictive biomarkers to guide patient selection and treatment adaptation are lacking. PATIENTS AND METHODS: In the randomized phase III NeoTRIPaPDL1 trial, 280 patients with high-risk TNBC received neoadjuvant carboplatin plus nab-paclitaxel (CT, n = 142) or the same regimen with atezolizumab (CT/A, n = 138). Tumor biopsies were collected …

Rank96.8
Randomized controlled trial

Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study.

Breast cancer research : BCR · 2026 · PMID 42806387

BACKGROUND: Sacituzumab tirumotecan (sac-TMT) is a novel anti-trophoblast cell-surface antigen 2 antibody-drug conjugate and has been approved for second-line and subsequent treatment of metastatic triple-negative breast cancer (TNBC) in China. This post-hoc exploratory study aims to further characterize the safety profile of sac-TMT to inform clinical practice. METHODS: This analysis was based on the safety set from the OptiTROP-Breast01 study, including all subjects who have received at least one dose of sac-TMT …

Rank96.6
Randomized controlled trial

Pooled analysis of NeoCARH and NeoCART trials: patient-reported outcomes in patients with early-stage breast cancer receiving platinum-based or anthracycline-based neoadjuvant chemotherapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 38829506

PURPOSE: Anthracycline-based or platinum-based neoadjuvant chemotherapy belongs to the standard treatment for early-stage breast cancer (EBC) that is either triple-negative or human epidermal growth factor receptor 2 positive (HER2 +). Currently, there is a paucity of data comparing their impact on health-related quality of life (HRQoL). METHODS: Triple-negative or HER2 + EBC from our two prospective randomized controlled trials, neoCARH and neoCART, were divided into two groups based on the neoadjuvant chemotherap…

Rank96.6
Randomized controlled trialResult signal: null

Incidence Rates of Adverse Events (CTCAE Severity ≥3) During HER2-Directed Breast Cancer Treatment Assessing the Impact of App-Based Electronic Patient-Reported Outcomes in the Randomized Controlled PRO2 Trial.

Current oncology (Toronto, Ont.) · 2026 · PMID 42930185

(1) Background: the evaluation of app-based ePROs is increasingly being used in clinical trials with cancer patients while a medical effect for patients is a matter of controversy; (2) Methods: in the randomized (1:1) controlled PRO2 trial the effect of the mediduxTM app on the rate of "high-grade AEs" (HAEs, CTCAE severity ≥3) within patients receiving HER2-directed breast cancer treatment (arm A) was compared to a control-group that did not use the app (arm B); (3) Results: Among patients with observed (non-imput…

i
Research information notice

Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.